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ABSTRACT 
Total hip replacement (THR) is a highly effective operation for reducing pain and 
improving quality of life. An increasing number of patients are fertile-aged at the 
time of primary THR operation. There have only been a few previous studies that 
have analyzed reproductive health after THR. These studies have mainly focused on 
delivery method after THR, survival of the implant after delivery, and whether 
maternal THR increases the risk for congenital anomalies in the offspring. None of 
these studies have reported decreased implant survivorship or THR complicating 
delivery. There are two case reports in which congenital anomalies have been found 
in the offspring of women with metal-on-metal THR. These cases were considered 
to be hereditary. All previous studies have either been case reports or small local case 
series.  
The overall aim of our retrospective cohort study was to analyze reproductive 
health after THR in a nationwide setting. In study I, we analyzed the birth rate after 
THR in male and female patients. The risk for pregnancy ending in IA after primary 
THR was addressed in study II. Study III aimed to analyze delivery and neonatal 
health after maternal THR. Congenital malformations in the offspring of THR 
patients were analyzed in study IV. The impact of delivery on THR survival was 
analyzed in study V. 
The participants in this study were gathered from six national registries. The 
registers included in our study were as follows: the Finnish Arthroplasty Register, 
the Medical Birth Register, the Register of Induced Abortions, the Register of 
Congenital Malformations, the Register or Medical Reimbursements, and the 
Population Information System. Information on THRs was obtained from 1980 to 
2007 and information on pregnancies was gathered from 1987 to 2007. A total of 
2 429 fertile-aged (15 to 45 years) women at the time of THR were included and 
3 434 fertile-aged (15 to 50 years) men. For every patient, three matched referents 
(7 276 women and 10 299 men) without implants were identified and these formed 
the reference group. In statistical analyses, logistic regression models, Kaplan-Meier 
survival analysis, and Cox proportional hazard models were used. 
The probability for live birth was decreased after THR compared with the 
reference group in study I. The adjusted hazard ratio for the first children after THR 
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for women was 0.56 (95% confidence intervals (CI) 0.46 – 0.68) and for men 0.80 
(95% CI 0.69 – 0.92). In study II, the women had no increase in risk for pregnancy 
ending in IA after THR compared with reference group, adjusted odds ratio 1.50 
(95% CI 0.99-2.28), although the women were more likely to end their pregnancy 
due to maternal health issues (14.3% vs. 2.7% of the IAs). Cesarean section (CS) was 
a significantly more common delivery method in the THR patient group in study III 
(CS rate 52.9% vs. 19.3%). A higher proportion of the deliveries were preterm 
(adjusted OR 3.58 (95% CI 2.03 – 6.30)) and neonates were more likely to be born 
small-for-gestational-age (OR 2.83 (95% CI (1.35 – 5.93)) (study III). The risk for 
congenital anomalies was not increased in the offspring of THR patients (OR 3.93 
(95% CI 0.76 – 20.2, p=0.13). Delivery does not decrease THR survivorship 
(adjusted hazard ratio 1.12 (95% CI 0.77 – 1.62)).  
Our results suggest that delivery does not adversely affect THR survival. THR 
patients (both men and women) have lower birth rates after THR compared with 
the reference group. However, the risk for induced abortions is not increased among 
women with THR. THR clearly affects the choice of delivery method, and CS 
proportion is significantly higher after THR. It seems that adverse pregnancy 
outcomes are more common in the offspring of THR patients. The risk for 
congenital anomalies was not, however, increased. Future studies should also focus 
on the effects of metal-on-metal implants on reproduction.  
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TIIVISTELMÄ 
Lonkan tekonivelleikkaus on tehokas ja kustannusvaikuttava toimenpide, ja hyvien 
tuloksien myötä, näitä leikkauksia tehdään yhä enemmän myös nuorille, fertiili-
ikäisille potilaille. Aiempia tutkimuksia tekonivelleikattujen fertiili-ikäisten naisten ja 
miesten lisääntymisterveydestä on vain muutamia. Nämä aiemmat tutkimukset ovat 
keskittyneet lähinnä analysoimaan synnytystapaa leikkauksen jälkeen, tekonivelen 
pysyvyyttä synnytyksen jälkeen ja riskiä vastasyntyneen epämuodostumiin äidin 
tekonivelleikkauksen jälkeen. Näissä tutkimuksissa ei ole raportoitu tekonivelen 
vaikeuttavan synnytystä, eikä synnytyksen heikentävän tekonivelen pysyvyyttä. 
Epämuodostumia on raportoitu kahdessa potilastapauksessa, mutta molemmissa 
niitä pidettiin tekoniveleen liittymättömänä. Kaikki aiemmat tutkimukset ovat 
kuitenkin olleet lähinnä potilastapauksia tai pieniä paikallisia potilassarjoja. 
Tämän kohorttitutkimuksen tavoitteena oli selvittää kansallisella tasolla koko 
maanlaajuisia rekisteritietoja hyödyntäen retrospektiivisesti lonkan 
tekonivelleikkauksen vaikutusta kokonaisvaltaisesti lisääntymisterveyteen. I 
osatyössä selvitimme tekonivelen vaikutusta fertiliteettiin. II osatyössä tutkimme 
lisääkö lonkan tekonivel riskiä raskaudenkeskeytyksille. III osatyössä analysoimme 
synnytyksiä ja vastasyntyneen syntymäterveyttä ennen ja jälkeen tekonivelleikkausta. 
IV osatyössä tutkimme lisääkö äidin tekonivel riskiä synnynnäisille 
epämuodostumille. V osatyössä selvitimme synnytyksen vaikutusta lonkan 
tekonivelen pysyvyyteen.  
Aineistomme koostui kuudesta eri rekisteristä. Tekonivel-, syntymä-, 
raskaudenkeskeytys- ja epämuodostuma rekisterit ovat Terveyden ja Hyvinvoinnin 
laitoksen (THL) ylläpitämiä. Lisäksi hyödynsimme Kelan erityiskorvattavuus tietoja 
pitkäaikaissairauksista ja väestörekisteriä verrokkiryhmän poimintaan. 
Tekonivelleikkaukset kerättiin vuosilta 1980-2007. Tiedot raskauksista ja 
vastasyntyneistä ovat vuosilta 1987-2007. Tutkimusryhmän muodostivat 2 429 naista 
(leikkauksen aikana iältään 15-45 vuotta) ja 3 434 miestä (iältään 15-50 vuotta), joille 
oli leikattu lonkan tekonivel. Verrokkiryhmään kuului 7 276 naista ja 10 299 miestä, 
joilla ei ollut tekoniveltä ja jotka olivat iältään ja asuinpaikaltaan kaltaistettuja 
tutkimusryhmään. Tilastollisina analyyseinä käytettiin jakauman mukaisten 
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tunnuslukujen ja testausten (t-testi, Mann-Whitney U, Khiin neliö) lisäksi logistisia 
regressiomalleja, Kaplan-Meierin elinaika-analyysiä ja Coxin riskimallia. 
I osatyössä havaitsimme, että lonkan tekonivelpotilaiden leikkauksen jälkeinen 
lapsensaanti oli alentunutta verrattuna verrokkeihin. Naisten vakioitu 
riskitiehyssuhde saada lapsi leikkauksen jälkeen oli 0.56 (95% luottamusväli 0.46 – 
0.68) ja miesten vakioitu riskitieheyssuhde0.80 (95% lv 0.69 – 0.92).  II osatyössä 
osoitimme, että naisilla oli raja-arvoisesti lisääntynyt riski raskaudenkeskeytyksiin 
tekonivelleikkauksen jälkeen (vakioitu vedonlyöntisuhde 1.50 (95% lv 0.99-2.28)), 
vaikka tutkimusryhmässä suurempi osauus raskaudenkeskeytyksistä olikin äidin 
terveyden vuoksi (14.3% vs. 2.7%). III osatyössä tutkimusryhmässä oli selvästi 
suurempi osuus keisarinleikkauksia (52.9% vs. 19.3%). Lisäksi synnytykset olivat 
useammin ennenaikaisia (vakioitu vedonlyöntisuhde 3.58 (95% lv 2.03 – 6.30)) ja 
vastasyntyneet pienempipainoisia viikkoihin nähden (vakioitu vedonlyöntisuhde 2.83 
(95% lv (1.35 – 5.93)). IV työssä riski synnynnäisille epämuodostumille ei ollut 
kohonnut tutkimusryhmässä (vedonlyöntisuhde 3.93 (95% lv 0.76 – 20.2, p=0.13). 
V osatyössä näytimme, että synnytys ei heikennä lonkan tekonivelen kestävyyttä 
(vakioitu riskitiheyssuhde uusintaleikkaukselle 1.12 (95% lv 0.77 – 1.62)).  
Näiden tuloksien perusteella voimme todeta, että synnytys ei vaikuta lonkan 
tekonivelen pysyvyyteen. Lisäksi, fertiliteetti on verrokkiväestöä pienempää 
tekonivelleikkauksen jälkeen, sekä miehillä, että naisilla. Alentunutta syntyvyyttä ei 
selitä kuitenkaan lisääntynyt riski raskaudenkeskeytyksille, vaan pienempi lukumäärä 
raskauksia tekonivelpotilailla leikkauksen jälkeen. Tekonivelleikkaus vaikuttaa 
selvästi naisen synnytystapaan. Vastasyntyneiden syntymäterveys vaikuttaisi olevan 
heikompi tutkimusryhmässä, mutta riski epämuodostumille ei ole kohonnut. Riskiä 
epämuodostumiin ja hidastuneeseen sikiön kasvuun voisi tarkentaa 
jatkotutkimuksissa erityisesti metalli-metalli lonkkatekonivelen saaneilla potilailla.  
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1 INTRODUCTION 
Total hip replacement (THR) is a highly effective operation to reduce pain and to 
improve the quality of life of patients (Harris & Sledge, 1990; Rissanen, Aro, Slatis, 
Sintonen, & Paavolainen, 1995). Indeed, THR has been described as the operation 
of the 20th century (Learmonth, Young, & Rorabeck, 2007). Because of the success 
of THR, an increasing proportion of patients are fertile-aged (under 50 years) at the 
time of primary THR (Kurtz et al., 2009). In young patients, the most common 
indications for THR are rheumatoid arthritis (RA), developmental hip diseases, and 
avascular necrosis of the femoral head (Adelani, Keeney, Palisch, Fowler, & Clohisy, 
2013; Hannouche et al., 2016).  
Although the number of fertile-aged patients has increased, little is known about 
the effects of THR on reproduction. To date, no previous studies have analyzed 
birth rate after THR. THR is known to improve the sexual quality of life of hip 
patients, although it remains lower compared with persons without THR. THR does, 
however, affect sexual intercourse by reducing the number of possible positions 
(Klit, Jacobsen, Schmiegelow, Sonne-Holm, & Troelsen, 2015; Stern et al., 1991). 
Moreover, chronic diseases, such as RA and DM, have been shown to reduce the 
fertility rate (Sjöberg, Pitkäniemi, Haapala, Kaaja, & Tuomilehto, 2013; Wallenius et 
al., 2011). In addition, chronic diseases also increase the risk for spontaneous 
abortions. The risk for induced abortions, however,  seems to be similar to that 
found in healthy women (Blais, Kettani, & Forget, 2013; Kjaer, Hagen, Sandø, & 
Eshøj, 1992; Vinet, É, Kuriya, Pineau, Clarke, & Bernatsky, 2013). It could be 
possible therefore that THR reduces fertility rates.  
Previous studies of THR and fertility have focused mainly on delivery methods 
after THR. There have been a few case reports and small case series that suggest that 
normal delivery after THR is possible (Lally, Mandl, Huang, & Goodman, 2015; 
Reckling, 1976; Sierra, Trousdale, & Cabanela, 2005; Yazici et al., 2003; Yoon, H. J., 
Yoo, Yoon, Koo, & Kim, 2012). A few studies have also reported that women elect 
to be delivered by caesarean section due to the fear of vaginal delivery damaging the 
THR implant (Meldrum, Feinberg, Capello, & Detterline, 2003; Ostensen, 1993; 
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Stea, Bordini, De Clerico, Traina, & Toni, 2007). None of these studies, however, 
reported any delivery-related or neonatal complications.   
There have also been previous case reports on the possible teratogenic effect of 
the metal-ions released from metal-on-metal (MoM) THR. Metal-ions have been 
detected entering the fetal blood circulation. Moreover, the concentration of 
umbilical cord metal-ions has been reported to be elevated compared with the 
reference fetuses of women without THR (deSouza, Wallace, Costa, & Krikler, 2012; 
Fritzsche, Borisch, & Schaefer, 2012; Novak et al., 2014; Ziaee, Daniel, Datta, Blunt, 
& McMinn, 2007). Two case reports have reported congenital anomalies in the 
offspring of women with MoM THR (Brodner et al., 2004; Oppermann, Borisch, & 
Schaefer, 2015). Other case reports have reported normal health neonates without 
anomalies, even though  the neonate metal-ion concentrations have been elevated 
and have remained elevated for weeks (Fritzsche et al., 2012). 
Although pregnancy and delivery place a great deal of stress on the pelvis (Smith, 
M., Marcus, & Wurtz, 2008), it seems that neither pregnancy nor delivery decrease 
THR survivorship (McDowell & Lachiewicz, 2001; Meldrum et al., 2003; Sierra et 
al., 2005; Stea et al., 2007; Yazici et al., 2003). A single case report has described 
revision performed after pregnancy due to aseptic loosening (Boot, Heyligers, & 
Heins, 2003). Interestingly, delivery does not seem to affect or decrease patient 
reported outcome measures (PROMs) in THR patients (Lally et al., 2015; McDowell 
& Lachiewicz, 2001; Meldrum et al., 2003; Stea et al., 2007). However, increased 
groin pain has been reported during pregnancy among women with THR (Sierra et 
al., 2005). 
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2 REVIEW OF THE LITERATURE  
2.1 Total Hip Replacement 
The concept behind this common operation is simple, although the operation itself 
cannot be described as simple. During the operation, the head and proximal neck of 
the femoral bone are removed surgically, and a canal is created in the medullary space 
of the femoral bone. The femoral part of the prosthesis is then inserted into the 
femoral medullary canal. The acetabulum in the pelvis is enlarged using a reamer 
instrument and a cup is inserted into the created space. The bearing surfaces of the 
implants may vary, but they are designed to have long endurance as well as low 
friction. (Siopack & Jergesen, 1995) The goal of the operation is to decrease pain, 
restore functionality, and improve quality of life, and the operation has been shown 
to achieve this goal with excellent results (Harris & Sledge, 1990; Rissanen et al., 
1995). 
 
            
Figure 1.  Total hip replacement in the right hip and normal femur and acetabulum in the left hip in an 
anterior X-ray image of a female patient.  
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2.1.1 History of THR, briefly 
 
Total hip replacement (THR) has been described as the operation of the 20th century 
(Learmonth et al., 2007). The first attempts to operate lower limb traumas without 
amputation, however, were reportedly done as early as the 19th century. Hip 
osteotomies were then performed, where the whole joint was removed and 
manipulated to cause pseudarthrosis. The first operative attempts to treat 
osteoarthritis (OA) were done in late 1890 when JB Murphy performed a hip 
cheilectomy, where bone osteophytes were removed from the femoral caput and 
acetabulum. In the early 1900s, the first interpositional hip arthroplasties were 
performed. A variety of methods and materials (pig bladder, gold) were tried before 
M. Smith-Petersen provided the first mold arthroplasties. (Gomez & Morcuende, 
2005) At first, the mold was surfaced with glass, but in 1938 the vitallium cup was 
invented. This signaled the start of a new era of arthroplasties (Hernigou, 2014; 
Learmonth et al., 2007).  
In the same year, P. Wiles performed the first total hip replacement where 
stainless steel was used, and the fixation of the implant was done using screws and 
bolts (Gomez & Morcuende, 2005; Learmonth et al., 2007; Mellon, Liddle, & Pandit, 
2013). Later, Wiles and others experimented with many types of materials ranging 
from stainless steel to rubber, glass, and ivory (Mellon et al., 2013). K. McKee 
introduced the first proper metal-on-metal (MoM) bearing THR in the 1950s 
(Triclot, 2011). However, the first case report on a metallic hip prosthesis had been 
published already in 1943, where half of the femur was removed due to a tumor and 
replaced with an identical metallic prosthesis (Moore and Bohlman, 1943).  
In the late 1950s and early 1960s, Sir John Charnley revolutionized hip prosthesis 
operations with his low friction arthroplasty (Charnley, John, 1961). At the time, it 
had by far the best survival rates of all implants. Charnley was the first to use 
polymethyl methacrylate cement to fix the implants into the bone (Knight, Aujla, & 
Biswas, 2011). Today, the principle of modern THR is still the same as Charnley’s 
low friction arthroplasty (Knight et al., 2011; Learmonth et al., 2007; Mellon et al., 
2013). Charnley´s implant gained popularity over McKee’s MoM THR due to its 
better implant survival rates (Mellon et al., 2013). Charnley made a significant effort 
to understand prosthesis surgery and prosthesis failure, and he is also credited with 
the discovery of the theatre air microbes that cause prosthesis infections (Charnley, 
John, 1964). 
From the 1980s onwards, alternative bearings, such as metal-on-metal (MoM) or 
ceramic-on-ceramic (CoC), have been introduced with the aim of improving 
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performance (Triclot, 2011). The CoC implant was designed with harder bearing 
surfaces to decrease wear, but it is less commonly used due to high costs and 
squeaking (Knight et al., 2011). MoM implants are discussed in more detail later. 
Less invasive techniques as well as cementless fixations have also gained in popularity 
in recent years (Courpied & Caton, 2011). Currently, a metal head combined with a 
highly cross-linked polyethylene is the most common bearing couple used in 
contemporary THRs (AOANJRR, 2019; NJR, 2018; SHAR, 2019; THL, 2018c). 
 
2.1.2 Indications / diagnosis for THR 
2.1.2.1 Indications in all ages 
In the beginning, THR was mostly used to treat the pain and dysfunction caused by 
rheumatoid arthritis (RA) and primary osteoarthritis (OA) in elderly active people. 
Due to the advances in the medical treatment of RA, RA is now a relatively rare 
indication for THR in older patients. (Mellon et al., 2013) In 2017, the most common 
indications for primary THR in Finland were primary OA (86.2%), fracture of the 
femoral neck (4.4%), avascular necrosis of the femoral head (3.0%), RA (1.3%), and 
developmental dysplasia of the hip (DDH) (1.3%) (THL, 2018c). Between 1995 and 
2011, the most common indications were primary OA (82.4%), RA (4.6%), and hip 
fracture (3.7%). The proportion of hip fractures was much lower in Finland (4.4%) 
compared with the proportions of other Nordic countries (11.7 - 13.9%), whereas 
the proportion of primary OA diagnosis in Finland (86.2%) was higher (73.0 - 
78.7%). (Mäkelä et al., 2014b)  
2.1.2.2 Indications of young patients 
According to a recent review, for young patients (aged under 30 years at the time of 
THR), the most common indications for THR after 1988 were avascular necrosis of 
the femoral head (34.8%), juvenile RA (25.4%), DDH (14.6 %), and Perthes´ disease 
(5.4 %).  Before 1988, the most common diagnoses were juvenile RA (49.5 %), DDH 
(10.6%), following posttraumatic OA (8.2%), and avascular necrosis (7.6%) (Adelani 
et al., 2013). In a retrospective study, the most common indications for patients aged 
under 20 years old were avascular necrosis of the femoral head (56.2%), slipped 
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capital femoral epiphysis (11.4 %), and DDH (10.5 %) (Hannouche et al., 2016). 
Another study in the same age group (<20 years) had the same three indications in 
the same order as the most common diagnoses for THR: avascular necrosis, slipped 
upper femoral epiphysis, and DDH. (Patel, Luff, Whittingham-Jones, Gooding, & 
Hashemi-Nejad, 2012) A recent large Scandinavian register study combined all the 
Nordic arthroplasty registers and analyzed primary THRs performed on patients 
aged under 21 years at the time of the operation. In their study, the following 
diagnoses were the most common: pediatric hip diseases (including DDH and 
Perthes) (33%), systemic inflammatory disease (juvenile RA + other arthritis) (23%), 
avascular necrosis of the femoral head (12%), hip fracture sequelae (7%), 
osteoarthritis (4%), and other diagnoses (21%) (Halvorsen et al. 2019). (Figure 2)  
 
 
Figure 2.  Indications from 1995 to 2016 of primary THR in patients aged under <21 years old. Other: 
tumors, sequelae after infection, pharmaceutically induced femoral necrosis. Pediatric: 
developmental dysplasia of the hip (DDH), Perthes, slipped capital femoral epiphysis 
(SCFE). SIDs: systemic inflammatory diseases including rheumatoid arthritis, ankylosing 
spondylitis, and other inflammatory diseases. AVN: avascular necrosis. OA: osteoarthritis. 
Borrowed from the original source: Halvorsen V, Fenstad AM, Engesæter LB, Nordsletten 
L, Overgaard S, Pedersen AB, Kärrholm J, Mohaddes M, Eskelinen A, Mäkelä KT & Röhrl 
SM (2019) Outcome of 881 total hip arthroplasties in 747 patients 21 years or younger: 
data from the Nordic Arthroplasty Register Association (NARA) 1995–2016, Acta 
Orthopaedica, 90:4, 331-337, DOI: 10.1080/17453674.2019.1615263 
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2.1.3 Incidence and prevalence of THR 
In Finland, a total of 10 102 primary THRs and 1 725 revision THRs were performed 
in 2017.  Of these, 562 women and 665 men were aged under 55 years at the time of 
primary THR. During our study period (from 1987 to 2007), the total numbers have 
increased. In 1987, 281 women and 143 men aged under 55 had primary THR. In 
2007, the numbers were 442 women (52.3% increase) and 543 men (279% increase), 
showcasing the increase in incidence of THR, especially among men. (THL, 2018c)  
During our study period, the total incidences for primary THR in all age groups 
increased significantly from 153 per 100 000 person years in 1987 to 300 per 100 000 
person years in 2007. The current overall incidence for primary THR was 398 per 
100 000 person years in 2017. In the youngest age group (<55 years), the current 
incidences were 120 per 100 000 person years for men and 113 per 100 000 person 
years for women. In 1987, the incidences were 28 for men and 52 for women. The 
increase was seen already in 2007 when it was 91 for men and 82 for women. (THL, 
2018c) 
The incidences for younger patients (30-39 years old) have not, however, 
increased as much as the incidences for middle-aged (40-49 years old) patients in 
Finland. For middle-aged patients, the increase from 1980 to 2007 was 6 times higher 
than in the younger group. The incidence for primary THR was 5 per 100 000 person 
years in 2007 for the youngest age group. (Skytta, Leskinen, Eskelinen, Huhtala, & 
Remes, 2011) In the UK in 1996, the incidences for patients under 40 years old were 
2.1 per 100 000 person years for women and 1.3 per 100 000 person years for men 
(Dixon, Shaw, Ebrahim, & Dieppe, 2004).  
In the US, the overall prevalence of the THR among females aged under 50 has 
risen from 0.03% in the 1980s to 0.10% in the 2010s and among males from 0.05% 
to 0.12% (Maradit Kremers et al., 2015). The prevalence in Sweden for patients aged 
under 40 years was 12 THRs per 100 000 person years in 1999 and 19 THRs per 
100 000 person years in 2012 (Cnudde et al., 2018). Therefore, THR can be said to 
be relatively rare among fertile-aged patients, since the majority of the patients who 
undergo this otherwise common operation are elderly. In the United States, it has 
been estimated that the primary THR rate in the youngest age group (<45 years old) 
could possibly grow 3-fold by 2030 compared with 2006 rates. This would mean 
46 900 primary THRs every year for fertile-aged males and females. Without this 
expected growth, the THR rate would be a constant 15 600 THR per year for this 
age-group. (Kurtz et al., 2009) 
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2.1.4 Contemporary THR 
 
2.1.4.1 Different bearing couples, fixations and techniques 
The most common bearing couple used in modern THR is metal-on-highly cross-
linked polyethylene (MoXLP). Other possible bearing couples are metal-on-
conventional polyethylene (MoP), metal-on-metal (MoM), ceramic-on-ceramic 
(CoC), ceramic-on-polyethylene (CoP), and ceramic-on-metal (CoM) (López-López 
et al., 2017). For patients of all ages who underwent THR in the UK between 2003 
and 2017, the most popular bearing surfaces in primary THR were MoXLP (58.8%), 
followed by CoP (17.5%), CoC (14.7%), MoM (7.2%), and other (including CoM) 
(1.6%). The most common implant type in the UK was the all cemented MoXLP, 
which comprised 29.6% of all the primary THRs. (NJR, 2018) The different types 
of implant bearing/fixation combinations used are shown in Table 1.  
Of the implants operated in Finland in 2017 for patients under 55 years, 69.9% 
were uncemented, 1.5% cemented, 20.5% reverse hybrids, and 5.0% hybrids by 
fixation type (THL, 2018c). In the NJR report of patients of all ages who underwent 
THR between 2003 and 2017, the proportions of fixations were uncemented 
(38.9%), cemented (34.2%), hybrid (20.2%), reverse hybrid (2.6%), and resurfacings 
(4.0%). (NJR, 2018).  
The current MoP bearing couple is based on Charnley’s low friction arthroplasty. 
In this design, the bearing of the acetabular cup is polyethylene and the bearing of 
the femoral stem is metal. (Charnley, John, 1961; López-López et al., 2017). The 
polyethylene can be either highly cross-linked or not highly cross-linked. However, 
the highly cross-linked polyethylene performs better than the not highly cross-linked. 
Hence, highly cross-linked polyethylene is currently more commonly used. 
(AOANJRR, 2019; Marques et al., 2016; NJR, 2018; SHAR, 2019; THL, 2018c)  
Ceramic surfaces were introduced with high hopes of excellent durability and a 
low rate of wear (Hannouche, Zaoui, Zadegan, Sedel, & Nizard, 2011). Although the 
survival rates of CoC and CoP THRs have been at least similar compared with MoP 
THRs (D'Antonio, Capello, & Naughton, 2012; D'Antonio, Capello, & Naughton, 
2014), survival rates are still much lower than MoP THRs (AOANJRR, 2019; NJR, 
2018; SHAR, 2019; THL, 2018c). In addition, there are problems, such as squeaking, 
impingement, and ceramic ruptures, associated with the CoC implant, (Migaud et al., 
2016; Salo, P. P. et al., 2017).  
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Overall, the different implants have been shown to have quite similar survival 
rates with the exception of a few significantly worse bearing/fixation combinations. 
In a large meta-analysis (López-López et al., 2017) and in large register-based studies 
(Smith, A. J., Dieppe, Howard, & Blom, 2012; Smith, A. J., Dieppe, Vernon, Porter, 
& Blom, 2012a), cemented large-head MoM THRs and MoM resurfacings were 
found to have an especially higher risk for revision.  MoM bearings are discussed in 
more detail in chapter 2.1.4.3.  
The surgical techniques for THR have evolved. The use of the direct-lateral 
approach with patients in supine position has decreased. Instead, the antero-lateral 
approach in lateral decubitus (Hardinge approach) and the posterior approach have 
gained popularity (Cnudde et al., 2018). In Finland, 87.2% of the primary and 89.1% 
of revision THRs were performed using the posterior approach in 2018. The other 
technique commonly used in Finland was the Hardinge approach (12.2%). (THL, 
2018c)  
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Table 1.  Possible combinations of total hip replacement (THR) bearings and implant fixations 
used in the 21st century. Modified from the original sources (Marques et al., 2016; NJR, 2018) 
MoXLP= Metal-on-highly cross-linked polyethylene, MoP= Metal-on-polyethylene, MoM= Metal-
on-metal, CoC= Ceramic-on-ceramic, CoP= Ceramic-on-polyethylene, CoM= Ceramic-on-metal. 
 
Bearing materials Fixation 
MoXLP Cemented 
Uncemented 
Hybrid 
Reverse hybrid 
MoP Cemented 
 Uncemented 
 Hybrid 
 Reverse hybrid 
MoM Cemented 
Uncemented 
Hybrid 
Resurfacing 
CoC Uncemented 
Hybrid 
CoP Cemented 
Uncemented 
Hybrid 
Reverse hybrid 
CoM Uncemented 
 
2.1.4.2 Bearing wear and its consequences 
All implants have been shown to have bearing wear. These particles cause all kinds 
of harm and reactions to periprosthetic tissues and also have other possible systemic 
effects. Already in the 1970s and 1980s, the wear of polyethylene components were 
reported in a follow-up study of Charnley THRs by Charnley himself (Charnley, J. 
& Halley, 1975; Salvati et al., 1981). The effect of these wear particles has been 
discussed for the last three decades. In the early 1990s, many reports and studies 
were published on the local effects of polyethylene wear. Polyethylene wear was 
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shown to cause bone loss and osteolysis, which could have caused implant 
component loosening. (Bankston, Faris, Keating, & Ritter, 1993; Schmalzried, Jasty, 
& Harris, 1992; Schmalzried, Jasty, Rosenberg, & Harris, 1994) In 1994, Harris 
described these finding as particle diseases, where the wear particles from the THR 
(either polyethylene or metal) cause local problems (Harris, 1994).  
The etiology for the osteolysis are the extremely fine polyethylene wear particles 
released from the MoP or CoP THR (Jasty et al., 1994). In in vitro analysis, the 
submicron-sized polyethylene particles were similar to those found in in vivo analysis 
of the patients, and the particles were shown to cause osteolysis (McKellop et al., 
1995). These ultrafine particles cause local inflammation in soft tissues and bones 
that, in turn, leads to osteolysis (Goodman, 2007; Massin & Achour, 2017).  
Pseudotumors have been mostly associated with MoM bearings. However, since 
the tumors were also found among patients with low blood concentrations of Cr and 
Co, it was considered whether there might be other factors that cause pseudotumor 
other than the released metal-ions. (Hjorth et al., 2018) A recent study focused on 
adverse reaction to metal debris (ARMD) in patients with bilateral MoM THRs and 
showed that although the significantly differing amounts of wear was seen between 
the sides, majority of the histological findings were similar bilaterally and 
pseudotumors were found symmetrical in most cases (although the wear rate differed 
between sides). Therefore, they suggest that the host response to metal debris is 
individual and that the presence of ARMD might be due to a delayed hypersensitivity 
reaction to metal ions (Lehtovirta et al., 2019).  A few case reports have been 
published in recent years where pseudotumors were found among patients with 
MoP, CoP, and CoC THRs (Bisseling, Tan, Lu, Campbell, & van Susante, Job L C, 
2013; Campbell, Rajaee, Brien, & Paiement, 2017; Carli, Reuven, Zukor, & 
Antoniou, 2011; Scully & Teeny, 2013; Serrano et al., 2018). One recent study with 
a rather small study sample suggested that pseudotumors could also be common in 
MoP THRs (Hjorth et al., 2018). However, this finding has not been confirmed by 
others. The wear of MoM implants is discussed in the next chapter 2.1.4.3.  
The aim of the implant manufacturers and scientists has been to reduce wear and 
the release of these harmful particles and to improve implant durability. Many 
alternative tribology designs have been presented. (Chang, 2014) For example, highly 
cross-linked polyethylene reduces the wear rate significantly compared with standard 
polyethylene (Beksaç, Salas, González Della Valle, & Salvati, 2009; Devane et al., 
2017). Highly cross-linked polyethylene had lower rates of wear and no signs of 
osteolysis in a ten-year follow-up study, where it was compared with MoM, standard 
MoP, and CoC bearings (Atrey et al., 2017).   
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2.1.4.3 Metal-on-Metal bearing 
The first generation MoM THR was introduced in the 1950s by McKee and Watson-
Farrar (McKee & Watson-Farrar, 1966). The implant was used for a while until the 
Charnley low-friction MoP THR gained popularity due to better results and because 
the McKee implant struggled with implant loosening (Triclot, 2011). The interest in 
alternative bearings again evolved in the 1980s (Singh et al., 2013), mostly due to the 
polyethylene wear of MoP implants and osteolysis (Gallo, Raska, Mrázek, & Petrek, 
2008; Noordin & Masri, 2012). The second generation MoM was introduced by 
Weber in 1988 (Weber, 1992), and early results were reported to be excellent (Weber, 
1996). In the 1990s, the next generation of hip resurfacing arthroplasties with large 
diameter heads were introduced. These were believed to have lower wear, lower risk 
for dislocation and fractures, and easier revisions (McMinn, 2003). The promising 
early results of these resurfacing arthroplasties led to the introduction of the large 
diameter MoM THR. The large-diameter MoM was initially used as a revision 
implant for dislocated THR (Lombardi, Skeels, Berend, Adams, & Franchi, 2011), 
but gained popularity due to good first experiences, and by 2010, 35% of the primary 
THRs in the US were MoM THRs (Singh et al., 2013). In 2012, it was estimated that 
over one million MoM hip replacements had been implanted globally (AAOS, 2012). 
As adverse tissue reactions had already been described shortly after the 
introduction of MoM implants (Evans, Freeman, Miller, & Vernon-Roberts, 1974), 
the introduction of large-diameter MoM THRs lasted for less than a decade before 
the first reports of tissue defects were published (Ollivere, Darrah, Barker, Nolan, & 
Porteous, 2009; Park et al., 2005a; Willert et al., 2005). Although these reports were 
published in the mid-2000s, it was not until 2010 that the real debate about the 
problems with MoM implants began, and the British authorities published a medical 
device alert due to soft tissue reactions caused by metallic wear from the MoM 
implants (MHRA, 2010). The ASR implants were recalled by the company before 
the poor survival results (6-year revision rate for ASR THR was 48.8%) were 
published by the National Joint Register (Langton, Jameson et al., 2011).  
The main problems with MoM THRs were caused by bearing surface metal 
particle wear. The released metal ions are very harmful, and are generally referred to 
as adverse reactions to metal debris (ARMD). (Natu, Sidaginamale, Gandhi, 
Langton, & Nargol, 2012) ARMD include metallosis, pseudotumors, inflammatory 
responses, and necrosis (Lari Lehtovirta et al., 2018). ARMD are seen in both high- 
and low-wear implants (Langton, Joyce et al., 2011), but the rate of these reactions 
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is high among patients with MoM THR (Reito, Puolakka, Elo, Pajamäki, & 
Eskelinen, 2013).    
The metallic wear from the MoM THR is composed of mainly cobalt and 
chromium ion particles. The concentrations of these ions in the blood of patients 
with MoM THR have been reported to be elevated compared with patients without 
THR, the first reports of which were published already in 1980 (Daniel, Ziaee, 
Pradhan, Pynsent, & McMinn, 2007; Dobbs & Minski, 1980; Sauvé et al., 2007). 
Moreover, the ion levels are also significantly higher when compared with patients 
with MoP THR or patients without THR (Dahlstrand et al., 2017). However, the 
metal-ion concentrations decrease after the MoM THR is revised and changed to a 
non-MoM bearing couple (Lainiala, Reito et al., 2015). The concentration of these 
ions is also increased in other body fluids, such as synovial fluid, whole blood, serum, 
plasma, erythrocytes, and urine (Hartmann et al., 2013; Lehtovirta et al., 2017). 
The first case reports of patients having symptoms associated with pseudotumors 
caused by local inflammatory reactions to MoM THRs were reported in the late 
2000s (Clayton et al., 2008; Shahrdar, 2011; Watters et al., 2010). The prevalence of 
these pseudotumors was much higher than expected (Bosker et al., 2012). These 
pseudoutumors are detected by MRI (Lainiala et al., 2014) and ultrasound (Lainiala, 
Elo et al., 2015). Pseudotumors may cause pain and discomfort in the groin but also 
periprosthetic soft tissue destruction and even neurovascular compressions 
(Hasegawa et al., 2016).  
Regarding osteolysis, the same principles are present in MoM THRs than in 
MoXLP, MoP and CoP, or CoC. Already in 2005, early osteolysis was reported 
among patients with second-generation MoM THRs. At that time, some authors 
suggested that it might be associated with hypersensitivity to metal. (Park et al., 
2005b) Histological analyses of revised MoM THRs showed metallosis as a reaction 
to metal debris (Korovessis, Petsinis, Repanti, & Repantis, 2006). Osteolysis was 
later described as an immunological reaction to metal wear debris (Delaunay, Petit, 
Learmonth, Oger, & Vendittoli, 2010). Blood Cr and Co levels have been shown to 
correlate with bearing wear volume and also to the degree of necrosis and 
macrophage infiltration in periprosthetic tissues, suggesting a dose-response 
relationship (Lari Lehtovirta et al., 2018) 
There has been a debate on whether MoM implants might increase cancer risk 
due to the possible carcinogenic effect of Cr and Co ions. In 1991, the first Finnish 
study was published in which patients with McKee MoM implants were found to 
have different types of cancers than people without THR, but with no overall 
increase in rates of cancer (Visuri & Koskenvuo, 1991). Following this, a large 
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Finnish cohort study was published in 1996, where  MoM patients had a slightly but 
not significantly elevated incidence ratio for cancer (Visuri, Pukkala, Paavolainen, 
Pulkkinen, & Riska, 1996). As the second-generation MoM THRs and resurfacing 
arthroplasties gained popularity and ARMD became more common, newer large 
cohort studies were conducted in the UK and Finland. None of these nationwide 
large cohorts reported an increase in cancer risk among MoM THR patients 
compared with THR patients with other bearing types or people without THR 
(Ekman et al., 2018; Hunt, Blom, Matharu, Porter, & Whitehouse, 2018; Mäkelä et 
al., 2012; Mäkelä et al., 2014a; Smith, A. J., Dieppe, Porter, & Blom, 2012). 
  
2.1.4.4 Metal ions and pregnancy 
The metal ions released from MoM THRs are mainly Cr and Co. Other ion levels 
remain low. In animal studies, elevated Cr ion blood levels have been shown to be 
toxic to the fetus and to cause malformations (Junaid, Murthy, & Saxena, 1995; 
Kanojia, Junaid, & Murthy, 1998). Co has been shown to have genotoxic and 
teratogenic effects (De Boeck, Kirsch-Volders, & Lison, 2003; De Boeck et al., 2003; 
Kasten, Mullenders, & Hartwig, 1997). Moreover, according to two studies, the ions 
released from MoM THRs to the synovial fluid have the potential to cause 
chromosomal damage to human cells in laboratory cultures (A P Davies et al., 2005; 
Daley, Doherty, Fairman, & Case, 2004). In a systematic literature review among 
industrial workers, exposure to Cr was reported to cause reproductive health 
problems and pregnancies were more likely to end in miscarriage (Keegan, 
Learmonth, & Case, 2008) 
The first study to investigate neonate outcome after maternal MoM THR and to 
report serum metal-ion levels was published in 2004 (Brodner et al., 2004). In their 
case series, three fertile-aged women with 3 pregnancies were followed and blood 
samples analyzed at delivery. Maternal blood samples had slightly increased Cr and 
Co concentrations, but the umbilical cord samples had concentrations below their 
detection limits (DL). However, the samples were analyzed using atomic absorption 
spectrometry that detects low concentrations worse than the inductively-coupled 
plasma mass spectrometry used in the other studies (Case, Ellis, Turner, & Fairman, 
2001). One of the neonates in this study had major multiform anomalies that were 
considered hereditary because the mother had had two previous children with 
congenital anomalies.   
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Ziaee et al. (2007) contacted 100 fertile-aged patients that had MoM THR 
operated between 1997 and 2006. Of these women, 10 reported being pregnant and 
participated in the study. For these 10 patients, they selected 10 referents without 
metal implants and compared their maternal and umbilical cord blood metal-ion 
levels between groups. As suspected, the MoM THR group had higher metal-ion 
levels in the maternal blood and umbilical cord. None of the neonates had any 
congenital anomalies in this study. (Ziaee et al., 2007) Later, in 2014, Novak et al. 
published a case series of elevated maternal blood metal-ion levels during pregnancy. 
In their study, a reference group was also present and comparisons of Cr and Co 
levels were made during delivery for both maternal and umbilical cord blood in both 
groups. In this study, the MoM THR group’s metal-ion levels were higher than in 
the reference group without metal implants. No congenital anomalies were detected 
in this study. (Novak et al., 2014) Both of these studies reported similar transfer rates 
of metal-ions from maternal blood to umbilical cord blood but concluded that the 
placenta prevents the major passage of these ions. For example, in the reference 
group, the transfer rates were over 90% and in the MoM patients the placenta 
reduced the passage rates to between 10 and 50% (Novak et al., 2014; Ziaee et al., 
2007). In their case series, DeSouza et al. (2012) presented three mothers with MoM 
hip resurfacing arthroplasties without a reference group. Cr and Co ion levels were 
slightly higher than in the previous three studies, but the transfer rate was similar. 
No anomalies were detected, and all the neonates were reported to be healthy when 
released from hospital. (DeSouza et al., 2012) 
The highest metal-ion concentrations were reported by Fritzsche et al. (2012) in 
a case report. The Co concentration was 50 times higher than in any other previous 
case report of maternal samples, and Cr levels were 10 times higher. In this study, 
the transfer rates during delivery were similar to previous reports, and also led to 
higher fetal Co and Cr levels at birth. They also reported the Cr and Co levels of the 
children at 8 weeks of age. During those 8 weeks, Co levels had already decreased 
significantly from a high of 75 at the time of delivery to 13 at 8 weeks and Cr levels 
remained the same as those at birth (2.1 and 2.5).  No anomalies were detected in 
this study. (Fritzsche et al., 2012). Oppermann et al. (2015) present similar high levels 
of Co and Cr with similar transfer rates in their case report. They detected a neonate 
born with major congenital anomaly that needed surgical treatment later. This is the 
only study to present metal-ions concentrations in breast milk. Co levels were high 
in milk, but Cr levels were below detection limit, which was 1.0ng/ml. At 9 weeks 
postpartum, the child’s Co levels had decreased from 31 at birth to 10, but Cr levels 
continued to rise from 2.3 to 6.7 during the same period. (Oppermann et al., 2015) 
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All of these studies present similar transfer rates of metal-ions from the maternal 
blood to umbilical blood. The placenta prevents major passage of these ions. 
However, the modulatory rate of the placenta also has limits. The most important 
previously published literature regarding metal-ion levels in delivery and neonates 
are summarized in Table 1. 
Johnson et al. retrospectively contacted 48 female patients aged under 40 at the 
time of hip resurfacing MoM-arthroplasty operated between 1996 and 2010. A total 
of 8 women reported 17 pregnancies with 14 deliveries and 3 miscarriages. In this 
study, no information on maternal or umbilical cord metal-ion levels was available. 
Of those 14 neonates, none had any delivery related problems or congenital 
anomalies, and in later follow-up they were reported to have normal developmental 
status matching to their ages at the time of the survey (1 to 11 years). (Johnson, 
Woon, Le Duff, & Amstutz, 2013) 
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2.1.5 THR implant survival 
 
2.1.5.1 Reasons for failure 
In 2018, over 1 500 revision THRs were performed in Finland. The most common 
indications for revision THR in all age groups were as follows: infection (21.7%), 
dislocation (19.7%), periprosthetic femoral fracture (12.9%), aseptic loosening of the 
acetabular cup (11.7%), and adverse reaction to metal debris (ARMD) (11.1%).  The 
proportion of the revisions due to ARMD has decreased from 17.8% in 2014, 
whereas the proportion of revisions for infections (15.9% in 2014) and dislocation 
(12.4%) have increased. (THL, 2018c)  
According to a systematic review, which included 16 studies between 1965 and 
2011 with 115 patients aged under 30 years old at the time of primary THR, the most 
common indications for revision THR were aseptic loosening (60.9%), wear 
(12.2%), infection (10.4%), instability (5.2%), and femoral component fracture 
(3.5%). The review compared results before and after 1988 and the proportion of 
revisions due to loosening has decreased (70.7% before and 48.0% after). However, 
revisions due to instability (0% before and 12.0% after) and wear (3.1% before and 
24.0% after) have increased (Adelani et al., 2013). Another study that included 92 
patients under 30 years of age, compared revision indications for older patients (>60 
years) and found that risk for revision was similar for deep infections, aseptic 
loosening, and periprosthetic fractures. Risk for revision due to MoM implants also 
increased, mainly due to higher rates of MoM implants among very young patients. 
(Makarewich, Anderson, Gililland, Pelt, & Peters, 2018) In a Norwegian study, the 
most common reason for revision THR among extremely young (<20 years old) 
patients were aseptic loosening and wear (Tsukanaka et al., 2016). In a recent 
Scandinavian study, the most common revision indications for patients aged under 
21 years at the time of THR were aseptic loosening (52%), other (31%), luxation 
(9.3), deep infection (5.1%), and periprosthetic fracture (2.5%) (Halvorsen et al. 
2019). 
 
 35 
2.1.5.2 Young age and implant survival 
Very young patients at the time of primary THR have worse survival and clinical 
outcomes than older patients, although the results have improved over the decades 
(Adelani et al., 2013). Younger patients place higher demands on the THR due to 
higher activity levels, and therefore the implants have increased rates of aseptic 
loosening and more bearing wear (Clohisy, Calvert, Tull, McDonald, & Maloney, 
2004; Kearns, Jamal, Rorabeck, & Bourne, 2006). A New Zeeland study found that 
patients aged under 50 have a higher risk for revision THR than dying, whereas the 
risk is 50-50 for 58 year old patients, and at the age of 62 years the patient is already 
more likely to die before revision THR. Therefore, younger patients should be 
warned that revision THR is likely to be needed during their lifetime. (Wainwright, 
Theis, Garneti, & Melloh, 2011) 
For males under 55 years of age, implant survival rates in Finland were 10 years 
85.8 %, 15 years 75.1%, and 20 years 62.6%. For women, the survival rates were 
lower: 10 years 80.7%, 15 years 67.9%, and 20 years 56.0%. (THL, 2018c) An 
American study examined THR survival rates among patients aged under 35 years 
operated due to osteonecrosis of the hip. A total of 135 patients were included and 
implant survival rates were 85.6% at 10 years, 76.7% at 15 years, and 66.3% at 20 
years. In stratified analysis, patients aged under 25 years at the time of operation had 
decreased survival rates compared with those aged over 25 years (Swarup et al., 2017) 
Patients aged less than 20 years at the time of operation had a 70% implant survival 
rate at 10 years in a Norwegian register study (Tsukanaka et al., 2016). Another study 
surveyed implant survival of CoC THRs among patients aged less than 20 years at 
the time of the THR. They reported a 10-year survival rate of 90.3% (95% CI 82.4 
– 98.9). The number of patients included was 83 with 105 THRs, and the patients 
were operated between 1979 and 2013.  (Hannouche et al., 2016) A large register-
based study showed that every additional year of age at the time of THR decreased 
the risk for revision due to aseptic loosening by 1.8% (Münger, Röder, Ackermann-
Liebrich, & Busato, 2006). 
A study of the combined Nordic arthroplasty registers showed that the overall 
implant survival rates in patients under 21 years of age have decreased compared 
with older patients. The survival rates did not differ by the primary THR indication. 
Cemented and uncemented THRs had similar implant survivorship in this study. The 
overall implant survival rate was 86% at 10 years. (Halvorsen et al. 2019) 
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2.1.5.3 Factors affecting implant survival 
The diagnosis affects THR implant survival. A large Norwegian register study found 
that after adjustments the following diagnoses had the worse survival rates compared 
with primary osteoarthritis: fracture of the femoral neck, congenital dislocation, and 
a heterogenous group of rare diagnoses. (Furnes, O. et al., 2001) Patients diagnosed 
with developmental dysplasia of the hip have, for example, had lower implant 
survival than THRs operated due to any another diagnosis (Tsukanaka et al., 2016). 
Comorbid diseases also decrease implant survivorship (Jämsen, Peltola, Eskelinen, 
& Lehto, 2013). 
Fixation technique also has an impact on implant survivorship. Uncemented 
implants seem to have a decreased risk for aseptic loosening in the long-term 
compared with cemented and hybrid implants, but in the short-term, cemented 
implants were superior (Pedersen et al., 2014). A Swedish register study suggested 
that a cemented THR has better survival than an uncemented THR (Hailer, 
Garellick, & Kärrholm, 2010). In the Finnish arthroplasty register, the 10-year 
revision rates for cemented implants among patients under 55 years is 18.4% (95% 
CI 16.8 – 20.1%) and 17.0% (95% CI 16.4-17.7%) for uncemented implants (THL, 
2018c). 
Bearing couples were discussed in detail earlier in chapter 2.1.4.1. To sum up the 
literature on bearing couples, MoM implants have inferior mid- and long-term results 
compared with non-MoM implants, and MoM implants cause adverse local tissue 
reactions due to released metal-ions. CoC bearing couples have been reported to 
have excellent results in terms of implant survival, but patients report squeaking and 
noise from these implants (Salo, P. P. et al., 2017). Metal on polyethene implants are 
the most commonly used bearings, although the PE tends to wear. (López-López et 
al., 2017) However, the highly crosslinked PE has provided more promising results 
in terms of wear than traditional conventional PE, and therefore the MoXLP is the 
most used combination in contemporary THR (AOANJRR, 2019; Johanson et al., 
2017; NJR, 2018; SHAR, 2019; Teeter et al., 2017; THL, 2018c). 
Weight and height are not independently associated with poorer implant 
survivorship results. However, in a European study it was reported that one unit 
increase in BMI has an odds ratio (OR) of 1.03 (95% CI 1.00-1.05) for implant 
revision. (Münger et al., 2006) A Norwegian study reported that overweight is 
associated with a significantly increased risk of revision (RR) of 2.5 (95% CI 1.0–6.3) 
(Flugsrud, Nordsletten, Espehaug, Havelin, & Meyer, 2007). A German study also 
showed that a higher BMI decreases implant survivorship (Fuchs & Wieder, 2000). 
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An American study suggested that rates of revisions or implant removals and 
common complications after primary THR were strongly associated with BMI 
(Wagner, Kamath, Fruth, Harmsen, & Berry, 2016). Patients with a high BMI (over 
35) have worse PROMs after surgery compared with patients with a normal BMI 
(Wu et al., 2016). 
In Finland, women aged under 55 years have lower mid- and long-term implant 
survival rates than men. The same is also seen in older age groups in Finland. (THL, 
2018c). In a European multinational register study, women had a lower risk for 
revision due to aseptic loosening of the stem or cup (Münger et al., 2006). 
Patients with higher activity levels have a higher risk for implant revision due to 
aseptic loosening of the stem than those with lower activity levels (Münger et al., 
2006). Men have a higher risk for aseptic loosening of the implant, especially if the 
patient has high levels of physical activity (Flugsrud et al., 2007). Generally, patients 
with higher activity levels have similar survival rates, at least for the short- and mid-
term (Jassim, Douglas, & Haddad, 2014; Lübbeke et al., 2014). Patients are, however, 
more likely to reduce their sporting activities after joint replacement surgery (Jassim 
et al., 2014; K Huch et al., 2006; Ritter & Meding, 1987). 
 
2.1.5.4 Influence of pregnancy and delivery on THR survival 
Since pregnancy places stress on the pelvis and can cause, for example, transient 
osteoporosis of the hip and lead to spontaneous hip fracture (Asadipooya, Graves, 
& Greene, 2017; Beaulieu, Razzano, & Levine, 1976; Bhardwaj & Nagandla, 2014). 
Also breastfeeding changes bone metabolism and might reduce bone mass and cause 
transient osteoporosis leading to fractures (Holmberg-Marttila et al., 1999; Kovacs 
CS. 2014; Miyamato et al., 2019). A study conducted in Thailand suggested that bone 
density in hip would decrease after 4-6 months lactation (Teerapornpuntakit et al., 
2017). Especially if Vitamin D levels are low and BMI in not normal at the beginning 
of the pregnancy (Yoshikata et al., 2019). Recent studies however have suggested 
that breastfeeding does not reduce bone density and mass as much as previously 
suspected (Cooke-Hubley et al., 2017).  There has been a concern that pregnancy 
and delivery could decrease the survivorship of the THR. One concern has also been 
that during vaginal delivery the flexion of the hip as well as possible rotations during 
pushing might loosen or dislocate the hip (Sierra et al., 2005). Indeed, women have 
concerns that delivery and pregnancy might affect the THR negatively (Meldrum et 
al., 2003; Ostensen, 1993; Sierra et al., 2005).  
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The first proper study to focus on THR after delivery was a case series by 
McDowell et al. that presented five pregnant women with seven THRs having six 
successful pregnancies. The patients were compared to five matching THR patients 
without pregnancies. They surveyed PROMs, implant survivorship, and radiographic 
outcomes. No harm caused by delivery to the THR was detected during their eight-
year follow-up. This was the only study to also report radiographic outcomes after 
delivery. (McDowell & Lachiewicz, 2001) 
Yazici et al. published the first larger case series in 2003 where they retrospectively 
contacted fertile-aged women operated between 1981 and 1988. A total of 21 women 
reported to have been pregnant after THR and had 20 deliveries. None of the 21 
women reported any THR related problems. However, no long-term results or 
survival rates were reported. (Yazici et al., 2003) Similar results were reported by 
Meldrum et al. in 2003 in their 13 patient case series. They also evaluated PROMs 
after deliveries and found no decrease in implant survivorship or PROMs compared 
with THR patients without deliveries. (Meldrum et al., 2003) 
In 2003, the first and only case report of delivery possibly harming THR was 
published. In this case report, the patient became pregnant one year after primary 
THR. The THR was performed through a posterolateral approach, using a 
hydroxyapatite coated stem and cup with additional screws and autograft of the 
femoral head. During the pregnancy, the patient was evaluated by her orthopedic 
surgeon, and at three months gestation the hip was clinically normal. The orthopedic 
surgeon recommended vaginal delivery to avoid any possible wound infections. 
During delivery, extreme flexion and internal rotation should be avoided. For 
obstetric reasons, CS was performed. In the next control, four months postpartum, 
the THR had signs of aseptic loosening, which resulted in revision THR six months 
postpartum due to the loosening. No signs of infections were detected. The 
association between the pregnancy/delivery and aseptic loosening, however, 
remained speculative and unlikely. The next pregnancy and delivery did not harm 
the revised THR. (Boot et al., 2003)  
The largest study on THR survival after delivery was published in 2005. Sierra et 
al. presented a case series of 47 patients with 52 THRs who gave birth after THR. 
They retrospectively contacted all fertile-aged women who had undergone THR 
between 1975 and 1995. A Kaplan-Meier survival model was presented for the whole 
study population instead of a comparison between women who had delivered  
after THR and those who had not. This was the only study to present the implant 
survival results in a Cox model. In their study, delivery did not increase the risk for 
revision. Young age was the only significant factor decreasing implant survivorship 
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in their model of the following variates: preoperative diagnosis, type of implant, and 
age at the time of THR. Delivery method (CS vs vaginal) did not affect implant 
survivorship. They also reported that hip and groin pain that continued after 
pregnancy predicted revision THR compared to those who did not suffer pain after 
pregnancy. (Sierra et al., 2005) 
In 2007, Stea et al. published a case series of 14 patients to present THR results 
after delivery. The authors retrospectively contacted 143 fertile-aged (at the time of 
THR) women and used a telephone questionnaire to evaluate pregnancies after THR 
was performed. In total, 14 patients had 19 pregnancies after primary THR. In this 
small series, delivery did not harm the survival of the THR and only one of the 14 
THRs were revised during follow-up. Unfortunately, the authors did not report the 
follow-up period, nor did they report the results of the Cox regression model they 
conducted (Stea et al., 2007). 
The most recent study on this topic was published by Lally et al. in 2015. The aim 
of the study was to report the pain and function of the hip after delivery compared 
with THR patients without deliveries. The primary outcome was the Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and 
function scores. They compared results between three group: no pregnancies at all, 
pregnancy before THR, and pregnancy after THR. Only ten women reported 
pregnancy after THR. Interestingly, these ten women reported better or similar 
WOMAC scores in pain and function than those in the other groups. Implant 
survivorship was not discussed in this study. (Lally et al., 2015) The key findings and 
main results of all of the most important previously published literature are presented 
in Table 3. 
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2.2 Fertility 
 
2.2.1 Birth rate in Finland and the Nordic countries 
In 2017, the fertility rate per woman was 1.49 in Finland (THL, 2018d). This was the 
lowest rate since the 1970s. However, in the preliminary report for 2018, the decrease 
in the fertility rate has continued to a figure of 1.40, which will be the lowest rate 
ever recorded in Finland (Figure 3). The overall fertility rate has decreased in all 
Nordic countries following a small peak that occurred at the end of 2010. From 2000 
to 2010, the fertility rate had increased every year, but after 2010 the rate has 
decreased in all the Nordic countries. In 2016, the fertility rates for each Nordic 
country were Sweden 1.85, Iceland 1.8, Norway 1.72, Denmark 1.71, and Finland 
1.65. (Worldbank, 2018) 
 
 
Figure 3.  Fertility rate per woman in Finland from 1987 to 2018. The rate for 2018 is based on 
preliminary results. 
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2.2.2 Factors decreasing birth rate 
Although there are a lot of unknown factors that affect the choice to conceive, 
certain non-medical conditions are known to affect fertility. According to the 
findings of a large nationwide questionnaire, the most common reasons for delaying 
pregnancy among childless 20 to 34 year old men and women in Finland 
(Perhebarometri 2015) were no permanent partner, child restricting current lifestyle, 
low income level, young age, and insecure job situation. (Miettinen, 2015) 
Socioeconomic status affects birth rate. Historically, the birth rate has first 
declined in the highest socioeconomic classes before transitioning to the overall 
population. Eventually, however, the fertility rate has either decreased or increased 
in all classes. (Dribe et al., 2017) Among young Finnish women, parents who are 
from a lower socioeconomic class predict a higher fertility rate compared to those 
from the upper classes (Väisänen & Murphy, 2014). Women with a higher level of 
education in Finland have a lower fertility rate according to a birth cohort study. The 
same study also presented that higher parental socioeconomic class and higher 
standard of living during childhood also led to lower fertility. (Nisén, Myrskylä, 
Silventoinen, & Martikainen, 2014) 
In Finland, women and men with higher levels of income have a higher preferred 
ideal family size than those who earn less. For example, in the lowest income group, 
20% wanted no children at all. (Miettinen, 2015) Interestingly, a nationwide study 
estimated that a higher minimum wage would decrease fertility among adolescents 
in the US (Bullinger, 2017). This finding along with the findings of Väisänen & 
Murphy shows that the fertility pattern among adolescents differs greatly from that 
of older persons.  
Smoking, alcohol, and obesity decrease male fertility (Fullston, McPherson, 
Zander-Fox, & Lane, 2017). Smoking decreases semen quality and decreases the 
success rate of fertility treatments (Kovac, Khanna, & Lipshultz, 2015). Women 
receiving fertility treatments have a significantly lower rate of smoking, which 
indicates that women having fertility problems are motivated to conceive (Tong et 
al., 2016). Women who currently smoke have a lower number of children than those 
who have never smoked or have stopped smoking (Oboni, Marques-Vidal, 
Bastardot, Vollenweider, & Waeber, 2016). 
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2.2.3 Chronic diseases and fertility 
The prevalence of the most common chronic diseases among fertile-aged women 
and men in Finland according to the reimbursement statistics of Kela are shown in 
Table 4 (interactive open access databases of Kela (www.kela.fi) and Tilastokeskus 
(www.tilastokeskus.fi)). The most common chronic diseases among pregnant 
women in Finland are asthma, hypothyroidism, epilepsy, RA, and DM. (Artama et 
al. 2011) 
DM especially affects male fertility since it has negative effects on reproductive 
functions, such as erectile dysfunction due to vascular and neural problems, 
ejaculatory dysfunction, and hypogonadism. For women, the reproductive problems 
include hypogonadism, dyspareunia, polycystic ovarian syndrome, and menstrual 
dysfunction. (Gandhi et al., 2017) A Finnish cohort study analyzed the birth rate in 
patients with childhood-onset type 1 DM and found that both men and women had 
a lower probability for offspring. They also presented that younger age at the time 
of diagnosis decreases fertility (Sjöberg et al., 2013). Fertility rates were analyzed pre 
and post type 1 DM diagnosis in a Taiwanese study, where a diabetic group had 
significantly lower rates of live births both before and after diagnosis compared with 
a reference group (Lin et al., 2018).  
RA decreases female fertility (Hargreaves, 1958; Katz, 2006; Skomsvoll, 
Ostensen, Baste, & Irgens, 2001; Wallenius et al., 2011). Large Scandinavian cohort 
studies have shown that RA patients have a lower number of births, a longer 
interpregnancy interval, a shorter reproductive time span, and lower fertility rates 
compared with women without RA (Skomsvoll et al., 2001; Wallenius et al., 2011). 
In a retrospective cohort study, time to pregnancy from the start of attempting was 
over 12 months in 42% of RA patients, which is much higher than the rate (20%) in 
the general population. Disease activity, the use of NSAIDs, and a prednisone dose 
over 7.5 mg per day were all risk factors for delayed pregnancy. (Brouwer, Hazes, 
Laven, & Dolhain, Radboud J. E. M., 2015) The most common reasons for fertility 
problems among RA patients in a study of 71 cases were unexplained subfertility, 
anovulation, and male factor. Fertility treatments seemed to be effective for RA 
patients. (Brouwer, Fleurbaaij, Hazes, Dolhain, Radboud J. E. M., & Laven, 2017) 
There is an increasing number of studies suggesting that asthma decreases 
fertility. A large Danish twin study showed that asthma was an independent risk 
factor for lower fertility and prolonged time to pregnancy, especially if the asthma 
was untreated (Gade, Elisabeth J. et al., 2014). A higher proportion of pregnancies 
involve fertility treatment among asthmatic women than non-asthmatic women 
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(Vejen Hansen et al., 2019). Asthmatic women also have worse outcomes in fertility 
treatments than those without asthma (Gade, Elisabeth Juul, Thomsen, Lindenberg, 
& Backer, 2016). 
It has been suggested that hypotyroidism decreases fertility; however, once 
treated, the fertility should be normal (Mintziori, Kita, Duntas, & Goulis, 2016). A 
Danish cohort study presented that higher TSH, TPOAb levels, and also mild 
(sub)clinical hypothyroidism could impair fertility (Anne-Dorthe Feldthusen et al., 
2015). The screening and treating of mild hypothyroidism or subclinical 
hypothyroidism during pregnancy or during the time attempting pregnancy remain 
under discussion, and further studies are needed to address the role they play 
(Medenica et al., 2015; Usadi & Merriam, 2016). 
Obesity has been shown to adversely affect male and female fertility. Obesity 
decreases male semen quality by decreasing the sperm count, reducing sperm 
mobility, and causing DNA damage to the sperm (Jensen et al., 2004; Kort et al., 
2006; Martini et al., 2010) In women, obesity causes a chronic low-grade 
inflammatory state which may lead to endocrine dysfunction and subfertility 
(Broughton & Moley, 2017; Chandrasekaran & Neal-Perry, 2017). Obese women 
also have more menstrual dysfunction, delayed conceptions, and a lower rate of 
successful fertility treatments (Brewer & Balen, 2010; Silvestris, de Pergola, Rosania, 
& Loverro, 2018).  
There are some controversial findings that suggest epilepsy may affect fertility 
rates. A previous Finnish register-study showed that women with epilepsy had a 
lower birth rate than women without epilepsy (Artama, M et al., 2004). However, 
another study suggested that epilepsy does not decrease fertility rates and that 
patients have a similar time to pregnancy compared with women without epilepsy 
(Pennell et al., 2018). 
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2.2.4 THR and sexual functions 
The first discussion on sexual functions after THR was already presented in 1979, 
when Baldursson et al. contacted 44 married THR patients. Questionnaires revealed 
that 28 of the 44 patients had sexual problems prior to THR due to hip problems. 
After THR, 27 patients of the 28 reported that the hip was no longer a problem in 
terms of their sexual life. (Baldursson & Brattström, 1979) In 1991, this problem was 
addressed and a guide booklet on intercourse after THR was written. The study 
revealed that males were faster to return to sexual activities after THR compared 
with females. The preferred positions for males were bottom and for females 
sideways on the non-operated hip. (Stern et al., 1991) 
In a Korean cohort, the most common concern towards intercourse after THR 
was the fear of THR dislocation during sex, which led to increased stress levels 
during sex (Yoon, B. et al., 2013). In later reviews, the supine (bottom/top) position 
is referred to as the safest coital position after THR (McFadden, 2013). Charbonnier 
et al. conducted an interesting study where they motion captured 12 of the most 
common sexual positions and 3D tested them for dislocation and impingement of 
the hip in a computer model. They found that intensive flexion (over 95 degrees) for 
women and external rotation (over 40 degrees) for men in a few positions were 
potentially harmful for the implant (Charbonnier et al., 2014). 
Since sexual activity was a problem for 46% of the patients prior to surgery and 
for only 1% after, THR has resulted in major improvements in sexual life. (Stern et 
al., 1991). A prospective cohort study has shown that nearly 50% of females under 
the age of 60 at the time of THR experienced increased intercourse frequency and 
that more positions were possible after THR than before (Klit et al., 2015). Another 
study reported similar findings and also suggested that women benefited more from 
THR regarding sexuality activities than men (Laffosse, Tricoire, Chiron, & Puget, 
2008). Wang et al. reported that THR increases male sexual satisfaction but not that 
of the partners of male patients (Wang, Yue, Liu, & Guo, 2014). In a review where 
12 studies were analyzed, the main outcome was that there is moderate evidence that 
THR improves the sexual quality of life among patients of all ages at the time of 
THR (Harmsen et al., 2016). Furthermore, the type of implant does not have any 
impact on sexual activity or functions (Nunley et al., 2015).  
In a questionnaire study in England, 55% of hip surgeons estimated that four 
weeks would be the optimal time to continue intercourses after THR (Wall, Hossain, 
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Ganapathi, & Andrew, 2011). However, surgeons were unlikely to discuss this topic 
with patients before THR. The most common reason for this was that: “patients 
don’t ask about it”, or: “I am not aware of the problem”. Experienced surgeons 
were, however, more likely to discuss the topic with the patient. (Harmsen et al., 
2017) In 2017, Issa et al. published their review study on this topic and presented 
the following results: 44% of THR patients reported improved sexual satisfaction, 
27% of the patients reported increased intercourse frequency, and 86% of hip 
surgeons reported rarely or never discussing sexuality with patients (Issa et al., 2017). 
 
2.3 Induced Abortions 
 
2.3.1 Induced abortions in Finland and elsewhere 
In 2017, 9 360 induced abortions (IAs) were performed and registered in Finland. 
IAs are procedures started by a gynecologist in hospitals in Finland, although the 
medical IA can and is usually done after evaluation at home. To have a pregnancy 
ending in IA, a statement from two doctors is required. The abortion rate in 2017 
was 8.2 IAs per 1 000 fertile-aged (15-49 year old) females. The overall IA rate has 
decreased every year and the rate in 2017 was the lowest since 1970. (Figure 4) The 
highest rate in Finland was among 20 to 24 year olds (14.7/1000), but the rate has 
decreased from previous reports, and the current rate has decreased by 4.1% in 
comparison to 2016. Of the women who underwent IAs, 38% had one or more 
previous IA, and 7.6% had had an IA in 2016. (Raskaudenkeskeytykset - THL 2018) 
 According to the World Health Organization’s statistical report, from 2010 to 
2014, Finland had the fifth lowest IA rate. The lowest rate was in Switzerland (5 per 
1 000 women aged 15-49). (WHO, 2018) Compared to other Nordic countries, 
Finland has the lowest IA rate and Sweden has the highest IA rate (17.6 IAs per 
1 000 fertile-aged women) (THL, 2017). Worldwide, the IA rate among females aged 
15 to 44 was 29 per 1 000 in 2003, which means a total of 42 million IAs. Of those, 
48% were unsafe and most of the unsafe IAs occurred in developing countries. 
Europe has generally the lowest IA rates (12 to 18 per 1 000), except for Eastern 
Europe that has one of the highest IA rates. In eastern Europe, 105 IAs were 
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performed for every 100 livebirths. (Sedgh, Henshaw, Singh, Ahman, & Shah, 2007) 
Between 2010 and 2014, the IA rate worldwide was 35 per 1 000 among 15 to 44 
year old females. The rate was higher in the developing countries (36 per 1 000) than 
in the developed countries (27 per 1 000). The present trend is that the IA rate will 
decrease in developed countries but remain stable in the developing countries. 
(WHO, 2018)  
In 2017, the most common indication for IA in Finland was social reasons 
(92.5%) followed by termination due to detected / suspected fetal anomaly (3.8%), 
age over 40 (3.3%), 4 or more previous children (2.4%), and age under 17 (1.9%). 
Most of the IAs were performed before the 12th gestational week, and of those, 
62.2% were early (before 8th gestational week) IAs. At the time of the IA, 51.7% of 
these women had not previously borne offspring. The most common contraception 
method among IA patients was condom following no contraception. Most patients 
planned to have long acting reversible contraception after IA. 
(Raskaudenkeskeytykset - THL 2018) 
 
 
 
 
Figure 4.  Rate of Induced abortions (IA) per 1 000 similar-aged women in Finland from 1975 to 
2017. Our study period (1987 to 2007) highlighted with white background.  
Modified from the original publication: THL statistical report, Induced Abortions 2017, 
https://thl.fi/fi/tilastot-ja-data/tilastot-aiheittain/seksuaali-ja-
lisaantymisterveys/raskaudenkeskeytykset/raskaudenkeskeytykset  
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2.3.2 Risk factors for pregnancy ending in induced abortion 
There are a few known risk factors for pregnancy ending in IA. One of the most 
common risks is unintended pregnancy, which leads to IA in 56% of pregnancies. 
Although the rate of unintended pregnancies has decreased, especially in developed 
countries, the proportion of those ending in IA has remained the same (WHO, 
2018).  
Young age (under 19) has been shown to be a high-risk factor for IA (Rasch et 
al., 2008). Teenagers in lower socioeconomic class were more likely to become 
pregnant and have an IA compared with those in higher socioeconomic classes in a 
Finnish birth cohort study (Väisänen & Murphy, 2014). In their study, Leppälahti et 
al. reported that repeat IAs among teenagers increased by 95% (18-19 years old) and 
120% (16-17 years old) in Finland between 1993 and 2009 (Leppälahti, Gissler, 
Mentula, & Heikinheimo, 2012). First intercourse before the 18th birthday was a risk 
factor for later IA in a Russian / Estonian / Finnish population comparison study 
(Regushevskaya et al., 2009).  
Socioeconomic status has a major impact on pregnancy ending in IA or delivery. 
According to a Danish study, the highest risk factor for pregnancy ending in IA is 
single-status. Unemployment and student status also increased the risk for IA, mainly 
due to lower income level (Rasch et al., 2008). Lower income compared to higher 
income increases the risk for IA. (Jones, Darroch, & Henshaw, 2002) In Finland, 
women with basic level education had a higher IA risk compared with women who 
had higher educational levels (Väisänen, 2015). A low level of education was also a 
risk factor for repeat IA (Väisänen, 2016).  
Other risk factors for repeat IA, according to another Finnish cohort study, are 
parity and previous IA. However, age over 25 and intrauterine contraception are 
decreasing the risk factors for IA. (Heikinheimo, Gissler, & Suhonen, 2009) The 
immediate initiation of contraception after IA reduces the rate of repeat IA, and 
intrauterine contraception is the most effective in reducing repeat IA (Heikinheimo, 
Gissler, & Suhonen, 2008). The benefits of intrauterine contraception implanted 
immediately after IA were supported in a RCT, where the study group received 
intrauterine contraception and had significantly fewer numbers of IAs during the 
follow-up (Pohjoranta, Mentula, Gissler, Suhonen, & Heikinheimo, 2015). Short 
time from previous delivery is also a risk factor for IA, and therefore family planning 
should also be provided after delivery (Vikat, Kosunen, & Rimpela, 2002). It can be 
therefore concluded that short interpregnancy intervals should be avoided. 
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The use of contraception in the Nordic countries is relatively easy due to liberal 
attitudes towards reproduction. Hognert et al. presented in their study that lower 
contraceptive use among 20 to 24 year olds in Sweden resulted in higher IA rates 
compared with Denmark and Norway. (Hognert et al., 2017) The same was seen in 
an earlier postal survey study, where insufficient use of contraception was suggested 
to be the reason for high IA rates (Regushevskaya et al., 2009). In Finland, many 
cities provide free contraception for women aged under 25, since they are at the 
highest risk, and contraception decreases the IA rate (Gyllenberg, Saloranta, But, 
Gissler, & Heikinheimo, 2018) as well as being cost-effective (Cleland, Peipert, 
Westhoff, Spear, & Trussell, 2011). 
 
2.3.3  Chronic diseases and induced abortion 
No studies have been carried out on THR patients’ risk of pregnancy ending in IA. 
A major proportion (20 to 49%) of young THR patients suffer from RA (see chapter 
2.1.2.2), and therefore chronic diseases were taken as part of this present study, since 
chronic diseases have been shown to affect reproduction. The impact of RA on 
reproduction is mainly due to the medications used to treat the disease. For example, 
methotrexate increases the risk for congenital malformations. However, Vinet et al. 
compared the rate of induced abortions among RA patients using methotrexate with 
patients using biological medications. The results of the study showed that 
methotrexate users had a lower rate of IAs. Moreover, the overall IA rate among RA 
patients was similar to national levels in this study. (Vinet, E., Kuriya, Pineau, Clarke, 
& Bernatsky, 2013) 
Women with asthma have a higher risk for spontaneous abortion, but not for IA 
generally. Women with uncontrolled asthma have a higher risk for both spontaneous 
and induced abortion. (Blais et al., 2013) One smaller previous study showed that 
severe asthma would increase IA rates (Tata et al., 2007). 
A few studies have discussed IA in patients with diabetes mellitus (DM). A 
Danish study reported that IA was not more common among women with DM 
(Kjaer et al., 1992). However, another Danish study suggested that patients with type 
1 DM had increased rates of spontaneous and induced abortions (Lorenzen, Pociot, 
Johannesen, Kristiansen, & Nerup, 1999). An Italian prospective cohort study 
showed no increase in spontaneous or induced abortions among women with either 
type 1 or type 2 DM (Lapolla et al., 2008) 
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A recent study reported that chronic diseases were not risk factors for 
complications in uterine evacuation IA compared with women without 
comorbidities. Furthermore, there was no evidence to suggest that any specific 
comorbidity would increase the complication risk either. Therefore, the authors 
concluded that surgical IA is safe among women with chronic diseases (Guiahi, 
Schiller, Sheeder, & Teal, 2015) 
 
2.4 Pregnancy and delivery 
 
2.4.1 Pregnancies and deliveries in Finland 
In 2017, there were 50 151 deliveries in Finland of which 99.5% occurred in 
hospitals. Outside hospital deliveries have increased because the number of delivery 
hospitals has been reduced. In 1991, there were 49 delivery hospitals but only 25 
remained in 2017. Furthermore, 7 of the 25 did not fulfil the criteria for delivery 
hospitals of a minimum 1 000 deliveries per year. Of the total outside hospital 
deliveries, 93 deliveries occurred on the way to hospital and an additional 87 were 
otherwise unplanned outside hospital births. (THL, 2018d) 
The mean age at delivery was 30.9 years for all deliveries and 29.2 for primiparas. 
In recent years, parturient age has increased in all Nordic countries. The mean BMI 
before the pregnancy was 24.8. Over a third of parturients were overweight. 
Gestational diabetes was diagnosed for 16% of women during pregnancy. In 
Finland, smoking during pregnancy has decreased in recent years, and in 2017 only 
12.5% of women smoked during early pregnancy.  Similar trends can be seen in all 
Nordic countries. (THL, 2018d; THL, 2018f) 
The overall proportion of caesarean sections (CS) has been 16 to 17% for the 
past 20 years. However, only 5% are emergency sections. CS is more common 
among older (over 35 years of age) primipara women. During delivery, the most 
common analgesia used were nitrous oxide (53.5%), epidural (50%,) and spinal 
(20%). Non-pharmaceutical pain relief was common, and almost 40% of the women 
used it. Only 7.8 % of women did not use any analgesia during delivery. (THL, 
2018d)  
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2.4.2 Delivery methods, briefly 
The most common vaginal delivery position is the “supine” position in which the 
woman lays on her back on the delivery table and the legs are rested in flexion 
position to gain better push and angle to the pelvis. However, there are plenty of 
possible vaginal delivery positions including either lying down or upright positions. 
There are RCTs and a Cochrane review that suggest upright positions are equally as 
safe to the lying down positions (Gupta, Sood, Hofmeyr, & Vogel, 2017; Thies-
Lagergren, Kvist, Christensson, & Hildingsson, 2011; Thies-Lagergren, Kvist, 
Christensson, & Hildingsson, 2012; Zhang et al., 2017). Moreover, the upright 
positions may reduce perineal traumas and the delivery can be faster requiring less 
assistance, but they may also lead to higher blood loss (Gupta et al., 2017).   
CS can be divided into planned and unplanned. The most common reasons for 
elective CS are abnormal fetal positions, small pelvis, previous CS, early 
preeclampsia, and the fear of vaginal delivery. The most common indications for 
unplanned emergency CS are fetal bradycardia, umbilical cord prolapse, and 
placental ablation. The goal of emergency CS is to have the neonate born within 10 
minutes after the CS decision has been made. Therefore, emergency CS is done 
under general anesthesia, whereas planned CS is performed under regional 
anesthesia. (Tapnainen, Heikinheimo, & Mäkikallio, 2019) Planned CS is usually 
performed by horizontal incisions (Phannenstiel or Joel-Cohen). Emergency CS is 
done vertically. (Salo, H., Tekay, & Mäkikallio, 2015) 
2.4.3 Chronic diseases and pregnancy / delivery 
The most common long-term diseases among fertile-aged women in Finland are 
presented in Table 3. The diseases with the highest prevalence are Asthma, DM, 
rheumatoid diseases, and major psychiatric diseases. The most common long-term 
diseases among pregnant women in Finland, according to a previous study, are 
asthma, hypothyroidism, epilepsy, RA, and DM. (Artama, Miia et al., 2011). In a 
German population-based study, the highest prevalence was recorded for allergies, 
metabolic disorders, asthma, chronic nervous diseases, and chronic skin diseases. 
This study concluded that women with any chronic disease have a higher risk for 
adverse pregnancy outcome than those with non-chronic diseases (Kersten et al., 
2014).  
There are only a few chronic diseases in which the pregnancy is contraindicated 
due to an increased risk of death during pregnancy. Mostly, these diseases are heart 
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diseases which may greatly increase maternal mortality during pregnancy, delivery, 
and postpartum care (Siu & Colman, 2001). For example, maternal mortality has 
been 30 to 50% in pulmonary vascular diseases (Weiss & Hess, 2000).  
In one third of asthmatic women, the symptoms get worse during pregnancy, for 
one third the symptoms remain the same, and one third have fewer symptoms 
(Schatz et al., 1988). Asthma increases the risk for hypertension during pregnancy, 
preterm delivery, and CS (Källén, Rydhstroem, & Aberg, 2000; Murphy, Vanessa E., 
Jensen, & Gibson, 2017; Shaked, Wainstock, Sheiner, & Walfisch, 2019). A 
nationwide Swedish cohort study found that asthmatic women have a higher risk for 
preeclampsia, premature labor, and placental abruption (Rejnö et al., 2014). Asthma 
exacerbations during pregnancy are associated with higher adverse pregnancy 
outcomes (Ali, Hansen, & Ulrik, 2016). 
Pregestational DM increases risk related to pregnancy and delivery. There is no 
difference in risk for pregnancy between type 1 and type 2 DM mothers. (Sato et al., 
2014) However, women with pregestational DM have a higher risk for CS (Berger 
et al., 2016; Ehrenberg, Durnwald, Catalano, & Mercer, 2004). PDM increases the 
risk for hypertensive pregnancy disorders and preeclampsia (Berger et al., 2016; Sibai, 
B. M. et al., 2000; Sibai, Baha M., 2002).  
Rheumatoid diseases do not substantially increase the risk for adverse pregnancy 
outcomes, and RA symptoms are relieved in the majority of the women during 
pregnancy (Nelson & Ostensen, 1997). However, women with RA have higher rates 
of CS than women without RA (Aljary, Czuzoj-Shulman, Spence, & Abenhaim, 
2018; Bowden, Barrett, Fallow, & Silman, 2001; Wallenius, Salvesen, Daltveit, & 
Skomsvoll, 2014). Women with RA have a higher risk for preeclampsia and 
hypertension during pregnancy (Aljary et al., 2018; Wallenius et al., 2014). 
Maternal pre-pregnancy obesity increases the risks relating to pregnancy and 
delivery (Marchi, Berg, Dencker, Olander, & Begley, 2015). Obese women have 
higher risks for gestational hypertension, preeclampsia, GDM, and CS delivery 
(Gaillard et al., 2013; Vernini et al., 2016; Vinturache, Moledina, McDonald, Slater, 
& Tough, 2014). Obesity increases the risk for induced deliveries and emergency CS 
(Reiss et al., 2016; Vinturache et al., 2014). Obesity also increases the risk for 
complications after CS (Vegel, Benden, Borgert, Kallies, & Kothari, 2017). 
Epilepsy increases the risk for adverse pregnancy outcomes. Epileptic women 
also have a higher risk for CS delivery (Artama, Miia et al., 2017; Razaz, Tomson, 
Wikström, & Cnattingius, 2017; Viale et al., 2015) and are more likely to have 
preeclampsia, hypertension, placental problems, infections, and ante/postpartum 
hemorrhage (Razaz et al., 2017; Viale et al., 2015).  
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2.4.4 Delivery after THR 
 
The first case reports on delivery and pregnancy after THR were published already 
in the 1970s and 80s. These reports reported successful pregnancies and deliveries 
among women with THR, where THR did not affect delivery or pregnancies. 
(Monaghan, Lenehan, Stronge, & Gallagher, 1987; Reckling, 1976; Wittich, 1982) In 
the 1990s, Ostensen described the first problems with deliveries after THR. In a case 
series of eight women who underwent THR due to RA, all eight deliveries were CS 
due to the concern that vaginal delivery could adversely affect implant survivorship. 
(Ostensen, 1993) In later studies, Meldrum et al. (2003) presented a lower CS 
proportion than Ostensen, but four of the eight CS deliveries were performed due 
to the patients fear of vaginal delivery harming the THR. Additionally, Stea et al. 
(2007) had a 92.9% CS proportion in their case series. Of the 14 deliveries, 13 were 
CS. The CS deliveries were performed because of the preferences of obstetricians 
for planned cesareans due to THR. Furthermore, the authors explain the higher CS 
rate by the country’s higher CS rate compared to those in previous studies, and that 
women with developmental dysplasia of the hip have reduced pelvic size. (Stea et al., 
2007) 
Lower CS rates were presented in a majority of the previous studies. Yazici et al. 
presented 20 deliveries and six of those were CS. Moreover, they concluded that 
THR does not have an impact on pregnancy and delivery. (Yazici et al., 2003) By far 
the largest study on this topic also had similar rates of CS after THR to national 
levels. Sierra et al. (2005) had 47 singleton deliveries in their retrospective case series 
and 17 of those were CS. They concluded by stating that THR does not seem to 
adversely affect pregnancy or delivery. (Sierra et al., 2005) Yoon et al. reported similar 
findings to these previous studies in their case series of 16 deliveries and seven CS 
(Yoon, H. J. et al., 2012). However, none of the previous studies have had a reference 
group. Hence, all the pregnancy and delivery results have been compared to national 
statistics. 
The latest study (Lally et al., 2015) was the first to compare pre-THR and post-
THR pregnancies and deliveries. However, in their study, no reference group 
without THR is presented. The study suggested that THR does not affect pregnancy 
or delivery method compared with pre-THR pregnancies. (Lally et al., 2015) In all of 
the previous studies, the CS proportion among women with THR has been higher 
compared with Finnish standards, even though vaginal deliveries after THR have 
been stated to be safe. The results of the previous studies are summarized in Table 
5.  
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2.5 Neonates 
 
2.5.1 Neonates in Finland 
In 2017, 50 854 neonates were born in Finland. Of these, 50 710 (99.7%) were born 
alive and only 144 were stillbirths. Most of the neonates (99.5%) were born in 
hospital. The perinatal death rate (comprising those born dead or died during first 
week after delivery) in 1987 was 8.7 / 1 000 births. This figure decreased to 5.9 / 
1 000 births in the early 2000s and 3.9 / 1 000 births in 2017. The rate of preterm 
birth has also decreased in recent years and 5.3% of births were preterm. The rate of 
low-birth-weight (LBW) (4.3%) and very-LBW neonates (0.7%) has remained stable. 
Mean birth-weight was 3 554 grams for boys and 3 439 grams for girls. At the age of 
one week, 93.5% of the neonates were at home in 2017, whereas the proportion in 
1987 was only 75.9%. (THL, 2018d) 
 
2.5.2 Maternal chronic diseases and neonate birth outcome 
Maternal obesity increases the risks for intrauterine growth restriction and SGA 
infants, but also for LGA infants. Obesity also increases the risk for preterm delivery 
due to obesity related pregnancy complications. (Chandrasekaran & Neal-Perry, 
2017; McDonald, Han, Mulla, & Beyene, 2010; Torloni et al., 2009) Obesity increases 
the risk for LGA infants and the risk for childhood obesity (Gaillard et al., 2013). 
Children born to obese mothers had later hospital discharge after delivery compared 
with non-obese mothers (Vernini et al., 2016). Obese women also have a higher risk 
for stillbirth and fetal death (Aune, Saugstad, Henriksen, & Tonstad, 2014; Flenady 
et al., 2011). Obese mothers are also less likely to breastfeed and to quit breastfeeding 
earlier (Turcksin, Bel, Galjaard, & Devlieger, 2014). 
Maternal asthma is an increased risk for preterm delivery but not for adverse 
neonatal outcomes, according to a large Israeli cohort study (Shaked et al., 2019). An 
older Swedish register study showed that women hospitalized due to asthma before 
pregnancy had a higher risk for stillbirth than those without asthma (Källén et al., 
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2000). A Canadian population-based register study found that maternal asthma 
increased the risk for perinatal mortality, mainly because more of these neonates 
were preterm and SGA (Breton et al., 2009). Neonates born to mothers with asthma 
had a higher risk for infant hypoglycemia  (Ali et al., 2016; Källén et al., 2000). 
Maternal pregestational DM increases the risk for adverse neonatal outcomes. 
The perinatal mortality rate, for example, is increased by up to five-fold compared 
with non-diabetic pregnancies (Colstrup, Mathiesen, Damm, Jensen, & Ringholm, 
2013; Eidem, I. et al., 2011; Galindo, Burguillo, Azriel, & Fuente, 2006; Lauenborg 
et al., 2003; Mathiesen, Ringholm, & Damm, 2011). Neonates with maternal 
pregestational DM are more likely to be born preterm and to be SGA or LGA 
compared with neonates without maternal pregestational DM. (Colstrup et al., 2013; 
Eidem, I. et al., 2011; Macintosh et al., 2006; Sibai, B. M. et al., 2000). These adverse 
events can be minimized with good preconception care and optimal glycemic 
control, which requires adjustments during pregnancy (Sugrue & Zera, 2018).  
A previous study reported that neonates born to mothers with active RA during 
pregnancy had significantly lower birthweight that those with RA in remission or 
with no RA (Bowden et al., 2001). Another study found that neonates were more 
likely to be born preterm and that RA activity during pregnancy did not have an 
impact on this finding, with 28% of the neonates born preterm (Langen, 
Chakravarty, Liaquat, El-Sayed, & Druzin, 2014). Larger cohort studies have also 
confirmed the finding of an increased risk for preterm birth and SGA (Aljary et al., 
2018; J.F Skomsvoll, V Baste, M Østensen, L.M Irgens, 1999; Wallenius et al., 2014). 
Stillbirth and neonatal death rates are not, however, increased in RA pregnancies 
(Aljary et al., 2018; Eudy, McDaniel, & Clowse, 2018; J.F Skomsvoll, V Baste, M 
Østensen, L.M Irgens, 1999; Wallenius et al., 2014) 
Pregnancies complicated by epilepsy have a higher risk for adverse neonatal 
outcome (Soontornpun, Choovanichvong, & Tongsong, 2018). Indeed, in a Finnish 
cohort study, maternal epilepsy increased the risk for SGA neonate, admission to 
neonatal intensive care unit, and need for respiratory care (Artama, Miia et al., 2017). 
In addition, a Swedish cohort study showed an increased risk for stillbirth, SGA, 
neonatal infections, preterm birth, asphyxia, low Apgar scores, and hypoglycemia 
(Razaz et al., 2017).  
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2.5.3 Maternal THR and neonates 
The first reports on healthy neonates born to mothers with THR were published in 
the 1970s and 1980s. Three case reports described successful births with healthy 
neonates after maternal THR. (Monaghan et al., 1987; Reckling, 1976; Wittich, 1982) 
Ostensen (1993) published the first case series in which eight healthy neonates were 
born by CS for mothers with THR due to RA. 
Since then, five more case series and one cohort study have investigated neonates 
after THR. Yazici et al. (2003) only reported that 20 healthy neonates were born 
between 1981 and 1988 in their case series and provided less precise information 
than the other studies. Meldrum et al. reported 20 pregnancies with 19 deliveries 
from 1981 to 2000 in their series. There was one emergency CS due to the 
transposition of the child in the uterus that did not affect the neonate outcome. One 
neonate suffered from Rh immunization, but overall the THR seemed to not affect 
neonate outcome. (Meldrum et al., 2003) The largest previous study, with 47 
pregnancies, focused mainly on delivery method and prosthesis survival. The authors 
state that all of the 47 pregnancies had successful outcome, which indicates that all 
the neonates were born healthy. 
Stea et al. were the first to report more specific results of the neonates born after 
maternal THR. They reported 14 successful livebirths. Of the 19 deliveries, only one 
was preterm and no adverse birth outcomes were detected. The mean birthweight 
and height did not differ from the national means. Breastfeeding was successful 
among all the mothers who wanted to breastfeed. (Stea et al., 2007) 
None of these previous studies had a reference group. Furthermore, only one 
study compared pre- and post-THR pregnancy outcomes. Ten pregnancies occurred 
after THR and 82 before THR. Nine singletons and one pair of twins were born and 
all of them were reported to be healthy. The mean birthweight did not differ from 
the national means. One of the deliveries was classified as complicated, but the 
outcome was not adverse. (Lally et al., 2015) 
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2.6 Congenital anomalies 
 
2.6.1 Congenital anomalies in Finland 
In 2014, 2 822 major congenital anomalies were diagnosed in Finland. The rate of 
major congenital anomalies was 546/10 000 live or stillborn neonates. The rate has 
been stable for the past few years. Termination of pregnancy was preformed due to 
detected fetal anomaly in 357 pregnancies. Of the liveborn neonates, 4.9% had major 
congenital anomalies, and 17.6% of the stillborn neonates had one or more major 
anomaly. (THL, 2018a) 
The most common anomalies in Finland in the 21st century have been trisomy 21 
(27.6 cases per 10 000 neonates), cleft palate (15.0), limb reduction defect (12.3), cleft 
lip without or with cleft palate (10.8), and coarctation of the aorta (10.3). Some 
anomalies are more lethal than others. A high percentage of the following anomalies 
lead to stillbirth: anencephaly (42.3% were stillbirths out of all births with this 
anomaly), trisomy 18 (36.0%), bilateral renal agenesis (23.5%), and trisomy 13 
(16.1%). The proportions of infantile deaths out of all births with the anomaly for 
the most lethal anomalies in Finland were as follows: anencephaly (100.0%), bilateral 
renal agenesis (94.9%), trisomy 13 (91.5 %), trisomy 18 (85.7%), and hypoplasia of 
left heart syndrome (45.5 %). (THL, 2018a) 
In Finland, women are screened for congenital anomalies during pregnancy. 
Three screening options are available for families. The first is to not participate in 
any of the screenings, which are voluntary. The second is to participate in 
ultrasonography screening, but not in chromosomal screening, in which the 
ultrasound is performed in gestational weeks 10+0-13+6. The third and the best 
option is to participate in both the ultrasound and chromosomal screening. In 
gestational weeks 9+0-11+6, a blood serum sample for chromosomal risks is taken, 
and then in gestational weeks 11+0-13+6 ultrasound in performed. Then, the results 
of these are combined to calculate the individual risk for the most common 
chromosomal disorders (trisomies, 21,18 and 13). (Leipälä, Ignatius, Autti-Rämö, & 
Mäkelä, 2009). Each hospital district and town is obligated by the state law on 
screenings (339/2011) to provide these screenings for every pregnant woman, but 
each of them has its own particular practices for the screenings. 
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2.6.2 Chronic diseases and congenital anomalies 
Many chronic diseases have an increased risk for congenital anomalies in offspring. 
All drugs are tested for malformation risk and classified according to the perceived 
risk. In Finland, Medbase Oy maintains the GravBase database as part of the 
Terveysportti services. It contains over 1 100 drugs and information on their impact 
on the fetus. 
There have been controversial findings as to whether RA increases the risk for 
congenital anomalies. Some studies suggest that RA could increase the risk compared 
with non-RA pregnancies (J.F Skomsvoll, V Baste, M Østensen, L.M Irgens, 1999; 
Nørgaard et al., 2010). A larger Norwegian register study compared RA pregnancies 
with non-RA pregnancies but found no increase in risk for congenital anomalies 
(Wallenius et al., 2014). In Finland, RA patients are given reproductive counseling 
since some of the drugs commonly used to treat RA are prohibited for use not only 
during pregnancy and lactation but also for months prior to  pregnancy (Sihvonen 
& Pertovaara, 2019). 
DM types 1 and 2 have been shown to increase the risk for congenital anomalies 
(Eidem, Ingvild et al., 2010; Macintosh et al., 2006). Gestational diabetes also 
increases the risk, but less than pregestational diabetes (Sheffield, Butler-Koster, 
Casey, McIntire, & Leveno, 2002; Zhao, Zhang, Zeng, & Liu, 2015). The risk for 
congenital heart anomalies is increased, especially if there is history of diabetic 
complications (Øyen et al., 2016). The most common anomalies in the offspring of 
insulin-dependent diabetic mothers were neural tube defects, heart defects, and 
bilateral renal agenesis (Becerra, Khoury, Cordero, & Erickson, 1990; Nasri, Houde 
Ng, Westgate, Hunt, & Holmes, 2018). 
Chronic hypertension is an independent risk factor for congenital anomalies, 
whether it is treated or untreated (Bateman et al., 2015). Asthma also increases the 
risk for certain congenital anomalies, although researchers have not been able to 
conclude whether the drugs used to treat asthma or the disease itself increases the 
risk for congenital anomalies. (Garne et al., 2015; Murphy, V. E. et al., 2013) Certain 
drugs used to treat diseases, such as epilepsy and depression, have been shown to 
increase the risk for congenital malformations, although the diseases themselves are 
not thought to increase the risk. (Artama, M., Auvinen, Raudaskoski, Isojärvi, & 
Isojärvi, 2005; Bromley, Weston, & Marson, 2017; Malm, Artama, Gissler, & 
Ritvanen, 2011; Weston et al., 2016) 
Maternal obesity increases the risk for certain congenital anomalies. In particular, 
the risk for neural tube defect, spina bifida, and cardiovascular anomalies is 
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increased. Overall, the absolute increase was concluded to be small in this meta-
analysis. (Stothard, Tennant, Bell, & Rankin, 2009) However, another cohort study 
suggested that the overall risk for congenital anomalies increased in both obese and 
underweight women compared with women of a recommended weight (Rankin et 
al., 2010).  
 62 
3 AIMS OF THE STUDY 
The overall aim of the present study was to provide important nationwide 
information on reproductive health of fertile-aged THR patients. 
 
The specific aims of the studies were to investigate the following: 
 
1. Birth rates after THR performed for fertile-aged males and females 
compared with a reference group without THR. 
2. The risk for pregnancy ending in IA after THR compared with preoperative 
pregnancies and a reference group without THR. 
3. The safety of pregnancy and delivery, the delivery method, and neonate 
outcomes compared between the THR patient group and  reference group 
both before and after THR / index date. 
4. The risk for congenital anomalies in the offspring of women who had 
undergone THR compared with a reference group. Further, to compare the 
risk of congenital anomalies between women with MoM THR-implants with 
non-MoM implants in a subgroup analysis. 
5. The survival of primary THR after pregnancy and delivery in comparison 
with a reference group of women with THR without deliveries and to 
compare revision indications between groups. 
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4 METHODS AND PATIENTS 
4.1 Study design 
This nationwide retrospectively formed register-based cohort study contained 
information from six different national registers in Finland. The registers used in this 
study were the following: the Finnish Arthroplasty Register (FAR), the Population 
Information System (PIS), the Medical Birth Register (MBR), the Register of 
Induced Abortions (RIA), the Register of Congenital Malformations (RCM), and the 
Register of Medical Reimbursements (RMR). All the information gathered from the 
registers was combined by using the unique social security code of each person 
selected for the study. The whole study period was from the 1st of January 1980 to 
26th of January 2011.  
 
4.2 Registers 
Finland has a long history of personal registers. The first personal registers were 
established in the 16th century, and the first personal health registers during the 20th 
century. Personal health registers are designed to improve the quality of healthcare 
and to provide data for national statistics and research. (Statistics Finland, 2018) 
Finnish legislation the Personal Data Act (523/1999) and the Act on National 
Personal Data Registers kept under the Health Care System (556/1989) enables the 
registers to be maintained and used for research purposes and allows the use of 
confidential data in research without the need for the written consent of the 
participants when register data only are used. This legislation obligates hospitals to 
collect the required information and to report it to the registers.  
The new European General Data Protection Regulation (GDPR) (GDPR 
2016/679) came into effect on the 25th of May 2016, and the member states of the 
European Union (EU) started to enact the GDPR on the 25th of May 2018. On the 
1st of January, the Data Protection Act (1050/2018) replaced the old Finnish 
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Personal Data Act. The Data Protection Act is set to complement and clarify the 
GDPR in Finland. Our study permissions were granted before the GDPR came into 
force and were therefore based on the old standards of the Personal Data Act 
(523/1999). The new Data Protection Act (1050/2018) enables the continued use 
of register data for scientific research in Finland. 
 
4.2.1 The Finnish Arthroplasty Register 
The Finnish Arthroplasty Register (FAR) is maintained by the National Institute of 
Health and Welfare (THL). The FAR contains information on all prostheses 
operated since 1980. The following information was gathered from the register and 
used in this study: the date of the surgery, THR indication, age at the time of THR, 
implant type and materials, date of possible revision, number of revisions, and 
revision indications. All females aged between 15 and 45 at the time of the operation 
and operated between 1980 and 2007 were selected for the study. For the first part 
of the study, all males aged 15 to 49 at the time of the operation and operated from 
1980 to 2007 were selected. Information on all the prostheses operated for one 
person during the study period was gathered. The current (2017) completeness of 
the FAR for primary THR is 95%, and it matches well with the hospital discharge 
data. For revision THR, the completeness of the FAR is slightly lower at 81%. (THL, 
2018c) During our study period the completeness was 90% in 1995 and 95% in 2000 
(Puolakka T et al 2001). During the study period, information on prosthesis 
operations was gathered from paper forms filled-out by surgeons and sent to THL. 
The FAR has undergone major improvements. At the end of 2015, the whole register 
was totally renewed and completely digitalized to match current standards. The FAR 
provides interactive and updated reports on their website: thl.fi/far.  
 
4.2.2 Population Information System 
The Finnish Population Information System (PIS) is maintained by the Population 
Register Centre of Finland. The first population registers were created in the 16th 
century in Finland. The PIS contains information on all permanent residents in 
Finland. The following personal data are gathered in the register: name, personal 
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identity code, citizenship, native language, family relations, date of birth, and death.  
(Population Register Centre, 2019). The contents of the PIS are made available for 
research in accordance with the Population Information Act (661/2009). 
From the PIS, three reference persons for each study patient were selected. The 
referents were matched by age, gender, and native language, and they had no 
implants according to FAR. Further, dates of emigration and death were gathered 
from the PIS for each participant. For the first part of the study, information on all 
the biological children born was gathered from the PIS because information on the 
offspring of males is not included in the Medical Birth Register (MBR). The common 
closing date for the information on the children born was the 26th of January 2011. 
 
4.2.3 Medical Birth Register 
The MBR is a nationwide mandatory register maintained by THL. Furthermore, the 
MBR contains information on all pregnancies, deliveries and neonates up to seven 
days postpartum in all pregnancies that had lasted for over 22+0 gestational weeks 
or fetuses weighing over 500 grams at birth. The MBR was established in 1987, and 
since then, it has been renewed in 1990, 1996, 2004, and 2017. The goal of the 
register is to collect data for statistics and research and to develop reproductive 
health in Finland. The current coverage of the register is nearly 100%. (THL, 2018e) 
In this study, we collected all the live and stillbirths recorded in the MBR for 
women from both the THR and reference groups from 1987 to 2007. For this study, 
we used all the available variables that were in the MBR during the study period. The 
most important missing variables were the lack of delivery durations as well as the 
lack of 5-minute Apgar points and maternal BMI before pregnancy, since they only 
became part of the register in 2004. Also, the coding for CS was two-parted (planned 
or other) instead of the current coding (planned, urgent, emergency). The MBR uses 
electronic reporting from the delivery hospitals, and in planned home deliveries the 
midwives assisting the delivery report the births to the register. An up-to-date list of 
the information recorded to the MBR can be found on the homepage of the MBR 
(https://thl.fi/en/web/thlfi-en/statistics/information-on-statistics/register-
descriptions/newborns). 
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4.2.4 Register of Induced Abortions 
The Register of Induced Abortions (RIA) is maintained by THL, and it is one of the 
mandatory health registers in Finland. The RIA was first established in 1983, but 
information on the numbers and indications of IA is available from 1955. The aim 
of the register is to provide data for statistics and research. (THL, 2018g). The 
completeness of the register in 2011 was excellent 97% (Heino, Niinimäki, Mentula, 
& Gissler, 2018). Since 2015, information has been gathered electronically from 
hospitals. During our study period, the information was provided using paper forms 
filled-out by the performing physicians and mailed by the hospitals to THL. 
For our study, information on all IAs from 1987 to 2007 was gathered for both 
THR patients and the reference group. The variables used in this study were the 
following: number of IAs during study period, previous IAs at the time of current 
IA, date of the IA, age at the time of IA, indication of IA, SES of women, and 
number of previous pregnancies and deliveries. Up-to-date information on the 
content recorded to the RIA can be found from the homepage of the RIA. 
(https://thl.fi/en/web/thlfi-en/statistics/information-on-statistics/register-
descriptions/register-of-induced-abortions) 
 
4.2.5 Register of Congenital Malformations 
The Register of Congenital Malformations (RCM) was established in 1963 and is 
now maintained by THL. The main goal of the RCM is to provide actual information 
on nationwide anomalies and to help detect possible new teratogens and prevent 
major anomalies by providing information on current rates. The RCM has 
information on all pregnancies ending in livebirth or stillbirth where the fetus has 
one or more major anomalies. Information on the terminations of pregnancies due 
to detected or suspected fetal anomaly (TOPFA) is also recorded to the register. 
Anomalies are usually recorded to the register during the first year after birth. Every 
year, over 2000 major anomalies are reported to the register. (THL, 2018b) 
Anomalies categorized as major were included for this part of the study. Major 
anomalies include those severe anomalies and chromosomal diseases that either 
demand surgical treatment or seriously affect everyday life. All the anomaly 
diagnoses and categorization to major or minor were checked manually, and 
diagnoses were classified and grouped using the International Classification of 
Disease, version 10 (ICD-10). 
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4.2.6 Register for Medical Reimbursement 
The Register for Medical Reimbursement (RMR) is maintained by Kela. The Health 
Insurance Act (1224/2004) grants Kela the right to maintain this register. The 
register holds information on all reimbursable diseases and their medications. Kela 
has three categories of reimbursements at the moment: Basic (40% of the expenses), 
Lower special (65%), and Higher special (100%). For the special categories, a medical 
certificate issued by a doctor on form B is required to gain entitlement for the 
reimbursement of medication expenses. (Kela, 2018) In this study, we gathered all 
the reimbursements due to chronic diseases registered to the RMR before the 26th 
of January 2011 for the whole study population to gain information on their long-
term diseases. If no record of reimbursements for medical costs was found in the 
RMR, the person was classified as not having the disease. Information on medical 
drug purchases was not obtained for this study. 
 
4.3 Patients 
Information on a total of 2 429 women and 3 434 men who underwent THR surgery 
between 1980 and 2007 were obtained from the FAR. The reference group 
comprised 7 276 women and 10 299 men that had no implants according to the FAR 
and were matched by age, hometown, and mother tongue. Due to missing data and 
inclusion restrictions, participant numbers differ between studies I to V, and are 
therefore described in detail in following chapters.  
 
4.3.1 Study I 
In the study on birth rate after THR (I), all women aged between 15 and 45 at the 
time of THR and all men aged 15 to 49 at the time of the THR operated between 
1980 and 2007 were included in the study and formed the THR group. The THR 
group comprised 2 429 women and 3 434 men. The reference group had 7 276 
women and 10 299 men. Information on biological live born neonates was gathered 
from the PIS. Additional information obtained from the PIS included marital status, 
number of previous children, and date of emigration or death. Information on 
chronic diseases was gathered from the RMR, and the diseases selected as part of 
 68 
this study were RA and DM type 1, since they are both known to have a negative 
effect on birth rate. 
 
4.3.2 Study II 
In the study on IA’s after THR (II), all women aged between 15 and 44 years at the 
time of their first primary THR performed between 1987 and 2007 were included. 
If the first operation during this period was a revision, the person was excluded. 
Information on these operations was obtained from the FAR. Of the 2 429 THR 
patients identified, 1 713 were included and formed the THR group in this study. 
For every patient in the THR group, three reference persons were obtained and only 
the matching referents (5 148) were included and formed the reference group. 
Information on induced abortions was gathered from the RIA for the period 1987 
to 2007. Further, information on pregnancies was obtained for the same period from 
the MBR for both the THR and reference group. Information on chronic diseases 
was obtained from the RMR. In this study, RA was the only disease selected for 
analysis. The study population and events are shown in figure 5. 
 
  
 69
 
Fi
gu
re
 5.
  
Flo
w 
ch
ar
t o
f s
tud
y p
op
ula
tio
n a
nd
 ev
en
ts 
in 
the
 se
co
nd
 p
ar
t o
f th
e 
stu
dy
, w
he
re
 ris
k f
or
 pr
eg
na
nc
y e
nd
ing
 in
 In
du
ce
d a
bo
rtio
n a
fte
r T
HR
 w
as
 
stu
die
d. 
W
om
en
 ag
ed
 15
 to
 44
 ye
ar
s o
ld 
at 
the
 tim
e o
f o
pe
ra
tio
n w
er
e i
nc
lud
ed
 an
d t
hr
ee
 m
atc
hin
g r
efe
re
nts
 w
ith
ou
t T
HR
 w
er
e s
ele
cte
d. 
IA
= 
Ind
uc
ed
 A
bo
rtio
n, 
TH
R=
tot
al 
hip
 re
pla
ce
me
nt
 
 
 
 
 
TH
R 
gr
ou
p 
1 
71
3 
w
om
en
 
Re
fe
re
nc
e 
gr
ou
p 
5 
14
8 
w
om
en
 
Ti
m
e 
be
fo
re
 T
H
R 
Ti
m
e 
af
te
r T
H
R 
TH
R 
op
er
at
io
n 
/ 
 
In
de
x 
da
te
 
19
9 
pr
eg
na
nc
ies
 
16
4 
de
liv
er
ies
 
35
 IA
s 
1 
12
6 
de
liv
er
ies
 
1 
30
8 
pr
eg
na
nc
ies
 
92
3 
de
liv
er
ies
 
10
75
 p
re
gn
an
cie
s 
4 
02
6 
pr
eg
na
nc
ies
 
18
2 
IA
s  
51
6 
IA
s 
3 
51
0 
de
liv
er
ies
 
15
2 
IA
s 
 70 
4.3.3 Study III 
In the study on delivery outcome and method after THR (III), all the women aged 
15 to 45 who had undergone a THR operation between 1980 and 2007 were selected 
from the FAR and formed the THR group. Their matching referents without THR 
formed the reference group. Information on pregnancies was obtained from the 
MBR from 1987 to 2007. All singleton pregnancies ending in delivery were included 
in the study. Twin and other multiple pregnancies were excluded. Deliveries were 
included both before and after the THR / index date in the referents. A total of 2 
429 women formed the THR group, and 7 276 women were in the reference group. 
(Figure 6) For the THR group, information on THR bearings was classified as MoM 
or non-MoM. Information on chronic diseases were obtained from the RMR and 
RA was the only chronic disease to be part of the analysis, since the prevalence of 
all the other chronic diseases remained under 1%.  
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THR group 
2 429 women 
986 singleton deliveries  
Index date THR 
(Index date) 
575 women 2 805 women 144 women 
204 singleton deliveries  
912 women 
Reference group 
7 276 women 
1 417 singleton 
deliveries  
5 112 singleton 
deliveries  
before after after before 
Figure 6.  Flow chart of the study population and deliveries in the patient group (women with total hip 
replacement (THR)) and the control group. Index date is the date of THR. Deliveries of the 
patient group were classified as taking place before or after THR, and likewise the 
deliveries of the control group were matched according to the index date.  
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4.3.4 Study IV 
In the study on congenital anomalies after THR (IV), all women aged 15 to 45 at the 
time of THR who were operated between 1980 to 2007 were included and formed 
the THR group. The matching referents without THR formed the reference group. 
Information on pregnancies was obtained from the MBR, RIA, and RCM for the 
period 1987 to 2007. (Figure 7) Information on THR bearings was gathered for the 
THR group and classified as MoM or non-MoM.  
 
Figure 7.  Flow chart of study population and events in the study on congenital anomalies after THR 
(IV) 
IA= Induced abortion, THR= total hip replacement, TOPFA= termination of pregnancy due 
suspected fetal anomaly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 IAs 
3 TOPFA 205 livebirths 
4 stillbirths 
1 434 deliveries 236 IAs 
1 451 livebirths 
8 stillbirths 
13 TOPFA 
8 major 
anomalies 
1 major 
anomaly 
47 major 
anomalies 
13 major 
anomalies 
THR group  
2 429 women 
Reference group  
7 276 women 
256 pregnancies 1 670 pregnancies 
205 deliveries 
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4.3.5 Study V 
For this part of the study of the 2 429 women who underwent THR between 1980 
and 2007, only their primary THRs operated from 1987 to 2007 were included. In 
total, 2012 women with 2 499 THRs matched the criteria. Of these, 23 were excluded 
due to important missing information. During the study period, 111 women with 
133 THRs had at least one delivery after primary THR and during the follow-up and 
formed the delivery group. In addition, 1 878 women with 2 343 THRs had no 
deliveries after THR and formed the reference group. The start of the THR survival 
follow-up was the operation day of the primary THR. If the woman had both hips 
operated during the study period, both THRs were followed independently. The 
endpoint for the follow-up was either the first revision of the hip, date of death, or 
the common end date of the study (31.12.2007), whichever came first. (Figure 8) 
Information on RA diagnosis was obtained from the RMR. 
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Figure 8.  Flow chart of study population and events in the study on primary THR survival after 
delivery 
FAR= Finnish arthroplasty register, THR = total hip replacement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 012 women with  
2 499 primary THRs 
obtained from the 
FAR 
645 Revisions 51 Revisions 
Reference group 
1 878 Women 
2 343 THRs 
Delivery group 
111 Women 
133 THRs 
22 excluded due to 
missing information 
1 excluded due to 
wrong personal 
identification code 1 989 women 
included and 2 476 
THRs 
Delivery after THR 
YES NO 
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4.4 Statistical Methods 
 
4.4.1 Statistics overall 
Statistical analyses were performed mainly by SPSS for Windows statistical analysis 
software versions 18.0-25.0. STATA v.8.2 was used for the first study and a P-value 
under 0.05 was considered statistically significant in all analyses.  
Basic statistical key numbers were calculated. For continuous variables, in 
Gaussian population means with standard deviations were calculated and in non-
Gaussian population medians with interquartile ranges were used. Students two-way 
t-test was used to evaluate the statistical differences of normally distributed 
continuous variables, and Mann-Whitney U-test was used for non-normally 
distributed variables.  
For categorized variables, proportions were counted and, if needed, 95% CI. Chi 
square test or Fischer’s exact test was used to analyze the statistical differences of 
the categorized variables between patient group and reference group. The test was 
not eligible if intergroup differences inside the patient group or reference group were 
analyzed before the start of the follow-up and during the follow-up, since the same 
woman could appear in both groups and possibly multiple times. Instead, we used 
the 95% CI for the proportional difference between two proportions. The difference 
was statistically significant if the 95% CI range was positive.  
Generally, the start of the follow-up was the day that the person underwent THR. 
The same date was used as the index date for the three matching individuals in the 
reference group without THR. 
 
4.4.2 Birth rate after THR (study I) 
The start of the follow-up was the THR operation day and the same day was used 
for the matching referents. The endpoint for the follow-up was the date of the first 
live-born child or the date of emigration or date of death, or the common closing 
date of this study (26th of January 2011), whichever occurred first. 
The Cox proportional regression model was used to evaluate risk and calculate 
HR for the first liveborn child after THR in relation to the reference group without 
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THR. Stratified analyses were conducted by age at the start of the follow-up (< 20, 
20–34, 35–39 and ≥ 40 years) number of live births before THR / index date, marital 
status, DM, and RA. Separate adjusted Cox multivariable analyses with the following 
potential modifiers were conducted: age at the time of THR (continuous), marital 
status, previous children, DM, and RA. All the analyses were performed separately 
for men and women.  
 
4.4.3 Induced abortions (II) 
In the second part of the study, logistic regression model was used to count adjusted 
odds ratios (ORs) with 95% CI for pregnancy ending in IA after THR and before 
THR compared with the reference group without THR. Variables taken as part of 
the adjusted models and that were potential modifiers were previous deliveries, 
previous IAs, age at the time of IA, and marital status. IA indications, and rates were 
compared between the groups both before and after THR / index date.  IA rates 
were counted per 1 000 person years and per 100 births for both groups. The start 
of the IA follow-up was either the 1st of January 1987 or the 15th birthday of the 
woman, whichever came first. The end of the IA follow-up was either the 45th 
birthday, date of death, date of immigration, or the 31st of December 2007, 
whichever occurred first. IA follow-up periods are referred to as before the THR / 
index date and after THR / index date. In this study, the intergroup comparison 
between before and after THR / index date was done by the 95% CI of the PD of 
the variable. 
 
4.4.4 Pregnancies, deliveries and neonates after THR (III) 
Pregnancies were observed and compared between the THR group and the reference 
group both before and after THR / index date. Diagnoses of small for gestational 
age (SGA) and large for gestational age (LGA) were calculated separately for boys 
and girls according to the standards of the new Finnish growth references (Saari et 
al., 2011). An SD lower than -2.0 was classified as SGA and an SD higher than +2.0 
was classified LGA. A neonate weighing under 2 500 grams was classified as LBW.  
Neonates born before gestational week 37+0 were classified as preterm. The 
neonatal death rate comprised stillbirths and neonates who died before the age of 8 
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days postpartum. Logistic regression model was used to calculate adjusted ORs for 
adverse pregnancy and neonatal outcomes (Stillbirth, SGA, LBW and Preterm). 
Adjustments were made using the following covariates: maternal age at delivery, 
smoking during pregnancy, and maternal RA. 
 
4.4.5 Congenital anomalies in the offspring of THR patients (IV) 
Congenital anomalies after THR were analyzed in the fourth part of the study. ORs 
with 95% CI for major congenital anomaly in the patient group in comparison to the 
reference group were calculated. Subgroup analysis was performed in which the 
MoM implant’s risk for congenital anomalies in the offspring was compared with the 
non-MoM THR. For both groups’ anomaly types were also categorized by the ICD-
10 classification and compared between groups.  
 
4.4.6 Survival of the THR after delivery (V) 
In the final part of the study, Kaplan-Meier analysis with 95% CI was performed to 
evaluate the survival of the hip after delivery compared with women without 
deliveries. Kaplan Meier survival rates were counted until there were 20 at risk in the 
model. The start of the follow-up was the day of the primary operation of the hip. 
Since the presumptions of the Cox proportional model were not met due to the 
crossing of the survival curves in the Kaplan Meier analysis, the piecewise Cox 
proportional hazard model was performed to evaluate the possible confounders and 
count HR for risk of revision in any indication after delivery in relation to the 
reference group without deliveries. Adjustments taken as part of the piecewise Cox 
model were age at the time of THR, RA, stem fixation, and cup fixation. Intervals 
before and after the crossing of the curves were analyzed independently. Bilateral 
observations were included, since previous studies have shown that this does not 
bias the results (Lie, Engesaeter, Havelin, Gjessing, & Vollset, 2004; Ranstam & 
Robertsson, 2010). 
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4.5 Ethics and permissions 
 
4.5.1 Ethics of the study 
In accordance with the instructions of the local Ethical Committee of Pirkanmaa 
Hospital District our register-based cohort study did not need ethical approval, and 
therefore it did not undergo ethical evaluation by the local ethical committee (TAYS, 
2017). However, this study has been conducted according to the standards and good 
scientific practice set by the World Medical Association’s Declaration of Helsinki. 
 
4.5.2 Research permission 
For the purposes of scientific research, data could be processed and no written 
consent from the data subjects were required because, in accordance with Section 
14.1 of the Personal Data Act (523/1999) and the New European GDPR, research 
could not have been carried out without data identifying the person and the consent 
of data subjects could not have been obtained due to the quantity of the data and 
the number of subjects. Permission for the processing of the data was granted by 
the data controllers after evaluating our research plans and applications. Permission 
number: THL/599/5.05.00/2010. 
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5 SUMMARY OF THE RESULTS 
5.1 Birth and pregnancy rate after THR (Study I, II, III, IV) 
In study I, the THR patient group comprised 3 434 men and 2 429 women, and the 
reference group comprised 10 299 men and 7 276 women. The mean follow-up time 
was 11 (0-31) years for patients and 11 (0-31) years for referents among men, and 14 
(0-31) years for patients and 14 (0-31) years for referents among women. The mean 
age at the start of the follow-up was 43 years (15-50) among men and 38 years (15-
46) among women. During the follow-up, the number of first liveborn children after 
THR was 435 among the patients and 2 213 among the referents (Table 6). The 
overall birth rate in Study I was 0.07 children per male for male THR patients and 
0.11 children per male for male referents. The livebirth rate for female THR patients 
in this study was 0.07 per female and 0.15 per female for female referents. In study 
I, only the first birth after THR was included.  
In the studies II, III, and IV, the pregnancy and birth rates were lower in patients 
with THR compared with reference women without THR. When the IAs were 
included, the pregnancy rate for the THR patients included in study II was 0.12 
pregnancies per woman after THR. In the reference group, the rate was 0.25 
pregnancies per woman. The overall pregnancy rate in study II was 0.96 per woman 
during the study period 1987 to 2007. The results of study II are presented in more 
detail later. The IAs were also included in study IV in which all the patients were 
included. In study IV, the pregnancy rate after THR was 0.11 per woman in the THR 
patient group and 0.23 per woman in the reference group.  
In the third part of the study, all singleton deliveries were analyzed after THR 
instead of only the first delivery analyzed in study I. The mean number of children 
after THR was 0.08 in the THR patient group during the follow-up. In the reference 
group, the mean number of children after index date was 0.19. The birth rate in study 
IV was 0.08 livebirths (multiple births included) per woman in the THR patient 
group after THR and 0.20 livebirths per woman in the reference group after index 
date.   
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Table 6.  Number of subjects and livebirths in patients with total hip arthroplasty (THA) and 
referents without THA according to age at start of follow-up, number of previous liveborn children 
before THA, marital status, Diabetes Mellitus diagnosis, and Rheumatoid Arthritis diagnosis, 
Finland 1985-2006 
 
 Men  Women 
 No. of subjects No. of livebirths  No. of subjects No. of livebirths 
 patient referent patient referent  patient referent patient referent 
Total 3 434 10 299 254 1 104  2 429 7 276 181 1 109 
Age at the start of the follow-up        
 15-19 28 84 6 29  50 150 15 90 
 20-34 414 1 240 127 571  621 1 847 140 824 
 35-39 509 1 528 64 257  571 1 722 22 167 
 40-45 1 151 3 465 36 193  1 187 3 557 4 28 
 46-50 1 332 3 982 20 54  N/A N/A N/A N/A 
No. of previous liveborn children        
 0 1 101 2 984 95 435  831 1 871 100 552 
 1 or more 2 333 7 315 159 669  1 598 5 405 81 557 
Marital status          
 never married 887 2 466 32 183  628  1 370 34 190 
 ever married 2 547 7 833 222 921  1 801 5 906 147 919 
Diabetes Mellitus          
 yes 87 174 4 6  35 48 2 4 
 no 3 347 10 125 250 1 098  2 394 7 228 179 1 105 
Rheumatoid arthritis         
 yes 505 86 44 4  811 68 70 6 
 no  2 929 10 213 210 1 100  1618 7 208 111 1 103 
 
 
The birthrate varied by age at the start of follow-up, number of previous liveborn 
children before THR, and marital status (Table 7). However, the birthrate was lower 
in all patient groups when compared with referents among both genders regardless 
of number of previous children. Male patients with THR and DM had a higher 
birthrate than their referents without THR but with DM. The same was seen among 
male patients with THR and RA. In women, the birthrate was lower in patients with 
either DM or RA and THR than among referents. The birthrate was also lower in all 
age groups of the patient population compared with referents. These differences 
were especially obvious among women in the 2 youngest age groups and among male 
patients aged between 20 and 35 years.  
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Table 7.  Birthrate (per 10 000 person-years) with 95% confidence interval (CI) in patients with 
total hip replacement (THR) and referents without THR according to age at start of follow-up, 
number of previous liveborn children before THR, marital status, Diabetes Mellitus diagnosis, and 
Rheumatoid Arthritis diagnosis, Finland 1985-2006. 
 Men  Women 
 Patient Referent  Patient Referent 
 Rate 95% CI Rate 95% CI  Rate 95% CI Rate 95% CI 
Total 67 59 – 75 95 89 - 100  52 45 - 60 110 104 – 116 
Age at the start of the follow-up        
 15-19 216 97 – 480 377 262 – 542  216 130 – 358 570 463 – 700 
 20-34 300 252 – 357 515 474 – 559  165 140 – 195 400 374 - 429 
 35-39 114 89 – 145 149 132 – 169  25 16 – 38 63 54 – 74 
 40-45 27 20 – 38 47 41 – 54  2.4 0.9 – 6.4 5.4 3.7 – 7.8 
 46-50 13 8.7 – 21 12 8.9 – 15  N/A N/A N/A N/A 
No. of previous liveborn children        
 0 82 67 – 100 145 132 – 159  86 70 – 104 247 227 – 268 
 1 or more 60 51 – 70 77 72 – 83  35 28 – 44 71 65 – 77 
Marital status          
 never married 36 25 – 50 78 67 – 90  39 28 – 55 116 101 – 134 
 ever married 76 67 – 87 99 93 – 106  57 48 – 66 109 102 – 116 
Diabetes Mellitus         
 Yes 52 19 – 138 38 17 – 84  46 12 – 185 70 26 – 186 
 No 67 59 – 76 95 90 – 101  52 45 – 61 110 108 – 117 
Rheumatoid arthritis         
 Yes 64 47 – 86 40 15 – 108  53 42 – 68 73 33 – 163 
 no  67 59 – 77 95 90 - 101  52 43 – 62 110 104 – 117 
 
The decreased probability of a liveborn child when patients were compared with 
referents could also be seen in Cox regression models (Table 3). Overall, the 
probability of having a liveborn child after THR was lower among males (HR 0.69, 
95% CI 0.60 to 0.79) and females with THR (HR 0.47, CI 0.40 to 0.55) than referents 
also in adjusted analyses (men adjusted HR (aHR) 0.80, CI 0.69 to 0.92, women aHR 
0.56, CI 0.46 to 0.68) (Table 8). Female patients with THR had a lower probability 
of having a liveborn child than their referents in all but the oldest age group (40-45 
years). The same phenomenon was seen among male patients in all but the youngest 
age group (15-19 years). Adjustment for potential confounding factors (age at the 
start of the follow-up, number of liveborn children before THR, marital status, DM, 
and RA) lowered the probability of having a liveborn child among patients with THR 
compared with the referents. Among THR patients with DM or RA, however, HRs 
were similar. 
 82 
Table 8.  Table 3. Hazard ratio (HR) with 95% confidence intervals (CI) for the first liveborn child 
after total hip replacement (THR) among patients with THR in relation to referents without THR 
according to various demographic factors, Diabetes Mellitus diagnosis, and Rheumatoid Arthritis 
diagnosis, Finland 1985-2006. 
 
 Men  Women 
 HR (95% CI)  HR (95% CI) 
Crude  0.69 (0.60–0.79)  0.47 (0.40–0.55) 
Adjusted* 0.80 (0.69–0.92)  0.56 (0.46–0.68) 
Age at the start of the follow-up   
 15-19 0.57 (0.24–1.4)  0.34 (0.20–0.60) 
 20-34 0.61 (0.50–0.74)  0.43 (0.36–0.51) 
 35-39 0.74 (0.56–0.97)  0.38 (0.25–0.60) 
 40-45 0.57 (0.40–0.81)  0.43 (0.15–1.2) 
 46-50 1.12 (0.67–1.9)  N/A 
No. of previous liveborn children   
 0 0.58 (0.46–0.72)  0.36 (0.29–0.44) 
 1 or more 0.75 (0.63–0.89)  0.48 (0.38–0.61) 
Marital status    
 never married 0.48 (0.33–0.70)  0.36 (0.25–0.51) 
 ever married 0.74 (0.64–0.86)  0.51 (0.43–0.61) 
Diabetes Mellitus    
 Yes 1.32 (0.37–4.7)  0.64 (0.12–3.5) 
 No 0.69 (0.60–0.79)  0.47 (0.40–0.55) 
Rheumatoid arthritis    
 Yes 1.81 (0.65–5.1)  0.84 (0.37–1.9) 
 No 0.67 (0.58–0.78)  0.44 (0.36–0.54) 
 
HR: hazard ratio. Reference (HR = 1.0) are individuals without THR. 
*Hazard ratio adjusted for age at the start of follow-up, number of previous live births before 
THR, marital status, diabetes mellitus, and rheumatoid arthritis.  
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5.2 Induced abortions (II) 
The THR patient group comprised 1 713 women, with 1 274 pregnancies and 187 
(14.7%) IAs. Of these, 199 pregnancies and 35 (17.9%) IAs occurred after THR. The 
reference group comprised 5 148 women with 5 334 pregnancies and 698 (13.1%) 
IAs. Of these, 1 308 pregnancies and 182 (13.9%) IAs occurred after the index date. 
Mean age at the beginning of the abortion follow-up was 27.4 years and mean age at 
the THR/index date was 37.3 years in both groups. The basic demographics of both 
the THR patient and reference groups are presented in Table 9. 
Before the THR/index date, there were 152 (14.1%) IAs in the THR patient 
group and 516 (12.8%) in the reference group, p=0.25. After the THR/index date, 
the THR patient group had 35 (17.9%) IAs and the reference group 182 (13.9%), 
p=0.17. In the THR patient group, the proportion of IAs increased from 152 
(14.1%) before THR to 35 (17.9%) after THR (PD= 3.5, CI -1.7 - 9.7). In the 
reference group, the number of IAs before the index date was 516 (12.8%) and 182 
(13.9%), PD= 1.1, CI -1.0 - 3.3) after the index date. The median time from THR to 
IA was 4.0 years (range 0.1 to 20.4 years) in the THR patient group. Before the THR, 
the median time from IA to THR was 8.4 years (0.2 to 20.5). Median times in the 
reference group were 3.9 years (0.0 to 19.7 years) after the index date, and 7.1 years 
(0.0 to 20.7 years) before the index date. 
In the THR patient group, the abortion rate was 9.0/1 000 person years before 
the THR and 3.9 /1 000 person years after the THR. In the reference group, the 
rates were 10.2 /1 000 person years before the index date and 6.6 /1 000 person 
years after the index date. In the patient group, abortion rates were 17/100 livebirths 
before the index date and 21/100 livebirths after the index date. In the reference 
group, the abortion rate was 15/100 livebirths before the index date and 16/100 
livebirths after the index date. 
Induced abortion indications varied slightly between the women with and without 
THR (Table 10). More abortions were carried out for maternal health reasons in the 
THR patient group. The rate of the first abortion was higher after THR compared 
with rates before the THR and the reference group. Interestingly, married women 
seemed to have fewer abortions after THR than unmarried women. 
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Table 9.  Background characteristics of study population (study II) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THR= Total hip replacement 
Index date= Date of the operation in the THR patient group and the same date for matching 
referents. 
Start of the abortion follow-up= Day of the 15th birthday or the 1st of January 1987, which 
ever came first. 
 
  
 THR patient group  Reference group 
 n=1713 %  n=5148 % 
Age at the start* of the abortion follow-up     
 15-19 340 19.8  1017 19.8 
 20-24 353 20.6  1062 20.6 
 25-29 335 19.6  1009 19.5 
 30-34 361 21.1  1072 20.8 
 35-39 230 13.4  703 13.7 
 40-44 94 5.5  285 5.5 
Age at THR/index date      
 15-19 39 2.3  117 2.3 
 20-24 80 4.7  236 4.6 
 25-29 155 9.0  465 9.0 
 30-34 230 13.4  684 13.3 
 35-39 435 25.4  1310 25.4 
 40-44 774 45.2  2336 45.4 
Marital status      
 ever married 1238 72.3  4059 21.2 
 never married 475 27.7  1089 78.8 
Nulliparous at the start of the 
abortion follow-up 
979 57.2  2706 52.6 
Follow-up time (years + SD)      
 before THR/index date 9.8 5.9  9.8 5.9 
 after THR/index date 5.2 4.5  5.3 4.6 
Chronic diseases      
  Rheumatoid Arthritis 521 30.4  42 0.8 
  Diabetes Mellitus 28 1.6  33 0.6 
  Epilepsy 6 0.4  12 0.2 
  Major mental disease 3 0.2  8 0.2 
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Table 10.  Total number of abortions for women with and without total hip replacement (THR) 
before and after THR/index date in Finland between 1987 and 2007.   
 
 THR patient group  Reference group 
 Before THR  After THR  Before index 
date 
 After index 
date 
 n=152 %  n=35 %  n=516 %  n=182 % 
No previous pregnancies 46 31.1  9 25.7  176 34.3  37 20.4 
Previous pregnancies 102 68.9  26 74.3  337 65.7  144 79.6 
No previous IA 95 63.8  28 80.0  340 66.3  115 63.5 
One or more previous IA 54 36.2  7 20.0  173 33.7  66 36.5 
Nulliparous 57 38.0  12 34.3  229 44.4  49 26.9 
Previous delivery 93 62.0  23 65.7  287 55.6  133 73.1 
Induced abortion indications           
 Social reasons 118 77.6  24 68.6  447 86.6  126 69.2 
 Age (<18 or >40) 5 3.3  4 11.4  31 6.0  23 12.6 
 Maternal health 17 11.2  5 14.3  14 2.7  5 2.7 
 Fetal health 6 3.9  1 2.9  13 2.5  12 6.6 
 4+ previous births 6 3.9  1 2.9  11 2.1  16 8.8 
Socioeconomic status 37 24.3  18 51.4  141 31.2  95 52.2 
 Upper white collar 1 2.7  3 16.7  14 8.7  20 21.1 
 Lower white collar 19 51.4  6 33.3  57 35.4  38 40.0 
 Blue collar 6 16.2  5 27.8  34 21.1  16 16.8 
 Other** 11 29.7  4 22.2  36 22.4  21 22.1 
Age at THR/index date            
 under 20 0 0.0  4 11.4  3 0.6  15 8.2 
 20-24 4 2.6  4 11.4  35 6.8  27 14.8 
 25-29 16 10.5  3 8.6  58 11.2  45 24.7 
 30-34 30 19.7  12 34.3  100 19.4  37 20.3 
 35-39 35 23.0  9 25.7  117 22.7  43 23.6 
 40 or more 67 44.1  3 8.6  203 39.3  15 8.2 
Age at the time of abortion           
 under 20 12 7.9  1 2.9  49 9.5  5 2.7 
 20-24 29 19.1  4 11.4  105 20.3  13 7.1 
 25-29 40 26.3  4 11.4  119 23.1  30 16.5 
 30-34 37 24.3  5 14.3  136 26.4  40 22.0 
 35-39 29 19.1  13 37.1  79 15.3  58 31.9 
 40 or more 5 3.3  8 22.9  28 5.4  36 19.8 
Never married 51 33.6  12 34.3  159 30.8  46 25.3 
Ever married 101 66.4  23 65.7  357 69.2  136 74.7 
No RA 131 86.2  24 68.6  509 98.6  182 100.0 
RA 21 13.8  11 31.4  7 1.4  0 0.0 
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Women in the THR patient group were more likely to undergo their first IA after 
THR rather than before THR or women in the reference group. Women in the 
youngest and the oldest age groups had higher IA proportions than those in the 
moderate age groups. Women with previous IA had higher rates of pregnancies 
ending in IA in both the THR patient and reference groups. Ever married women 
had significantly lower IA proportions than those never married in both groups. RA 
patients had no differences in IA proportions. Table 12 
Unadjusted OR for pregnancy ending in induced abortion in the THR patient 
group after THR/index date was 1.32 (CI 0.89 – 1.96), p=0.17, in relation to the 
reference group (Table 11). When adjusted with the variables of marital status, age 
(<20 or >39), previous IAs, and previous deliveries, there was a trend for higher risk 
for pregnancy to end in IA in the THR group in relation to the reference group (OR 
was 1.50, CI 0.99 – 2.28; p=0.05). In this logistic model, age, marital status and 
previous IA significantly increased the risk for pregnancy ending in IA. 
 
 
Table 11.  Odds ratios (OR)s with 95% Confidence intervals (CI) for pregnancy ending in induced 
abortion of women with total hip replacement (THR) in relation to the reference cohort of women 
without THR before and after THR/index date, Finland 1987-2007. 
 Before THR/index date  After THR/index date 
 Univariate 
OR 
95% CI p-value  Univariate 
OR 
95 %CI p-value 
THR patient group 1.12 0.92-1.36  0.25  1.32 0.89-1.96 0.17 
Age 5.51 4.16-7.29 <0.001  2.42 1.69-3.47 <0.001 
Never married 3.50 2.91-4.23 <0.001  1.89 1.35-2.64 <0.001 
Previous delivery 0.80 0.68-0.95 0.008  1.26 0.92-1.73 0.15 
Previous IA 5.79 4.76-7.04 <0.001  4.49 3.20-6.28 <0.001 
Adjusted OR for 
patient group 
1.09 0.88-1.34 0.46  1.50 0.99-2.28 0.05 
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5.3 Deliveries (III) 
The THR group comprised 2 429 women, 719 (29.6%) of whom had 1 190 
pregnancies ending in singleton deliveries. Prior to THR, 575 women had 986 
singleton deliveries, and 144 women had 204 singleton deliveries after THR. The 
reference group comprised 7 276 women, 2 805 (38.6%) of whom had 5 112 
pregnancies ending in singleton deliveries. Of those, a total of 1 893 women had 3 
695 singleton deliveries before the index date, and 912 women had 1 417 singleton 
deliveries after the index date. The mean age at birth after THR/index date in the 
THR group was 33.4 years and 32.6 years in the reference group, p=0.046. Smoking 
habits during pregnancy and marital status did not differ between groups. Women 
in the THR group had a naturally higher rate of RA than those in the reference group 
without THR. Baseline information and background characteristics of the pregnant 
women are described in Table 13. 
The proportion of elective CS was higher after THR in the THR group than in 
the reference group after the index date. The CS rate was, however, also slightly 
higher in the THR group before THR than in the reference group before the index 
date. Trial of labor resulted significantly more often in acute CS in the THR group 
after THR. Women in the THR group also had a higher rate if they had a previous 
CS. Women spent more time in hospital both before and after delivery in the THR 
group compared with women in the reference group. (Table 13).  
Comparisons of labor analgesia and delivery related procedures in attempted 
vaginal deliveries are shown for both the THR and the reference group before and 
after THR/index date in Table 14. There was no difference in the proportions of 
vacuum and forceps extractions between the groups. The use of epidural analgesia 
was more common in the reference group after THR/index date. Use of non-
pharmaceutical analgesia was similar between the groups. Episiotomy was more 
common in the reference group after index date. Amniotomy was performed more 
often in the reference group than in the THR group after THR/index date. The third 
stage of labor was equally successful in all the groups. (Table 14)   
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5.4 Neonate outcome (III) 
Stillbirth was more common in the THR group after THR compared with the 
reference group after the index date. The rate of stillbirth was also higher after THR 
compared with before THR (4 (2.0%) vs 3 (0.3%), proportional difference 1.7 (95% 
CI: 0.3 – 4.6)), (Table 15). Perinatal mortality rates were similar between THR and 
reference groups. After THR, neonates had a lower birthweight and birth height and 
were more likely to be born preterm compared with the reference group and before 
THR. In addition, neonates born after THR also had higher LBW, VLBW, and SGA 
proportions. The proportion of LGA was lower after THR in the THR group 
compared with other groups. Furthermore, neonates born after THR needed more 
neonatal high dependency care unit treatment and phototherapy compared with the 
reference group and before THR. Delivery related asphyxia rates were similar in both 
groups before and after THR/index date. Resuscitation and respiratory treatments 
were rare in all groups and there were no differences in the neonatal intensive care 
unit admissions between the groups. Table 15 
When these findings were adjusted with potential confounders (maternal age at 
delivery, smoking during pregnancy, and maternal rheumatoid arthritis), THR 
remained as an independent risk factor for preterm birth, LBW, and SGA, but not 
for stillbirth. The unadjusted OR for stillbirth after THR was 3.52 (95% CI 1.05 – 
11.81) and the adjusted OR was 2.72 (95% CI 0.58 – 12.67). Women with THR also 
seemed to have a higher risk for preterm birth before THR compared with women 
without THR (Table 16). 
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In subgroup analysis, the MoM-implant THR group was compared with the non-
MoM implant group. There were 16 pregnancies and neonates in the MoM group 
and 188 pregnancies in the non-MoM THR group. No stillbirths occurred in the 
MoM group. The groups had no differences in the rates of stillbirths, preterm births, 
and LBW neonates. The MoM implant group had a higher rate of SGA neonates 
than the non-MoM group (25.0% vs 6.9%, p=0.03). The SGA rate in the MoM 
implant group was also significantly higher compared with the rate in the reference 
group (25.0 % vs 2.8 %, p<0.001). (Table 17) 
 
Table 17.  Pregnancy outcomes after total hip replacement (THR), THR patients with metal-on-
metal (MoM) implants compared with non-MoM implant THR patients by chi square test. 
 
 MoM THR  non-MoM THR   
 n=16 %  n=188 %  p-value 
Stillbirth 0 0.0  4 2.1  1.00 
Preterm 4 25.0  24 12.8  0.25 
SGA 4 25.0  13 6.9  0.03 
LBW 3 18.8  22 11.7  0.42 
SGA = Small for gestational age 
LBW = low birthweight 
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5.5 Congenital anomalies (IV) 
In the THR patient group, a total of 2 429 woman had 256 pregnancies, and 80.1% 
of those (n=205) ended in delivery, and the remaining 19.7% (n=51) ended in IA. 
In the reference group, 7 276 women had 1 670 pregnancies of which 86.4% (n=1 
434) ended in delivery and 13.6% (n=236) in IA, p=0.02. The mean age at the start 
of the follow-up was 37.7 years (SD 0.1) in both groups.  
In the THR patient group, 209 births occurred of which 205 (98.1%) were 
livebirths and 4 (1.9%) stillbirths, respectively. Eight (3.8%) neonates had one or 
more major anomaly. In the THR patient group, 3 (5.9%) of the 51 IAs were 
performed due to suspected fetal defects. Of these, 1 had at least one major anomaly 
recorded to the register.  In the reference group, a total of 1 451 births occurred of 
which 1 443 (99.4%) were livebirths and 8 (0.6%) stillbirths. In total, 47 (3.3%) 
neonates had one or more major anomaly. In this group, 13 (5.5%) of the 236 IAs 
were performed due to suspected fetal defects, and all of them had at least one major 
anomaly recorded to the register. No major differences between these group were 
observed. The background characteristics and a comparison between the groups are 
presented in Table 18. 
In the subgroup analysis, women who had undergone MoM THR had 19 
births/fetuses with 2 (10.5%) major anomalies. There was no significant difference 
in the incidence of major anomalies between women with a MoM THR (10.5%, 
n=2/19) and those with a non-MoM THR (3.0%, n=7/241), OR being 3.93 (95% 
CI 0.76 – 20.2, p=0.13). Furthermore, there was no significant difference in 
incidence between women with a MoM THR and those without THR (3.6%, 
n=60/1687; p=0.15).  
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In the THR patient group, 9 neonates and fetuses with major anomalies had 25 
anomaly diagnoses, and in the reference group 60 neonates and fetuses with major 
anomalies had 143 anomaly diagnoses. The most common major anomalies were 
heart and circulatory organ anomalies, ICD-10 codes Q20 – Q28 (5 neonates/fetuses 
in the THR patient group and 21 in the reference group), chromosomal, Q90 – Q99 
(n=2 and n=14), and musculoskeletal anomalies Q65 – Q79 (n=4 and n=12). (Table 
19)   
 
Table 19.  Proportions of major congenital anomalies in births/fetuses in the THR patient group 
and the reference group without THR. 
 
 
 
  
  Women with THR  Women without THR 
  cases  anomalies  cases  anomalies 
 ICD-10 
codes 
n %  n %  n %  n % 
Total  9 100  25 100  60 100  143 100 
Type of anomaly              
   Heart and 
circulatory organs 
Q20-Q28 5 55.6  7 28.0  21 35.0  31 21.7 
   Musculoskeletal  Q65-Q79 4 44.4  5 20.0  12 20.0  19 13.3 
   Central nervous 
system  
Q00-Q07 2 22.2  3 12.0  11 18.3  16 11.2 
   Chromosomal  Q90-Q99 2 22.2  2 8.0  14 23.3  15 10.5 
   Genitourinary  Q50-Q56,  
Q60-Q64 
2 22.2  2 8.0  4 6.7  7 4.9 
   Gastrointestinal  Q38-Q45 2 22.2  2 8.0  7 11.7  8 5.6 
   Facial (ear, 
mouth, nose, eye)  
Q10-Q18,  
Q35-Q37 
1 11.1  2 8.0  14 23.3  32 22.4 
   Respiratory  Q30-Q34 1 11.1  2 8.0  4 6.7  4 2.8 
   other  Q80-Q89 0 0.0  0 0.0  10 16.7  11 7.7 
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5.6 THR survival after delivery (V) 
In total, 1 989 women with 2 476 THRs were included in the study. (Table 20) Of 
these, 111 (5.6%) women with 133 (5.4%) THRs had a delivery during the follow-
up. The mean follow-up in the delivery group was 9.3 years (0-21), and the median 
age at the start of the follow-up was 29 years. In the reference group, 1 878 women 
with 2 343 THRs had no deliveries. The mean follow-up was 8.1 years (0-21), and 
the median age at the start of the follow-up was 40. 
RA was the most common indication for THR in both groups. It was, however, 
more prevalent in the delivery group (47%) than in the reference group (33%) 
(p=0.001). Other chronic diseases were more common in the reference group. The 
distribution of THR fixation method or bearing-type was similar between the 
groups. The delivery group had 51 revisions, and 30 (59%) of the revisions were 
performed due to aseptic loosening. In the reference group, 645 THRs were revised, 
and 318 (49%) revisions were performed due to aseptic loosening. 
The deliveries were analyzed and recorded per THR. During the follow-up, 170 
deliveries occurred (mean of 1.3 deliveries per THR). The maximum number of 
deliveries per patient during the follow-up was 5. Of the deliveries, 75 (44%) were 
vaginal and 95 (56%) cesarean sections. Fifty women with 53 THRs had at least 1 
vaginal delivery after THR, and 61 women with 80 THRs had only cesarean sections 
after THR.  The primary THR diagnoses and revision indications were similar in the 
vaginal delivery group and the cesarean section group. (Table 21) 
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Table 20.  Background characteristics of the study population (study V), types of hip prosthesis, 
and indications for revisions between the delivery group and the reference group. 
 
  
  
 
 Delivery group  Reference group 
 n=133 %  n=2 343 % 
Age at primary THR      
 Mean + SD (t-test) 28.9 5.5  38.1 6.6 
 Median + IQR (MWU) 29.0 8.0  40.0 8.0 
Age at primary THR      
 Under 25 27 20.3  130 5.5 
 25 to 34 88 66.2  410 17.5 
 35 and over 18 13.5  1 803 76.9 
Follow-up period (years)      
  Mean + SD (t-test) 9.3 4.2  8.1 5.1 
 Median + IQR (MWU) 9.1 6.4  8.0 8.4 
Rheumatoid arthritis 62 46.6  774 33.0 
Other chronic disease** 5 3.6  208 8.9 
Nulliparous at primary THR 78 63.9  778 33.0 
Metal-on-metal bearing 16 12.0  390 16.6 
Type of THR fixation      
 Uncemented 114 85.7  1 859 79.4 
 Hybrid 7 5.3  237 10.1 
 Inverse hybrid 0 0.0  1 0.0 
 Cemented 12 9.0  245 10.5 
Indication for THR      
 Inflammatory arthritis 
 (RA+others) 
62 46.6  731 31.2 
 Primary osteoarthritis 12 9.0  532 22.7 
 Secondary arthrosis 21 15.8  363 15.5 
 Congenital hip luxation 22 16.6  493 21.0 
 Other 16 12.0  224 9.6 
Revisions 51 38.3  645 27.5 
Revision indications      
Aseptic loosening 30 58.8  318 49.3 
 Deep infection 1 2.0  11 1.7 
 Periprosthetic fracture 0 0.0  12 1.9 
 Dislocation 1 2.0  30 4.7 
 Pain 0 0.0  0 0.0 
 Others 14 27.4  193 29.9 
 Missing 5 9.8  81 12.5 
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Table 21.  Comparison of primary diagnoses and revision indications in the delivery group 
between women with at least 1 vaginal delivery after total hip replacement (THR) to women with 
only cesarean sections after THR.  DDH = developmental dysplasia of the hip 
 Vaginal delivery 
after THR 
 Cesarean section 
after THR 
Total no. of implants n=53  n=80 
Indication for THR    
 Inflammatory arthritis 19  43 
 Primary osteoarthritis 4  8 
 Secondary arthrosis 13  8 
 DDH 10  12 
 Other 7  9 
Revisions 15  36 
Revision indications    
 Aseptic loosening 10  20 
 Deep infection 1  0 
 Dislocation 0  1 
 Others 4  10 
 Missing 0  5 
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At 6 years, the implant survival rate in the delivery group was 91% (CI 85 – 96) and 
in the reference group 88%, (CI 87% – 90%). At 13 years, the survival rate was 50% 
(CI 39% – 62%) for the delivery group and 61% (CI 59% – 64%) for the reference 
group, respectively. (Figure 9, Table 22) 
 
Figure 9.   Kaplan Meier survival curves (with 95% confidence intervals) of primary total hip 
replacement among fertile-aged women aged 15 to 44 years at the time of THR having 
one or more deliveries after THR (delivery group) compared with no-deliveries after THR 
(reference group). 
During the first time period (0 to 6.8 years follow-up), the adjusted Cox 
regression model showed no difference in the risk for revision between the delivery 
and the reference groups (adjusted HR 0.72, 95% CI 0.43 – 1.23; p=0.23). During 
the later follow-up (6.8 to 21 years), there was still no difference in adjusted HR 
between the groups (HR 1.12, 95% CI 0.77 – 1.62; p=0.56). Older age was associated 
with a decreased risk for revision during both the first and the second time periods, 
HR 0.97 for revision per additional year. Diagnosis of RA significantly decreased the 
risk for THR revision, but only during the first time period.  (Table 23) 
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Table 22.  Kaplan Meier 6- and 13-year implant survival rates with 95% confidence intervals of 
primary Total Hip Replacement (THR) of fertile-aged women aged 15 to 44 years at the time of 
THR.  
 No. of 
Hips 
No. of 
Revisions 
No. 
at 
risk 
at 6 
years 
 
KM-survivorship 
at 6 years 
% (95% CI) 
No. 
at 
risk 
at 13 
years 
KM-survivorship 
at 13 years 
% (95% CI) 
Delivery 133 51 100 90.6 (85.3 – 95.9) 22 50.4 (39.0 – 61.8) 
No delivery 2 343 645 1 411 88.4 (87.0 – 89.8) 456 61.4 (58.7 – 64.1) 
Age       
 15 to 30 414 148 252 87.7 (84.2 – 91.2) 75 52.2 (45.5 – 58.9) 
 31 to 45 2 062 548 1 260 88.7 (87.1 – 90.3) 404 62.5 (59.6 – 65.4) 
THR fixation       
 Cementless 1 973 625 1 325 88.6 (87.0 – 90.2) 415 59.7 (56.8 – 62.6) 
 Hybrid 244 23 43 85.0 (78.1 – 91.9) 5 - 
 Cemented 257 47 143 91.3 (87.4 – 95.2) 47 71.5 (62.9 – 80.1) 
Bearings       
 MoM 406 17 21 94.1 (90.8 – 97.4) 0 - 
 Non-MoM 2 070 679 1 490 88.5 (87.1 – 89.9) 479 60.6 (57.9 – 63.3) 
Rheumatoid arthritis      
 Yes 836 261 607 92.4 (90.4 – 94.4) 216 63.2 (58.9 – 67.5) 
 No  1 640 435 905 86.3 (84.3 – 88.3) 263 59.3 (55.8 – 62.8) 
 
 
 
Table 23.  Adjusted piecewise Cox regression survivorships of primary total hip replacement 
(THR) between fertile-aged women aged 15 to 44 years at the time of THR having one or more 
deliveries after THR (delivery group) compared with no-deliveries after THR (reference group). 
 Follow-up <=6.8 years  Follow-up >6.8 years 
 HR (95 % CI) p-value  HR (95 % CI) p-value 
Delivery  0.72 (0.43 – 1.23) 0.23  1.12 (0.77 – 1.62) 0.56 
Age, per year 0.97 (0.95 – 0.98) <0.001  0.97 (0.96 – 0.99) <0.001 
Cemented stem 1.29 (0.82 – 2.03) 0.27  0.32 (0.08 – 1.27) 0.10 
Cemented cup 0.64 (0.34 – 1.19) 0.16  2.09 (0.50 – 8.82) 0.32 
Rheumatoid arthritis 0.49 (0.37 – 0.65) <0.001  0.98 (0.80 – 1.20) 0.86 
THR= Total Hip Replacement 
HR= Hazard Ratio 
95% CI= 95 percent Confidence Interval 
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6 DISCUSSION 
6.1 Birth rate 
The main finding in study I was that THR patients had lower fertility when 
comparing to reference individuals, in both women and men. THR patients had a 
lower birth rate and a lower probability of having a child after surgery. Even after 
taking possible confounding factors into account, THR patients still had a lower 
probability of having a child, and in women this difference was especially evident 
(for men, aHR = 0.80; for women, aHR = 0.56). Our study is the first of its kind 
and gives baseline information about the birth rate of offspring in both women and 
men who have undergone THR. 
Although the birth rate was not the main aim of studies II, III, and IV, it can be 
interpreted from the results. All of the studies showed inferior pregnancy and birth 
rates among women with THR compared with women without THR. The pregnancy 
rate in study IV was over twice as high as in the reference group. Moreover, the 
available IAs were also counted in study IV. The groups were matched by age, so 
age should not explain the results.   
Marital status did not confound the effect of THR on birth rate in our study, but 
it slightly modified the association. As exact information on marital status at the time 
of THR was not available, information on the first marriage was used and the groups 
were categorized as ever married or never married. Information on DM and RA 
diagnosis was obtained at the time of THR. DM is known to reduce fertility rates 
among men and women (Sjöberg et al., 2013). RA reduces female fertility compared 
with women without RA (Skomsvoll et al., 2001; Wallenius et al., 2011). Due to the 
missing information on possible changes in marital status, DM or RA, these factors 
were not included in the analyses as time-dependent covariates, and therefore 
residual confounding due to these factors is possible. 
We did not have information on possible gynecological or urological procedures, 
or any other factors that might reduce fertility or cause infertility. Also, no 
information on spontaneous or induced abortions was available for this part of the 
study, but this was analyzed in studies II and IV where no evidence of higher IA 
rates was found among THR patients. The exclusion of these factors may have 
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affected residual confounding in study I, so these results should be interpreted with 
caution. 
We restricted the age of the study cohort to women aged from 15 to 45 and to 
men aged from 15 to 50 at the time of THR. Aging affects a woman’s reproductive 
potential through menopause, but the effects of aging on the fertility of a man remain 
poorly defined (Johnson et al. 2015). However, men over 51 years are still of a fertile 
age. The exclusion of the offspring of men aged over 50 at the time of the THA may 
have biased our results, if the birth rate differed substantially between THA patients 
and reference individuals in this age group. 
According to earlier studies, pregnancy and delivery can occur safely after THR 
(Sierra et al., 2005; Stea et al., 2007). Pregnancy and delivery are not associated with 
lower function of the prosthesis, and the radiographic appearance of the prosthesis 
is not adversely affected by pregnancy (Lally et al., 2015; McDowell & Lachiewicz, 
2001; Meldrum et al., 2003; Sierra et al., 2005; Stea et al., 2007). Furthermore, 
pregnancy does not increase the number of early revisions of hip prostheses (Smith, 
M. et al., 2008), and pregnancy and delivery are not associated with a lower survival 
rate of hip prostheses. Furthermore, there is no increase in pregnancy-related 
complications in pregnancy after THR (McDowell & Lachiewicz, 2001; Smith, M. et 
al., 2008). In all these earlier studies (presented in Table 3), the study groups have 
been small and there have been no proper reference groups. In addition, no previous 
studies have been carried out on the birth rate of offspring of men in partnerships 
after THR. 
One explanation for the lower birth rate in all THR patients might be a lower 
quality of life in THR patients than in people with no THR. It has been reported 
that THR patients fared worse in many areas of perceived health. (Rasanen et al., 
2007) Another study showed that quality of life is similar in THR patients and in 
people without THR in most dimensions (Stea et al., 2007). In contrast, it has also 
been found that people who have a condition that may require THR suffer from a 
lower quality of life (Sierra et al., 2005; Stea et al., 2007). It has also been reported 
that THR reduces hip-related problems in the sexual life of RA patients (Baldursson 
& Brattström, 1979; Harmsen et al., 2016; Stern et al., 1991). Overall, THR improves 
quality of life compared to the pre-operational situation in many dimensions and 
may therefore increase birth rate as the patient’s quality of life improves after surgery. 
Having previously had live-born children before THR affected the birth rate after 
THR in both men and women. Compared with those who already had children, both 
patients and reference individuals with no children before surgery had a higher birth 
rate after surgery. While the birth rate was consistently higher in the reference 
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population, the difference in birth rates between THR patients and their designated 
references was less pronounced in those individuals who had previously had live-
born children. This change in birth rates can also be seen as a change in hazard ratios 
for a live-born child when comparing THR patients with reference individuals. This 
could be due to a tendency of the reference group to have reached their planned 
family size at a younger age because of their higher quality of life. 
 
6.2 Induced abortions 
Our study (II) showed no increase in the risk of pregnancy ending in induced 
abortion in women with THR compared with women in the reference group without 
THR. When adjusting for available and possible confounders, such as age, marital 
status, previous deliveries, and abortions, the risk for abortion was increased in 
relation to the reference group but remained borderline non-significant. More 
abortions were carried out due to maternal health reasons in the THR patient group 
than in the reference group. 
No differences in IA proportions between the groups were observed when the 
THR patients were compared with the referents. The IA proportions in all groups 
were similar to the overall national abortion proportion in 2015 (14.5%). IA rates in 
the THR patient group were lower compared with the reference group and national 
means. This finding was due to the lower number of pregnancies per woman in the 
THR patient group. We showed in study I that women have a lower birth rate after 
THR compared with women without THR. 
Since no previous studies have analyzed the connection between THR and IA, 
we had to evaluate the effect of other possible factors influencing IA risk. Women 
with THR had lower SES than the referents. Low SES is a risk factor for induced 
abortion. Women with a lower educational level or income have a higher rate of IA 
when compared with women with a higher educational level and income (Perez, 
Garcia-Subirats, Rodriguez-Sanz, Diez, & Borrell, 2010; Perez, Ruiz-Munoz, 
Gotsens, Cases, & Rodriguez-Sanz, 2014). Low income levels and low educational 
levels are risk factors for IA (Jones et al., 2002; Väisänen, 2015). The same effect was 
seen in our study population where blue-collar workers had a higher IA rate than 
persons with a higher SES. Although THR patients had lower SES, our study showed 
no increase in risk for IA in the THR group. However, the number of persons with 
missing information on SES was high in our study.  
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Previous IA was a high risk factor for IA in this study (Heikinheimo et al., 2009; 
Leppälahti et al., 2012; Väisänen & Murphy, 2014). Previous studies have verified 
evidence on repeat IA, where the decision to have a second IA is easier after a 
previous IA (Skjeldestad, 1994). The incidence of repeated IAs is decreasing, 
however (Laanpere et al., 2014).  Providing free, long-acting reversible contraception 
after IA has been proven to be effective in decreasing repeat IA (Heikinheimo et al., 
2008; Pohjoranta et al., 2015). After THR, women were more likely to have their 
first IA, which may indicate that THR might increase the IA risk.  
In the THR patient group, there were more abortions both before and after THR 
due to maternal health indications than in the referents. Women with THR might 
have concerns about pregnancy, which could lead to a higher IA rate, although there 
is no evidence of THR complicating pregnancy or affecting pregnancy outcome 
(Maffulli, Del Buono, & Denaro, 2012; McDowell & Lachiewicz, 2001; Sierra et al., 
2005; Stea et al., 2007). Our results could serve to reduce these concerns. The THR 
patients might have had more baseline diseases compared with the referents, and 
some diseases are known to increase IA rates. For example, women using 
psychotropic medication or biological RA medication have increased abortion rates 
(Gissler, Artama, Ritvanen, & Wahlbeck, 2010; Vinet, É et al., 2013). Asthma has 
also been shown to increase IA rates (Blais et al., 2013; Tata et al., 2007). This finding 
could not, however, be identified in our present study due to the small incidences of 
chronic diseases (except RA) and the information on exact medications was not 
available. 
 
6.3 Deliveries 
The intended modes of delivery differed between groups in study III. Women in the 
THR group had more elective CS and fewer trials of labor than women in the 
reference group. One explanation for the higher rate of elective CS could be that 
patients with a replaced hip opt to have elective CS because of a possible fear of 
damaging the THR implant and negatively affecting the delivery outcome in vaginal 
delivery. Earlier studies have reporter that patients with THR and their obstetricians 
have chosen CS because of the fear of vaginal delivery harming the implant 
(Meldrum et al., 2003; Ostensen, 1993). Women with congenital hip dysplasia might 
reportedly have a tighter pelvis that could complicate vaginal deliveries (Meldrum et 
al., 2003). Women in the THR group already had higher CS proportions before THR 
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compared with the reference group, which might be explained by the underlying 
diseases. A German cohort study showed that women with chronic diseases were 
more likely to deliver by CS than healthy referents. (Kersten et al., 2014) The 
following chronic diseases have been shown to increase the risk for CS: 
pregestational DM (Berger et al., 2016), RA (Wallenius et al., 2014), obesity (Vernini 
et al., 2016), and epilepsy (Artama, Miia et al., 2017). It is also possible that 
obstetricians more often want to carry out CS due to a fear of obstetric complications 
among patients with THR.  
The trials of labor were more likely to result in acute CS in the THR group 
compared with the reference group. It remains unclear whether this finding was due 
to possible abnormalities in cardiotocography or prolonged first or second stage 
labor since this information was not unfortunately available. It is also possible that 
not all THR patients classified as having a trial of labor were really opting for vaginal 
delivery. The small percentage of epidural analgesia and amniotomies after THR may 
be explained by the possibility that a considerable number of parturients in that 
group had actually planned elective CS, but it had been converted to emergency CS 
for reasons such as early onset of labor. Our results differ from those of the largest 
previous study by Sierra et al. who observed a total of 47 deliveries after THR and 
suggested that the percentage of CS (35.0%) in their patient series did not differ from 
national levels(Sierra et al., 2005). A couple of smaller patient series also reported 
similar CS rates compared to national levels in their studies (Lally et al., 2015; Yazici 
et al., 2003; Yoon, H. J. et al., 2012), while some smaller studies have reported 
increased rates of CS (41.1%-100%) (Meldrum et al., 2003; Ostensen, 1993; Stea et 
al., 2007). However, none of these previous studies have had control groups without 
THRs. 
 
6.4 Neonates 
The results of the study III raise the concern that adverse pregnancy outcomes are 
significantly more common in women after THR than women before THR or 
without THR. These complications included stillbirth, preterm birth, and LBW and 
SGA neonates. 
In Finland, the national stillbirth rate has been between 3 to 5 per 1000 births for 
the last 30 years.(Vuori & Gissler, 2016) The stillbirth rate of the control group, as 
well as the patient group before THR, was similar to national levels, but in the patient 
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group after THR it was four to five times higher. One reason for the increased 
stillbirth rate might be the underlying diseases of the THR patients. Two of the four 
women in the patient group with a stillbirth had RA. In large cohort studies, RA has 
been shown to increase the risk of preterm birth and SGA neonate, but not for 
stillbirths or perinatal mortality (Aljary et al., 2018; J.F Skomsvoll, V Baste, M 
Østensen, L.M Irgens, 1999; Wallenius et al., 2014). However, the prevalence of RA 
was also high in the patient group before THR. 
There have been some reports describing the possible effects of ion release from 
metal-on-metal implants on fetal health. Chromium and cobalt have been shown to 
be toxic, but it is believed that the increased blood metal ion concentration remains 
below teratogenic levels. The placenta also prevents a great proportion of the ions 
from entering the fetal blood circulation. (Brodner et al., 2004; Novak et al., 2014; 
Ziaee et al., 2007) Although the concentrations of metal ions may remain below 
teratogenic levels, the slightly elevated fetal blood metal ion level might influence the 
growth of the fetus and may be involved in preterm births or stillbirths. MoM-
implants gained popularity in Finland in 2000 and remained in use widely for the 
following 10 years. In this study, the MoM-implant THR group had a higher SGA 
proportion than the non-MoM group, but no other differences in pregnancy 
outcomes were found. We had no information available on maternal metal ion levels. 
 
6.5 Congenital anomalies 
We found in study IV that newborns after maternal THR have similar rates of 
congenital anomalies compared with referents without THR. According to these 
results, it seems safe to give birth after THR. Moreover, non-MoM implants had 
similar proportions of anomalies as the reference group. Since the birth rate is lower 
after THR (Studies I,II,III, and IV) and patients might have concerns about 
pregnancy after THR (Meldrum et al., 2003; Sierra et al., 2005), these findings could 
possibly serve to lessen these concerns.    
Although women with MoM-THR had a slightly higher incidence of congenital 
anomalies than either the patients with non-MoM THR or referents, these 
differences were not statistically significant. Due to the low number of MoM patients 
and events in this study, however, the true effect remains unclear. MoM implants 
have been shown to release metal ions (Cr and Co) into the blood circulation and 
may be harmful to human cells (Daley et al., 2004; Hartmann et al., 2013; Langton 
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et al., 2010). Even though the placenta prevents the majority of the ions from 
entering the fetal blood circulation (transfer rate for Cr 0.10-0.30 and for Co 0.46-
0.61), the ion levels in the fetuses of MOM THR patients have been shown to be 
elevated compared with fetuses without maternal MoM THR Table 2, (Novak et al., 
2014; Ziaee et al., 2007).  
There have been two previous case reports in which congenital anomalies have 
been detected in the offspring after maternal MoM THR. The other was thought to 
be hereditary and had multiform congenital anomalies similar to those found in elder 
siblings. The other case was hypospadias. (Brodner et al., 2004; Oppermann et al., 
2015) Johnson et al. contacted retrospectively 48 women aged under 40 at the time 
of MoM hip resurfacing. Among these women, 17 pregnancies occurred with 14 
livebirths. No congenital anomalies were reported. This study also reported no 
problems in childhood development among these children. (Johnson et al., 2013) 
Based on the previous literature and the results of our study, the possible teratogenic 
effect of the metal-ions released from the MoM implant cannot be ruled out.  
There were no major differences when the types of anomaly were compared 
between the groups. The most common anomaly in both groups was heart and other 
circulatory organ anomalies. Interestingly, neonates in the reference group seemed 
to have higher proportions of facial anomalies compared with the THR group. 
However, due to the small incidences of anomalies, the comparison of groups based 
on anomaly types was not statistically sound. 
Since THR patients have higher incidences of juvenile RA compared with 
national levels, it was also taken as part of the analysis in our study. RA does not 
increase the risk of congenital anomalies, although some of the drugs used to treat 
RA have been shown to be teratogenic and are thus prohibited during pregnancy 
(Posfai, Banhidy, Urban, & Czeizel, 2015; Sihvonen & Pertovaara, 2019; Wallenius 
et al., 2014; Williams & Chakravarty, 2014). In our study, the THR and RA patients 
had similar rates of congenital anomalies compared with non-RA patients. 
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6.6 Implant survival 
To the best of our knowledge, our study is the first one to assess THR implant 
survivorship in fertile-aged women in a large population-based study sample. Based 
on our results, delivery does not seem to adversely affect hip implant survivorship 
after primary THR. 
Our results are in concordance with previous smaller studies. In their study, Sierra 
et al. (2005) reported that delivery after primary THR does not decrease the survival 
rate of the implant. They had the largest number of participants prior to our study. 
In total, 343 women with 420 THR were contacted and 47 of those had pregnancy 
ending in delivery. The survival rates for the 5- , 10- and 15-year follow-up periods, 
however, were calculated for the whole cohort with no comparisons made between 
the delivery and non-delivery groups. Our 6-year survival rate in both groups was in 
line with these results. Meldrum et al. (2003) had 13 hips with deliveries in their study 
population and reported no adverse effects for THR. Yazici et al. (2003) reported 21 
THR patients with deliveries and no decrease in the survival rate of the THR. All 
these studies were retrospective with alternative response rates (30 to 75%). 
McDowell and Lachiewicz (2001) reported 5 women with 7 uncemented THRs 
having deliveries and compared them with matched referents, and no differences 
between survival or hip functions were reported. Our study is the only one to report 
a slight but not statistically significant decrease in implant survival rate in the Kaplan 
Meier analysis after delivery. 
Cesarean section (CS) rate was markedly increased in the delivery group 
compared to the overall CS rate in Finland. There have been previous reports in 
which it has been suggested that women with dysplastic hips have smaller pelvic 
diameters, and they therefore tend to have CS (Sierra et al. 2005; Stea et al. 2007). In 
our study, developmental dysplasia of the hip was an equally common indication for 
THR in women who only had cesarean sections after THR as in those who delivered 
vaginally after THR. Also, there were no differences in revision indications between 
them. The reason for the very high CS rate in the delivery group remains unknown. 
We can only speculate that the presence of THR may have affected the patients’ 
and/or the physicians’ choice of delivery. However, it did not have any effect of 
THR survival rates. 
Age was the only statistically significant variable that negatively affected THR 
implant survivorship. The median age of the delivery group at the start of the follow-
up was 29 years compared with the reference group´s 40 years. Previously, only 
Sierra et al. (2005) have applied the Cox regression model to analyze implant 
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survivorship after delivery. In their model, delivery seemed to decrease THR 
survivorship, but once age at the time of primary THR was taken as part of the 
model, no further differences between the delivery group and the reference group 
were obtained. Previous non-delivery related THR survival studies have reported 
similar findings of weaker implant survivorship in younger patients (Dorr et al. 1994; 
Nam et al. 2016; Tsukanaka et al. 2016). In particular, very young patients under 30 
years have been reported to have had decreased THR survivorship (Mohaddes et al. 
2019). This finding is probably because of higher activity levels. (Adelani et al., 2013; 
Dorr et al., 1994) Our survival rates were slightly lower compared to a recent study 
by Mohaddes et al. (2019) in which the 15-year THR survival rate for patients aged 
under 30 at the time of THR was 76%.  
In young patients (<50 years or less), indications for THR differ in comparison 
with older patients (+50 years). In younger patients, inflammatory arthritis and 
developmental hip diseases are more common, and primary osteoarthritis is rare 
(Adelani et al. 2013). Developmental dysplasia of the hip decreases the survival of 
the hip prosthesis in young patients (Havelin et al. 2000; Tsukanaka et al. 2016). 
There have been controversial results regarding the survival of the THR in RA 
patients. Some studies have suggested decreased THR survivorship, more common 
radiographic findings indicating implant failure, poorer function, and increased 
mortality among patients with RA (Creighton et al. 1998; Goodman et al. 2014; 
Havelin et al. 2000; Schrama et al. 2015; Singh & Lewallen 2013; Tang & Chiu 2001). 
Inflammatory arthritis as primary diagnosis for THR may also increase revisions due 
to deep infections (Dale et al. 2012). Previous large national cohort studies have, 
however, shown no decrease in THR survival due to RA (Eskelinen et al. 2006; 
Furnes et al. 2001; Havelin et al. 2000). Because of the high prevalence of RA among 
young patients, it was taken as part of the Cox model. In our model, RA did not 
decrease THR survival. Indeed, it seemed patients with RA had better results during 
the first follow-up period (< 6.8 years). A similar finding was seen in a previous THR 
and delivery study, where Serra et al. (2005) found no decrease in the survival of hips 
operated due to RA diagnosis in their step-by-step Cox results.  
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6.7 Strengths and limitations 
 
6.7.1 Strengths of the study 
Overall, the main strengths of this study are the following:  
First, a long study period provided us with by far the largest population of fertile-
aged THR patients and increased the accuracy of our analysis.  
Second, our study was a nationwide study that represented the whole country 
instead of a local population from one hospital region. This makes our results more 
generalizable, although the events in this study were rare.  
Third, the register-based approach eliminates any possible recall and reporting 
bias. For example, the indications of the surgeries are known, and the dates of the 
events are exact, which allowed us to calculate reliable follow-up periods if needed. 
Additionally, the data for the registers are gathered as structured which increases the 
reliability.  
Fourth, the overall quality and completeness of the registers has been proven to 
be excellent (Heino et al., 2018; THL, 2018c; THL, 2018d).  
Fifth, the combination of the different registers enabled the unique study design.  
Sixth, we were able to compare birth rate, IAs, pregnancies, deliveries, and 
neonates both before and after THR with a reference group.  
 
6.7.2 Main limitations of the study 
There are also some limitations to our results in this study, which are mainly due to 
the register-based study design. Also, throughout the study, we had to analyze our 
results with caution, since the THR patient group had much higher proportion of 
RA. Due this reason, the RA has been taken as part of the analyses to control the 
bias of confounding by indication. This means, that the results might be due the 
underlying disease that has led to THR and not due the THR itself.  
First, although the register data have excellent overall coverage and completeness, 
there were, however, a few key variables in these registers with poor levels of content. 
For example, in study II, SES was only available for 34.1% of the participants, and 
in study III, information on previous preterm deliveries or previous SGA children 
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was not available. Moreover, no information on body mass index was recorded 
before 2004 and the register data had only contained information on 1-minute 
Apgar-scores, since 5-minute scores only became part of the register in 2004. Also, 
delivery stage durations were not found in most of the cases, since they also only 
became part of the register in 2004. Information on marital status in the studies was 
categorized as never married or ever married and was not fully time specific for our 
study period.  
Second, the information on long-term diseases was gathered from the medical 
reimbursement statistics instead of from hospital discharge data or medical treatment 
data. Everyone with at least one reimbursement period due to disease during their 
lifetime is included in the register. The reimbursement is based on the diagnosis of 
DM or RA, and therefore DM or RA medications prescribed for other indications 
are not included in the reimbursements for these chronic diseases. Furthermore, it 
is possible that some of the subjects with recently diagnosed DM or RA had not yet 
been included in the register. Also, some DM patients, such as diabetes type-II 
patients, are not reimbursed for medication due to the low cost of basic DM 
medications. 
Third, the long study period. During the 20-year period, delivery methods 
changed. The use of forceps has decreased, whereas the use of vacuum extraction in 
deliveries has increased. Also, the medications used for the treatment of RA have 
changed during this period, and especially when biological medications came in to 
use in the early 2000s. Trends in THR surgery have also changed back and forth 
during the 20-year period of the study.  
Fourth, our study period did not perfectly match with the main years of use of 
MoM implants. MoM implants gained popularity in Finland in the early 2000s and 
were widely used until 2012. These implants were known to have poorer survival 
rates than non-MoM implants (Furnes, Ove et al., 2014; Smith, A. J., Dieppe, 
Vernon, Porter, & Blom, 2012b; Varnum et al., 2015). However, this could not be 
seen in the results of the current study with a rather short follow-up period for MoM 
implants. Also, an even longer study follow-up would have aided us in evaluating 
more reliably whether MoM implants would potentially affect the incidence of 
anomalies. 
Fifth, the low number of events in study IV decreased the generality of our results 
and meant a lack of statistical power. Since THR is a relatively rare operation in 
younger fertile women, the number of pregnancies as well as the number of the 
anomalies remained quite small. 
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Sixth, there was a lack of PROMs in study V. Therefore, we had to focus solely 
on THR survival, and function after delivery could not have been analyzed in a larger 
setting.   
 
6.8 Future studies 
According to our results, future research should analyze the effects of maternal THR 
on fetal growth and adverse pregnancy outcomes in a larger multinational register-
based cohort study. Another possible future topic could be the effect of MoM 
implants on neonate outcome and risk of congenital anomalies. Such a multinational 
register-based cohort study would have a longer study period and a larger study 
population and initial participant inclusion to address the topic more precisely.   
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7 SUMMARY AND CONCLUSIONS 
The goal of this study to provide new information on reproductive health after THR 
in fertile-aged patients. We conducted a nationwide register-based cohort study for 
the period 1987 to 2007 to evaluate birth rate, induced abortions rate, deliveries, 
neonate outcome, and congenital anomalies after THR compared with a reference 
group without THR. Further, the survivorship of the hip implant after delivery was 
analyzed. The following are the principal findings and conclusions of each study: 
 
i. THR patients had a lower birth rate and probability of having a child after 
surgery, even after taking possible confounders into account. 
ii. The THR patient group had higher induced abortion proportions 
compared with the reference group before and after THR. After THR, 
patients were not more likely to have a pregnancy ending in induced 
abortion. This finding remained statistically insignificant after adjusting 
with possible confounders. 
iii. According to the findings of this study, adverse pregnancy outcomes 
(preterm birth, LBW, SGA, and stillbirth) are more common in women 
who have undergone THR. As a result, such women are more likely to 
have elective and emergency cesarean sections after THR.  
iv. Maternal THR does not increase the risk of congenital anomaly in 
neonates. Further studies with larger study populations and longer 
follow-up are needed to confirm our finding of unelevated risk for 
anomalies in the offspring of women having undergone MoM THR. 
v. Based on the findings of this nationwide study delivery does not seem to 
decrease THR implant survivorship. Hence, women should not be afraid 
of or try to avoid becoming pregnant after THR. 
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Background and purpose — There have been few studies on the 
effect of THR on pregnancy or delivery, and they have mainly 
been based on small and regional data. We evaluated the birth 
rate nationwide in patients of fertile age with THR.
Patients and methods — This nationwide population-based 
cohort study was based on registry data on 5,863 Finnish THR 
patients who had undergone a THR between 1985 and 2006, and 
who were aged 15–45 years (females) or 15–50 years (males) at the 
time of THR. The matched reference cohort consisted of 17,575 
sex- and age-matched individuals (3 for each patient) who were 
alive and resident in Finland at the time of the patient’s THR. 
Birth rate and Cox hazard ratios (HRs) with 95% CI for live 
births were calculated.
Results — The birth rate after THR was approximately 20–60% 
lower in the male and female patient groups than in the reference 
individuals. The probability of having a live birth after THR was 
lower in female patients than in reference individuals, in all but 
the oldest age group (40–45 years). The same phenomenon was 
seen in male patients in all but the youngest age group (15–19 
years). Adjustment for potential confounders increased the prob-
ability of THR patients having a live birth compared to reference 
individuals, but the birth rate was still clearly reduced (in men, 
adjusted HR = 0.80, 95% CI: 0.69–0.92; in women, adjusted HR 
= 0.56, 95% CI: 0.46–0.68). 
Interpretation — THR has a substantial effect on the birth rate 
of offspring, in both women and men. THR patients had a lower 
birth rate and probability of having a child after surgery, even 
after taking possible confounders into account.
■
Approximately 25% of all total hip replacement (THR) pro-
cedures are carried out on younger people, and slightly more 
than 50% on women (Lucht 2000, Furnes et al. 2001, Puo-
lakka et al. 2001, Malchau et al. 2002).
There have been few studies on the effects of THR on 
pregnancy or delivery and vice versa. In addition, such stud-
ies have been mainly based on small material and regional 
data (Monaghan et al. 1987, Ostensen 1993, McDowell and 
Lachiewicz 2001, Boot et al. 2003, Meldrum et al. 2003, 
Yazici et al. 2003, Ginsel and Pijnenborg 2005, Sierra et al. 
2005, Stea et al. 2007). Previous studies have not found any 
correlation between THR and complications during preg-
nancy or delivery (McDowell and Lachiewicz 2001, Mel-
drum et al. 2003, Sierra et al. 2005). Furthermore, neither 
pregnancy nor delivery has been shown to reduce the survival 
of the THR (McDowell and Lachiewicz 2001, Meldrum et al. 
2003, Sierra et al. 2005, Stea et al. 2007). Previous studies 
have also suggested that THR is not a contraindication for 
normal vaginal birth (Monaghan et al. 1987, Ostensen 1993, 
Meldrum et al. 2003, Yazici et al. 2003, Sierra et al. 2005, 
Stea et al. 2007). Women of fertile age who have undergone 
a THR procedure are often concerned about the effect of 
their hip replacement on pregnancy and delivery (Smith et 
al. 2008). In addition, sex life can also be limited after THR, 
at least in patients with rheumatoid arthritis (RA) (Baldurs-
son and Brattström 1979). Previous studies have focused on 
pregnancy and delivery in women with THR. To the best of 
our knowledge, there have been no studies that have analyzed 
birth rate after THR.
We analyzed the effect of THR on birth rate using nation-
wide population-based registry data. We also assessed whether 
diabetes mellitus (DM) and RA affect the fertility of patients 
who have undergone THR. Our hypothesis of a lower birth 
rate was more sociologically-based than biologically-based. 
Women with THR may be more concerned about the course 
of pregnancy, and people with THR may have reduced sexual 
activity. Furthermore, the effects of the use of bone cement, or 
metal-on-metal articulation, on semen quality and fertility in 
men are still unclear.
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Patients and methods 
The study was based on information recorded in 4 national 
registries in Finland. Information on THRs was obtained from 
the Finnish Arthroplasty Register, which is part of the man-
datory Implant Register maintained by the Finnish National 
Institute of Health and Welfare. The Arthroplasty Register has 
information on all primary arthroplasty procedures carried out 
in Finland (Puolakka et al. 2001) The coverage of the Register 
is good, and most of the content corresponds well with hos-
pital record data. Currently, over 97% of all implantations are 
recorded (Finnish Arthroplasty Register 2015). 
We included patients who underwent a THR between 1985 
and 2006 and who were aged from 15 to 45 years (females) 
or 15 to 50 years (males) at the time of the THR. Although 
men are usually fertile long after 50 years of age, we did not 
include men over 50 years of age at the time of the THR, to 
avoid having senior THR patients during the follow-up (0–31 
years). Information on the reference group without THR was 
obtained from the mandatory Population Register, which is 
maintained by the Finnish Population Register Center. For 
each patient, 3 reference individuals without THRs, who were 
alive and resident in Finland at the time of the patient’s THR, 
were selected with matching for sex, age, place of residence, 
and mother tongue. Information on previous live-born chil-
dren before THR (0 vs. ≥ 1), marital status (never married vs. 
ever married), emigration, and death for the whole study pop-
ulation was gathered from the Population Register. Informa-
tion on diabetes mellitus (DM) and rheumatoid arthritis (RA) 
was obtained from the Social Insurance Institution of Finland, 
which maintains the register of medical reimbursements due 
to chronic diseases and includes information on DM and RA. 
The prerequisite for reimbursement is a medical certiﬁ cate 
showing that the diagnosis was based on clinical examination, 
that it fulﬁ lled international criteria, and that a board-certiﬁ ed 
medical doctor carried out the examination. If information on 
the person was not present in the register, he/she was classiﬁ ed 
as not having these diseases.
We were able to link all the information from these 4 
national registers using the unique personal identiﬁ cation 
number assigned to all residents of Finland. 
Statistics
The Cox multiple regression model with hazard ratios (HRs) 
and 95% conﬁ dence intervals was used to evaluate the risk for 
the ﬁ rst live-born child in patients after THR, in relation to 
reference individuals without THR. The start of the follow-up 
was the date of the patient’s THR. The date of the THR of the 
patient was also the start of the follow-up for the correspond-
ing reference individuals. The endpoint of the follow-up was 
the date of birth of a ﬁ rst live-born child after the start of the 
follow-up, date of emigration of the patient, date of death of 
the patient, or the common closing date (January 26, 2011), 
whichever occurred ﬁ rst. 
Stratiﬁ ed analyses were conducted according to age at 
the start of follow-up (< 20, 20–34, 35–39 and ≥ 40 years), 
number of live births before THR, marital status, DM, and 
RA. Separate adjusted multivariable analyses were conducted, 
which included age at the time of THR, marital status, number 
of previous live-born children before THR, and DM or RA 
diagnosis as potential confounding factors. The age at the start 
of the follow-up was used as a continuous variable in these 
adjusted analyses. All the analyses were conducted separately 
for men and women. PASW Statistics for Windows, SPSS ver-
sion 18.0, and STATA 8.2 were used for the statistical anal-
yses. The subjects registered in the registries were not con-
tacted, so according to Finnish regulations, informed consent 
was not required.
Results 
The THR patient group comprised 3,434 men and 2,429 
women, and the reference group comprised 10,299 men and 
7,276 women. The mean follow-up time was 11 (0–31) years 
for male patients and 11 (0–31) years for male reference indi-
viduals, and for women the mean follow-up time was 14 (0–31) 
years for patients and 14 (0–31) years for reference individuals. 
The mean age at the start of follow-up was 43 (15–50) years 
in men and 38 (15–46) years in women. During the follow-up, 
the number of ﬁ rst live-born children after THR was 435 for 
patients and 2,213 for reference individuals (Table 1).
Birth rate varied according to age at the start of follow-up, 
according to the number of previous live-born children before 
THR, and according to marital status (Table 2). However, birth 
rate was lower in all the patient groups than in reference indi-
viduals, in both sexes, and regardless of number of previous 
children. Male THR patients with DM had a higher birth rate 
than reference individuals without THR but with DM. The 
same was seen in male THR patients with RA. In women, the 
birth rate was lower in THR patients with either DM or RA 
than in reference individuals. Birth rate was lower in all age 
groups of the patient population than in reference individuals. 
These differences were especially obvious in female patients 
in the 2 youngest age groups and in male patients aged 20–35 
years. 
The reduced probability of a live-born child when compar-
ing patients with reference individuals could also be seen in 
Cox regression models (Table 3). Overall, the probability of 
having a live-born child after THR was lower in male THR 
patients (HR = 0.69, CI: 0.60–0.79) and female THR patients 
(HR = 0.47, CI: 0.40–0.55) than in reference individuals, and 
also in adjusted analyses (for men, adjusted HR (aHR) = 0.80, 
95% CI: 0.69–0.92; for women, aHR = 0.56, CI: 0.46–0.68) 
(Table 3). Female THR patients had a lower probability of 
having a live-born child than reference individuals, in all but 
the oldest age group (40–45 years). The same phenomenon 
was seen in male patients, in all but the youngest age group 
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(15–19 years). Adjustment for potential confounding factors 
(age at the start of follow-up, number of live-born children 
before THR, marital status, DM, and RA) reduced the prob-
ability of having a live-born child in THR patients compared 
to reference individuals. In THR 
patients with DM or RA, however, 
HRs were similar.
Discussion
The main result of this population-
based study was that THR had a 
substantial effect on birth rate when 
comparing THR patients and refer-
ence individuals, and in both women 
and men. THR patients had a lower 
birth rate and a lower probability of 
having a child after surgery. Even 
after taking possible confounding 
factors into account, THR patients 
still had a lower probability of 
having a child, and in women this 
difference was especially evident 
(for men, aHR = 0.80; for women, 
aHR = 0.56). Our study is the ﬁ rst of 
its kind and gives baseline informa-
tion about the birth rate of offspring 
in both women and men who have 
undergone THR.
The study had some limitations. 
The identiﬁ cation of patients with 
DM or RA may have been incom-
plete. The diagnosis of DM was 
based on special medication reim-
bursements due to chronic diseases. 
Everyone with at least one reim-
bursement period due to the disease 
during their lifetime is included in the 
register. The reimbursement is based 
on the diagnosis of DM or RA, and 
therefore DM or RA medications 
prescribed for other indications are 
not included in the reimbursements 
due to these chronic diseases. Fur-
thermore, it is possible that some of 
the subjects with recently diagnosed 
DM or RA were not yet included in 
the register. Also, some DM patients 
such as diabetes type-II patients are 
not reimbursed for medication and 
therefore do not use drugs for their 
treatment. Such patients were not 
included in the register. Informa-
Table 1. Numbers of subjects and live births in patients with total hip arthroplasty (THA) and 
reference individuals without THA according to age at the start of follow-up, number of previ-
ous live-born children before THA, marital status, diabetes mellitus diagnosis, and rheumatoid 
arthritis diagnosis in Finland, 1985–2006 
 Men Women
 No. of subjects No. of live births No. of subjects No. of live births
 Patient Ref. Patient Ref. Patient Ref. Patient Ref.
Age in years at the start of follow-up
 15–19 28 84 6 29 50 150 15 90
 20–34 414 1,240 127 571 621 1,847 140 824
 35–39 509 1,528 64 257 571 1,722 22 167
 40–45  1,151 3,465 36 193 1,187 3,557 4 28
 46–50 for men 1,332 3,982 20 54 N/A N/A N/A N/A
No. of previous live-born children before THA
 0 1,101 2,984 95 435 831 1,871 100 552
 ≥ 1 2,333 7,315 159 669 1,598 5,405 81 557
Marital status        
 Never married 887 2,466 32 183 628  1,370 34 190
 Ever married 2,547 7,833 222 921 1,801 5,906 147 919
Diabetes mellitus        
 Yes 87 174 4 6 35 48 2 4
 No 3,347 10,125 250 1,098 2,394 7,228 179 1,105
Rheumatoid arthritis        
 Yes 505 86 44 4 811 68 70 6
 No 2,929 10,213 210 1,100 1,618 7,208 111 1,103
Total 3,434 10,299 254 1,104 2,429 7,276 181 1,109
N/A: not applicable.
Table 2. Birth rate (per 10,000 person-years) with 95% CI in patients with total hip replacement 
(THR) and reference individuals without THR according to age at the start of follow-up, number 
of previous live-born children before THR, marital status, diabetes mellitus diagnosis, and rheu-
matoid arthritis diagnosis in Finland, 1985–2006
 Men Women
  Patient Reference Patient Reference
  Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Age in years at the start of follow-up
 15–19 216 (97–480) 377 (262–542) 216 (130–358)  570 (463–700)
 20–34 300 (252–357) 515 (474–559) 165 (140–195) 400 (374–429)
 35–39 114 (89–145) 149 (132–169) 25 (16–38) 63 (54–74)
 40–45 27 (20–38) 47 (41–54) 2.4 (0.9–6.4) 5.4 (3.7–7.8)
 46–50 for men 13 (8.7–21) 12 (8.9–15) N/A N/A
Number of previous live-born children
 0 82 (67–100) 145 (132–159) 86 (70–104) 247 (227–268)
 ≥ 1 60 (51–70) 77 (72–83) 35 (28–44) 71 (65–77)
Marital status
   Never married 36 (25–50) 78 (67–90) 39 (28–55) 116 (101–134)
   Ever married 76 (67–87) 99 (93–106) 57 (48–66) 109 (102–116)
Diabetes mellitus
   Yes 52 (19–138) 38 (17–84) 46 (12–185) 70 (26–186)
   No 67 (59–76) 95 (90–101) 52 (45–61) 110 (108–117)
Rheumatoid arthritis
   Yes 64 (47–86) 40 (15–108) 53 (42–67.5) 73 (33–163)
   No 67 (59–77) 95 (90–101) 52 (43–62) 110 (104–117)
Total 67 (59–75) 95 (89–100) 52 (45–60) 110 (104–116)
tion on patients who did not want reimbursement for DM or 
RA medication was not available. In addition, if the diagnosis 
of DM or RA was made for a permanently institutionalized 
patient, information on reimbursement would not necessar-
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ily be included in the database. Those patients were probably 
under-represented in our study. However, the cost of medica-
tions for DM and RA is high in Finland, so very few people 
with DM or RA decline reimbursement for these medications.
Marital status did not confound the effect of THR on birth 
rate in our study, but it slightly modiﬁ ed the association. As 
exact information on marital status at the time of THR was not 
available, information on the ﬁ rst marriage was used. Infor-
mation on DM and RA diagnosis was obtained at the time 
of THR. Due to missing information on possible changes in 
marital status, DM or RA,  these factors were not included in 
the analyses as time-dependent covariates, and residual con-
founding due to these factors is possible. 
We did not have information on possible gynecological or 
urological procedures, or any other factors that might reduce 
fertility or cause infertility. Also, no information on sponta-
neous or induced abortions was available. Exclusion of these 
factors may have affected residual confounding, so our results 
should be interpreted with caution. 
We restricted age of the study cohort to women aged from 15 
to 45 and to men aged from 15 to 50 at the time of THR. Aging 
affects a woman’s reproductive potential through menopause, 
but the effects of aging on the fertility of a man remain poorly 
deﬁ ned (Johnson et al. 2015). However, men over 51 years are 
still of fertile age. Exclusion of the offspring of men over 50 at 
the THA may have biased our results, if the birth rate differed 
substantially between THA patients and reference individuals 
in this age group.
According to earlier studies, pregnancy and delivery can 
occur safely after THR (Sierra et al. 2005, Stea et al. 2007). 
Pregnancy and delivery are not associated with lower function 
of the prosthesis and the radiographic appearance of the pros-
thesis is not adversely affected by pregnancy (Ostensen 1993). 
Pregnancy does not increase the number of early revisions of 
hip prostheses (Smith et al. 2008), and pregnancy and deliv-
ery are not associated with lower survival of hip prostheses. 
Furthermore, there is no increase in pregnancy-related com-
plications in pregnancy after THR (McDowell and Lachiewicz 
2001, Smith et al. 2008). In all these earlier studies, the study 
groups have been small. In addition, no previous studies have 
been carried out on the birth rate of offspring of men in part-
nerships after THR.
One explanation for the lower birth rate in all THR patients 
might be a lower quality of life in THR patients than in people 
with no THR (Räsänen et al. 2007). It has been reported that 
THR patients fared worse in many areas of perceived health 
(Räsänen et al. 2007). Another study showed that quality of 
life is similar in THR patients and in people without THR, in 
most dimensions (Stea et al. 2007). In contrast, it has also been 
found that people who have a condition that may require THR 
suffer from a lower quality of life (Sierra et al. 2005, Stea et al. 
2007). It has also been reported that THR reduces hip-related 
problems in the sexual life of RA patients (Baldursson and 
Brattström 1979). Overall, THR improves quality of life com-
pared to the pre-operational situation in many dimensions, and 
may therefore increase birth rate as the patient’s quality of life 
improves after surgery.
Having had live-born children before THR affected the birth 
rate after THR in both men and women. Compared to those 
who already had children, both patients and reference indi-
viduals with no children before surgery had a higher birth rate 
after surgery. While the birth rate was consistently higher in 
the reference population, the difference in birth rates between 
THR patients and their designated references was less pro-
nounced in those who had previously had live-born children. 
This change in birth rates can also be seen as a change in hazard 
ratios for a live-born child when comparing THR patients with 
reference individuals. This could be due to a tendency of the 
reference group to have reached their planned family size at a 
younger age because of their higher quality of life. 
In summary, patients with THR have a lower birth rate after 
surgery than people without THR. The most probable reason 
for this is the underlying hip disease causing a lower quality 
of life. 
MA, ES, HH, ML, and AE had full access to all of the data in the study and 
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analysis. MA, ES, and AE contributed to the conception and design of the 
study. ML drafted the manuscript. AE supervised the study. HH was respon-
sible for the statistical analyses. All authors participated in the interpretation 
of data and in critical revision of the manuscript.
Table 3. Hazard ratio (HR) with 95% CI for a live-born child after 
total hip replacement (THR) in patients in relation to reference indi-
viduals without THR according to various demographic factors, 
diabetes mellitus diagnosis, and rheumatoid arthritis diagnosis in 
Finland, 1985–2006
    Men Women
  HR (95% CI) HR (95% CI) 
Crude 0.69 (0.60–0.79) 0.47 (0.40–0.55)
Adjusted a 0.80 (0.69–0.92) 0.56 (0.46–0.68)
Age in years at the start of follow-up
 15–19 0.57 (0.24–1.4) 0.34 (0.20–0.60)
 20–34 0.61 (0.50–0.74) 0.43 (0.36–0.51)
 35–39 0.74 (0.56–0.97) 0.38 (0.25–0.60)
 40–45 0.57 (0.40–0.81) 0.43 (0.15–1.2)
 46–50 for men 1.12 (0.67–1.9) N/A 
Number of previous live births before THR
 0 0.58 (0.46–0.72) 0.36 (0.29–0.44)
 ≥ 1 0.75 (0.63–0.89) 0.48 (0.38–0.61)
Marital status   
   Never married 0.48 (0.33–0.70) 0.36 (0.25–0.51)
   Ever married 0.74 (0.64–0.86) 0.51 (0.43–0.61)
Diabetes mellitus
   Yes 1.32 (0.37–4.7) 0.64 (0.12–3.5)
   No 0.69 (0.60–0.79) 0.47 (0.40–0.55)
Rheumatoid arthritis
    Yes 1.81 (0.65–5.1) 0.84 (0.37–1.9)
    No 0.67 (0.58–0.78) 0.44 (0.36–0.54)
HR: hazard ratio. Reference (HR = 1.0) are individuals without THR.
a Hazard ratio adjusted for age at the start of follow-up, number of 
previous live births before THR, marital status, diabetes mellitus, 
and rheumatoid arthritis.
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ABSTRACT
Background and Aims: No previous studies have analyzed the connection between total 
hip replacement and induced abortion. We evaluated the nationwide induced abortion 
rates among women with and without total hip replacement.
Materials and Methods: Data for this cohort study were gathered from national registers 
from 1987 to 2007. All fertile-aged (15–44 years old) females who had undergone primary 
total hip replacement in Finland were selected. The total hip replacement patient group 
comprised 1713 women and the reference group 5148 women. Information on all pregnancies 
for both groups before and after total hip replacement/index date was gathered from the 
medical birth register and the register of induced abortion. Logistic regression model 
was used to analyze the adjusted odds ratio for induced abortion. Adjustment was made 
for age at induced abortion, parity, previous induced abortions, previous deliveries, and 
marital status.
Results: Women had higher induced abortion proportions after total hip replacement 
(17.9%) compared with women before total hip replacement (14.1%) and the referents 
(13.9%), but the differences were not statistically significant. Women in the total hip 
replacement patient group had significantly more induced abortions after total hip 
replacement due to maternal health issues (14.7%) compared with the referents (2.7%), 
p = 0.003. Patients in the total hip replacement group were not more likely to have their 
pregnancy ending in induced abortion than the women in the reference group (odds 
ratio 1.32, 95% confidence interval 0.89–1.96, p = 0.17). However, in the adjusted analysis, 
there was a trend for higher risk for pregnancy to end in induced abortion in the total hip 
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replacement group in relation to the reference group (adjusted odds ratio 1.50 (confidence 
interval 0.99–2.28, p = 0.05).
Conclusion: The total hip replacement patient group had higher, but statistically 
insignificant, induced abortion proportions compared with the reference group before and 
after the operation. After total hip replacement, the patients were not more likely to have 
a pregnancy ending in induced abortion. This finding remained statistically insignificant 
after adjusting with possible confounders.
Key words: Total hip replacement; orthopedics; joint replacement; induced abortion; reproduction; cohort 
study; register study; pregnancy; epidemiology
INTRODUCTION
Total hip replacement (THR) is a highly effective sur-
gical procedure (1) that results in major improvements 
in the patients’ quality of life, pain, sleep, physical 
ability, and sexual function (2–4). The main indica-
tions for THR in patients under 30 years of age are 
rheumatoid arthritis (RA) (36%) and avascular necro-
sis (23%) (5), whereas indications for overall primary 
THR for all ages in Finland are primary osteoarthritis 
(78%) and RA (7%) (6).
In Finland, the total number of primary THR per 
year has grown from slightly over 5000 in 2000 to 
over 10,000 in 2017 (7). Of these, almost 60% of 
patients were female. Every year, almost 500 THRs 
are carried out on patients under 50. The number of 
patients in this age group has grown slightly since 
2003 (7). In 2007, the incidence of THR for young 
patients (30–49 years old) was 39 per 100,000 person 
years and the incidences increased slightly from 
1980 to 2007 (8).
A few studies with small sample sizes and regional 
data have investigated the effects of THR on pregnan-
cies and deliveries and vice versa. According to these 
previous studies, THR does not seem to be a contrain-
dication for pregnancy or delivery (9, 10). Moreover, 
neither pregnancy nor delivery decrease implant sur-
vival after THR (9–13). Women who have undergone 
THR seem to have lower fertility rates (14). One rea-
son for the lower fertility rates might be that women 
have concerns about pregnancy and delivery after 
THR (9). These findings could therefore implicate 
reproductive problems or an increased induced abor-
tion (IA) rate.
The rate of IA in Finland was 8.7 per 1000 fertile-
aged women (15–49 years old) in 2013 (15), which was 
the lowest rate in the Nordic countries. In 2013, the IA 
rate for the Nordic countries was 13.5/1000 fertile-
aged women. Although rates of IA have been stable in 
the Nordic countries for much of the 21st century, a 
small decline has been seen during the last 2 years 
(15). Overall, the worldwide rate of IA has been stable 
(29/1000 fertile-aged women in 2003 versus 28/1000 
in 2008) (16). The main indications for IA in Finland 
are social reasons (91.8%), fetal defects (3.4%), female 
aged over 40 at the start of the pregnancy (3.1%), and 
female aged under 17 at the start of the pregnancy 
(2.7%) (15).
Women with a lower socioeconomic status (SES) 
have a higher risk for IA compared with those of a 
higher SES (17). A Brazilian study estimated that 
women over 40 years of age or unmarried have more 
IAs than any other group (18). Furthermore, a previ-
ous IA may lead to repeat abortion (19, 20). In addi-
tion, a short time between delivery and the next 
pregnancy increases the risk for abortion (21).
To the best of our knowledge, no previous studies 
have evaluated the relationship between THR and IA. 
The aim of the present study is therefore to investigate 
whether women with THR have a higher risk of IA 
compared with a reference group without THR at the 
national level.
MATERIALS AND METHODS
In this nationwide register-based retrospective cohort 
study, data were obtained from five national health 
registers: the Finnish Arthroplasty Register (FAR), the 
Register of Induced Abortion (RIA), the Finnish 
Population Information System, the National Medical 
Birth Register (MBR), and the register of medical reim-
bursement (RMR) due to chronic diseases maintained 
by the Social Insurance Institution of Finland.
The THR patient group consisted of all fertile-
aged women (15–44 years old) who had undergone 
their first primary THR in Finland between 1987 and 
2007. The THR patients were identified from the 
FAR that is maintained by Finnish National Institute 
for Health and Welfare (THL). The FAR contains 
information on all hip and knee prostheses carried 
out in Finland. All the information in the FAR has 
been collected prospectively. The current (2017) 
completeness of the register is 95% for primary THR 
and it matches well with data from the Finnish 
Hospital Discharge Register (7).
For every THR patient, three reference persons 
without THR were obtained from the Population 
Information System maintained by the Finnish 
Population Register Center. These reference persons 
were individually matched to THR patients by age, 
place of residence, and mother tongue. Information on 
the number of biological children born to the patients 
and the referents before the end of 2007 was also gath-
ered from the population information system. The 
index date for the referents was the day their matching 
patient underwent THR.
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Information on IAs from 1987 to 2007 was obtained 
from the RIA. The RIA contains information on abor-
tion rates and indications, as well as background 
information on females who have undergone IA. The 
overall coverage of the RIA is high, as is the validity of 
most of the variables. However, some problems have 
been reported with the coverage of SES and gesta-
tional age (22).
Information on pregnancies from 1987 to 2007 was 
obtained from the MBR. The register contains infor-
mation on all births after gestational week 22 + 0 or 
birth weight over 500 g. The MBR also contains infor-
mation on maternal background characteristics, preg-
nancy history, pregnancy and delivery diagnoses, and 
neonatal data up to 7 days after birth. The MBR has 
high coverage and good quality of data, which has 
improved over time (23).
The RMR contains information on reimbursable 
costs due to chronic diseases. For reimbursement, a 
medical certificate issued by a certified doctor is 
required. Information on RA was gathered for study 
population and participants with no record of RA 
reimbursement in the RMR were classified as not hav-
ing the disease.
The start of the abortion follow-up was the 1st of 
January 1987 or the day the patient turned 15 years 
old, whichever occurred last. The endpoints for the 
abortion follow-up were the 31st of December 2007, or 
the date of the patients’ 45th birthday, emigration, or 
death, whichever occurred first.
ETHICS
All the data were linked with the unique identification 
number assigned to all residents of Finland. In accord-
ance with Finnish regulations, no informed written 
consent was required because participants in the study 
were not contacted individually. Permission for the 
data use was granted by the register holders. 
Permission number: THL/599/5.05.00/2010.
STATISTICS
The logistic regression model was used to evaluate 
whether THR increased the risk of IA. Both unad-
justed and adjusted odds ratios (ORs) with 95% confi-
dence interval (CI) were calculated. In the adjusted 
model, the following potential confounders or modi-
fiers were adjusted for age at time of abortion, parity, 
previous IAs, previous deliveries, and marital status.
Comparisons between the groups both before and 
after the THR/index date on abortion rates as well as 
on indications for abortions were carried out. Chi-
square test or Fischer’s exact test was used to analyze 
categorized variables between the THR patient group 
and the reference group. The CI for the difference 
between two proportions (later as proportion differ-
ence = PD) was used to evaluate the intergroup differ-
ences before THR and after THR in the THR patient 
group and before and after index date in the reference 
group. Statistical analyses were conducted with IBM 
SPSS for windows version 22 software. P-values under 
0.05 were considered statistically significant.
RESULTS
The total number of female participants in this study 
was 6861. Among these, a total of 6608 pregnancies 
and 885 (13.4%) IAs occurred. The THR patient group 
comprised 1713 women, with 1274 pregnancies and 
187 (14.7%) IAs. Of these, 199 pregnancies and 35 
(17.9%) IAs occurred after the THR. The reference 
group comprised 5148 women with 5334 pregnancies 
and 698 (13.1%) IAs. Of these, 1308 pregnancies and 
182 (13.9%) IAs occurred after the index date. Mean 
age at the beginning of the abortion follow-up was 
27.4 years and mean age at the THR/index date was 
37.3 years in both groups. The basic demographics of 
the patients and the referents are presented in Table 1.
In the patient group, the abortion rate was 
9.0/1000 person years (pyrs) before the THR and 
3.9/1000 pyrs after the THR. In the reference group, 
the rates were 10.2/1000 pyrs before the index date 
and 6.6/1000 pyrs after the index date. In the patient 
group, abortion rates were 17/100 births before the 
index date and 21/100 births after the index date. In 
the reference group, the abortion rate was 15/100 
births before the index date and 16/100 births after the 
index date.
TABLE 1
Background characteristics of study population.
Women with 
THR
Women without 
THR
Age at the start* of the abortion follow-up
 15–19 340 19.8 1017 19.8
 20–24 353 20.6 1062 20.6
 25–29 335 19.6 1009 19.5
 30–34 361 21.1 1072 20.8
 35–39 230 13.4 703 13.7
 40–44 94 5.5 285 5.5
Age at THR/index date
 15–19 39 2.3 117 2.3
 20–24 80 4.7 236 4.6
 25–29 155 9.0 465 9.0
 30–34 230 13.4 684 13.3
 35–39 435 25.4 1310 25.4
 40–44 774 45.2 2336 45.4
Marital status
 Ever married 1238 72.3 4059 21.2
 Never married 475 27.7 1089 78.8
Nulliparous at the start of 
the abortion follow-up
979 57.2 2706 52.6
Follow-up time (years + SD)
 Before THR/index date 9.8 5.9 9.8 5.9
 After THR/index date 5.2 4.5 5.3 4.6
Chronic diseases
 Rheumatoid arthritis 521 30.4 42 0.8
 Diabetes mellitus 28 1.6 33 0.6
 Epilepsy 6 0.4 12 0.2
 Major mental disease 3 0.2 8 0.2
THR: total hip replacement; index date: date of the operation in 
the THR patient group and the same date for matching referents; 
start of the abortion follow-up: day of the 15th birthday or 1st of 
January 1987, whichever came first.
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IA indications varied slightly between the women 
with and without THR (Table 2). More abortions were 
carried out due to maternal health reasons in the THR 
patient group. The rate of the first abortion was higher 
after THR compared with rates before the THR and 
the reference group. Interestingly, married women 
seemed to have fewer abortions after THR than 
unmarried women.
Before the THR/index date, there were 152 (14.1%) 
IAs among the THR patient group and 516 (12.8%) in 
the reference group, p = 0.25. After the THR/index 
date, the THR patient group had 35 (17.9%) IAs and 
the reference group 182 (13.9%), p = 0.17. In the THR 
patient group, number of IAs varied from 152 (14.1%) 
before the THR to 35 (17.9%) after THR (PD = 3.5, CI 
−1.7 to 9.7). In the reference group, number of IAs 
before the index date were 516 (12.8%) and 182 after 
the index date (13.9%), PD = 1.1, CI −1.0 to 3.3. Median 
time after the THR to IA was 4.0 (range 0.1–20.4) years 
in the THR patient group and before the THR, the 
TABLE 2
Total number of abortions for women with and without total hip replacement (THR) before and after THR/index date in  
Finland between 1987 and 2007.
Women with THR Women without THR
 Before THR After THR Before the index date After the index date
n = 152 % n = 35 % n = 516 % n = 182 %
Previous pregnancies
 0 46 31.1 9 25.7 176 34.3 37 20.4
 1+ 102 68.9 26 74.3 337 65.7 144 79.6
Previous abortions
 0 95 63.8 28 80.0 340 66.3 115 63.5
 1+ 54 36.2 7 20.0 173 33.7 66 36.5
Previous births
 0 57 38.0 12 34.3 229 44.4 49 26.9
 1+ 93 62.0 23 65.7 287 55.6 133 73.1
Induced abortion indications
 Social reasons 118 77.6 24 68.6 447 86.6 126 69.2
 Agea 5 3.3 4 11.4 31 6.0 23 12.6
 Maternal health 17 11.2 5 14.3 14 2.7 5 2.7
 Fetal health 6 3.9 1 2.9 13 2.5 12 6.6
 Over 4 previous births 6 3.9 1 2.9 11 2.1 16 8.8
Socioeconomic status 37 24.3 18 51.4 141 31.2 95 52.2
 Upper white-collar 1 2.7 3 16.7 14 8.7 20 21.1
 Lower white-collar 19 51.4 6 33.3 57 35.4 38 40.0
 Blue-collar 6 16.2 5 27.8 34 21.1 16 16.8
 Otherb 11 29.7 4 22.2 36 22.4 21 22.1
Age at THR/index date
 Under 20 0 0.0 4 11.4 3 0.6 15 8.2
 20–24 4 2.6 4 11.4 35 6.8 27 14.8
 25–29 16 10.5 3 8.6 58 11.2 45 24.7
 30–34 30 19.7 12 34.3 100 19.4 37 20.3
 35–39 35 23.0 9 25.7 117 22.7 43 23.6
 40 or more 67 44.1 3 8.6 203 39.3 15 8.2
Age at the time of abortion
 Under 20 12 7.9 1 2.9 49 9.5 5 2.7
 20–24 29 19.1 4 11.4 105 20.3 13 7.1
 25–29 40 26.3 4 11.4 119 23.1 30 16.5
 30–34 37 24.3 5 14.3 136 26.4 40 22.0
 35–39 29 19.1 13 37.1 79 15.3 58 31.9
 40 or more 5 3.3 8 22.9 28 5.4 36 19.8
Marital status
 Never married 51 33.6 12 34.3 159 30.8 46 25.3
 Ever marriedc 101 66.4 23 65.7 357 69.2 136 74.7
Rheumatoid arthritis
 No 131 86.2 24 68.6 509 98.6 182 100.0
 Yes 21 13.8 11 31.4 7 1.4 0 0.0
Index date: date of the operation in the THR patient group and the same date for matching referents.
aAge under 18 or over 40.
bIncludes students and non-workers.
cOnly the date of the first marriage is known. No information about divorces or new marriages.
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median time from IA to THR was 8.4 years (0.2–20.5). 
Median times in the reference group were 3.9 years 
(0.0–19.7) after the index date and 7.1 years (0.0–20.7) 
before the index date.
Women in the THR patient group were more likely to 
undergo their first IA after THR rather than before THR, 
or women in the reference group. Women in the young-
est and the oldest age group had higher IA proportions 
than those in the moderate age groups (Table 3).
Unadjusted OR for pregnancy ending in IA in the 
THR patient group after index date was 1.32 (CI 0.89–
1.96), p = 0.17, in relation to the reference group (Table 
4). When adjusted with the variables of marital status, 
age (<20 or >39), previous IAs, and previous deliver-
ies, there was a trend for higher risk for pregnancy to 
end in IA in the THR group in relation to the reference 
group (OR 1.50, CI 0.99–2.28; p = 0.05).
DISCUSSION
Our study showed no increase in the risk of pregnancy 
ending in IA in women with THR compared with 
women in the reference group. When adjusting for 
available confounders, such as age, marital status, pre-
vious deliveries, and abortions, the risk for abortion 
was increased in relation to the reference group but 
remained non-significant. More abortions were car-
ried out due to maternal health reasons in the THR 
patient group than in the reference group.
No differences in IA proportions between the 
groups were observed when the THR patients were 
compared with the referents. The IA proportions in all 
groups were similar to the overall national abortion 
proportion in 2015 (14.5%). IA rates in the THR patient 
group were lower compared with the reference group 
and national rates. This finding was due to the lower 
number of pregnancies per woman in the THR patient 
group. Our previous study showed that women have 
lower birth rates after THR (14).
Since no previous studies have analyzed the con-
nection between THR and IA, we must evaluate the 
effect of other possible factors. Women with THR had 
lower SES than the referents. Low SES is a risk factor 
for IA. Women with a lower educational level or 
income have a higher rate of IA when compared with 
women with a higher educational level and income 
(24, 25). The same effect was seen in our study popula-
tion where blue-collar workers had higher IA num-
bers than persons with a higher SES. Although THR 
patients had lower SES, our study showed no increase 
in risk for IA in the THR group. However, the number 
of persons with missing information on SES was high 
in our study.
Previous IA was a high risk factor for IA in this 
study. Previous studies verify evidence on repeat IA, 
where the decision to have a second IA is easier after a 
previous IA (26). The incidence of repeated IAs is 
decreasing, however (27). After THR, women were 
TABLE 3
Proportions of pregnancies ending in induced abortion with 95% confidence interval (CI) among women with and without total hip replacement (THR) 
before and after THR/index date in Finland between 1987 and 2007.
Women with THR Women without THR
 Before THR 
pregnancies
After THR 
pregnancies
Before the index date 
pregnancies
After the index date 
pregnancies
 % CI % CI % CI % CI
Previous pregnancies
 0 14.7 10.8–18.6 17.0 8.7–25.3 15.3 13.2–17.3 12.3 8.3–16.2
 1+ 13.5 11.1–15.9 17.8 11.8–23.8 11.8 10.7–13.0 14.4 12.0–16.7
Previous abortions
 0 11.0 8.9–13.1 16.2 10.8–21.6 10.2 9.1–11.2 10.7 8.7–12.6
 1+ 41.5 33.1–50.0 36.8 23.1–50.6 39.6 35.0–44.2 36.7 27.8–45.5
Previous births
 0 13.5 10.2–16.8 16.2 8.9–23.6 15.1 13.3–16.9 11.9 8.6–15.2
 1+ 14.4 11.7–17.1 18.4 11.9–24.9 11.6 10.3–12.8 14.9 12.4–17.4
Age at the time of abortion
 15–29 46.2 27.0–65.3 100.0 0.0–100.0 55.1 44.7–65.4 50.0 6.2–93.8
 20–24 20.1 13.6–26.7 28.6 15.4–41.8 19.8 16.4–23.2 18.1 8.2–27.9
 25–29 10.6 7.5–13.8 11.4 3.8–19.1 8.5 7.0–10.0 11.0 7.1–27.9
 30–34 10.1 7.0–13.2 8.1 2.5–13.6 10.0 8.4–11.6 9.2 6.3–12.0
 35–39 19.9 13.4–26.3 22.4 13.3–31.6 14.2 11.3–17.1 15.9 11.8–20.0
 40–44 31.3 8.5–54.0 27.6 15.9–39.3 30.8 21.3–40.3 23.7 15.9–31.4
Marital status
 Never married 31.5 24.5–38.9 38.7 25.7–51.7 28.3 24.6–32.0 19.5 13.9–25.1
 Ever married 11.1 9.0–13.1 13.7 8.7–18.7 10.3 9.3–11.3 12.7 10.6–14.8
Rheumatoid arthritis
 No 15.0 12.6–17.4 20.3 13.4–27.3 12.8 11.7–13.8 14.0 12.0–16.0
 Yes 10.4 6.2–14.7 13.6 7.0–20.1 17.1 5.6–28.6 0.0 0.0–0.0
Index date: date of the operation in the THR patient group and the same date for matching referents.
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more likely to have their first IA, which may indicate 
that THR might increase the IA risk.
In the THR patient group, there were more abor-
tions both before and after THR due to maternal health 
indications than in the referents. Women with THR 
might have concerns about pregnancy, but the risk of 
IA was not increased (9). There is no evidence of THR 
complicating pregnancy or affecting pregnancy out-
come (9, 10, 13). The THR patients might have had 
more baseline diseases compared with the referents. 
Some diseases are known to increase IA rates. For 
example, women using psychotropic medication or 
biological RA medication have increased abortion 
rates (28, 29). This finding could not, however, be 
identified in our present study due to the small inci-
dences of chronic diseases (except RA) and the infor-
mation on exact medications was not available.
This is the first study that has evaluated the relation-
ship between THR and IA. One of the strengths of the 
study is the large, nationwide study population with 
long follow-up. Our study also compares the IA rates 
before and after THR. Another strength of the study is 
the high quality of the register data (6, 23). Our study 
provides nationwide population-based findings that 
include a large and comprehensive study population 
of THR patients and the reference cohorts. Furthermore, 
the register-based approach eliminates possible recall-
bias, that is, possible previous IAs were identified from 
reliable registers, not with questionnaires.
Although the register data had high coverage and 
validity in most variables, information on SES was not 
fully available for this study. For example, data on the 
SES of only 34.1% of the participants were available. 
Moreover, even though the coverage was better in the 
MBR than in the RIA, it was still not possible to calculate 
reliable abortion ratios for each SES group or use them as 
a part of the logistic model. In addition, information on 
the marital status of the women at the exact time of the 
abortion was not available. Instead, we only had infor-
mation on whether the women had ever been married.
CONCLUSION
Further studies are needed to confirm the clinical sig-
nificance of these novel findings. This study shows 
that THR does not seem to be an independent risk fac-
tor for pregnancy ending in IA, although maternal 
health issues were a more common IA indication in 
the THR patient group. Further studies are needed to 
provide information on pregnancies and deliveries 
after THR.
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A B S T R A C T
Objective: Only a few small studies have been published on pregnancies after total hip replacement (THR),
and they have reported no adverse pregnancy outcomes after THR. The aim of our study was to evaluate
whether maternal THR affects pregnancy outcomes on a population-based level.
Study Design: Data for this nationwide register-based cohort study have been collected from four national
registries in Finland from 1980 to 2007. All females who had undergone THR during that period formed
the patient group, and three controls for each patient without THR were selected. Patient group
comprised 2429 women, 719 (29.6%) of whom had 1190 pregnancies ending in singleton deliveries. Of
those births, 986 were before THR and 204 after THR. The control group comprised 7276 women, 2805
(38.6%) of whom had 5112 pregnancies ending in singleton deliveries, 3695 occurred before the index
date (time point when THR took place within the patient group) and 1417 after. Logistic regression model
was used to analyze univariable and adjusted odds ratios (aOR) for adverse neonatal outcomes after
maternal THR compared with controls. Data were adjusted using the following variables: maternal age,
smoking, rheumatoid arthritis.
Results: Stillbirth was more common in the patient group compared with control group 4 (2.0%) vs 8
(0.6%) p = 0.02. Moreover, neonates in the patient group were more likely to be born preterm (aOR 3.58,
p=<0.001), small for gestational age (aOR 2.83, p = 0.006) and low birthweight (aOR 4.79, p=<0.001),
compared to control group. Trial of labor more likely ended in emergency cesarean section in the patient
group than in the control group 39 (28.9%) vs 150 (11.6%), p=<0.001. Adverse pregnancy outcome was
more common after THR also when compared to pregnancies before THR.
Conclusions: Neonates born after maternal total hip replacement have an increased risk of stillbirth, small
for gestational age, low birthweight and preterm birth. Trial of labor is more likely to end in emergency
cesarean section.
ﾩ 2019 Elsevier B.V. All rights reserved.
Introduction
Total hip replacement (THR) is a highly effective operation for
decreasing pain and improving quality of life in affected
individuals [1]. The most common indications for THR in fertile-
aged patients are rheumatoid arthritis (RA), avascular necrosis of
the femoral head and developmental dysplasia of the hip [2,3]. In
Finland, the annual incidence of primary THR among 30–39 year
olds was 59.5 per 100 000 person years in 2007 [4]. The prevalence
of THR in Sweden in 1999 was 12 per 100 000 women aged under
40 years and 19 per 100 000 in 2012 [5]. In the United States, it has
been estimated that the annual primary THR rate in the less than
45 years old group could possibly increase 3-fold by 2030
compared with 2006 rates [6].
There have only been a few studies that have evaluated the
effect of previous THR on later pregnancy and delivery or vice
versa. The results of these previous studies have not shown an
increased risk for complications in delivery after THR, although the
numbers of included patients in these studies have been small
(n = 10–50) [7–14]. Interestingly, some of these studies have
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reported an increased rate of cesarean sections (CS) after THR
[10,13,15].
Some studies have raised concerns regarding elevated fetal
blood metal ion (chromium and cobalt) levels in women with
metal-on-metal hip replacements and the possible passage of the
metal ions to the fetus via the placenta [16–18]. Most of the case
reports, however, have not shown any teratogenic impact, despite
elevated placental blood metal ion levels [18–20]. Two case reports
have described a neonate with high metal ion levels combined
with congenital anomalies [21]. Considering the previous litera-
ture, women may still have concerns regarding pregnancy and
vaginal delivery after THR operation [11].
The aim of this present study was to evaluate the effect of THR
on the delivery and health of neonates on a population-based level
using data routinely recorded into national health registers in
Finland.
Materials and methods
The study population in this register-based nationwide cohort
study was gathered from four different national registers in
Finland. Information on all women aged 15 to 45 years who had
undergone primary THR between 1980 and 2007 was retrieved
from the Finnish Arthroplasty Register and included in this study
(n = 2429 women with primary THRs). The register was established
in 1980 and is maintained by the National Institute for Health and
Welfare. The coverage of the register has been high over the years,
especially with regard to primary THR (approximately 95%), and it
matches well with the hospital discharge register data [22]. Based
on the bearing material, the type of implant was categorized as
either metal-on-metal or not metal-on-metal.
For each patient included in the patient group, three control
women without THR matched by age at the time of THR and place
of residence were obtained from the Finnish Population Informa-
tion System maintained by the Population Register Centre and
formed the control group (n = 7276 control women without THR).
The start of the follow-up was the date of THR operation in the THR
group and the operation date was the index date for the matching
controls. The common closing date for this study was 31st
December 2007.
In this study, information on singleton pregnancies and
deliveries for both groups was gathered from the national Medical
Birth Register, which was established in 1987. The register is
maintained by the National Institute for Health and Welfare and
contains information on all pregnancies ending in birth or stillbirth
after gestational week 22 and neonates weighing over 500 g. The
Medical Birth Register also contains the background characteristics
of the pregnancies and basic information on deliveries and neonate
outcome up to hospital discharge or seven days postpartum [23].
Of the 2429 women in the patient group, 719 (29.6%) had 1190
pregnancies ending in singleton deliveries. Of these, 575 women
had 986 singleton deliveries prior to THR, and 144 women had 204
singleton deliveries after THR. The control group comprised 7276
women, 2805 (38.6%) of whom had 5112 pregnancies ending in
singleton deliveries. Of these, a total of 1893 women had 3695
singleton deliveries before the index date, and 912 women had
1417 singleton deliveries after the index date. The deliveries after
THR/index date were included in the analysis. In addition, a
subgroup comparison in the patient group was performed for
before and after THR deliveries (Fig. 1).
Information on long-term chronic diseases was obtained from
the Register of Medical Reimbursements that is maintained by the
Social Insurance Institution of Finland and contains information on
reimbursable medical costs for chronic diseases. Reimbursements
for medical costs are granted with a medical certiﬁcate issued by a
licensed doctor. Information on the most common long-term
disease, RA, among the study population was obtained, and those
persons who did not have a reimbursement for RA medication in
the register were classiﬁed as not having RA.
Standard deviations (SD) for birth weight and birth length were
calculated by using the new Finnish growth references for male
and female children and adolescents [24]. A SD of less than 2.0
from mean was considered as small for gestational age (SGA), and a
SD greater than +2.0 from mean was considered as large for
gestational age (LGA). Standard deviations were calculated for all
neonates. Neonates born before gestational week 37 + 0 were
deﬁned as preterm. Neonates weighing less than 2 500 g were
deﬁned as low birthweight (LBW).
All the singleton pregnancies were observed and compared
between the groups. Chi-squared test was used to analyze
intergroup differences in the categorical variables between the
patient group and the control group. A p-value under 0.05 was
considered statistically signiﬁcant. Conﬁdence intervals (95% CI)
for the difference of the two proportions were used when
Fig. 1. Flow chart of study population. Index date is the date of THR. Deliveries of the patient group were classiﬁed as taking place before or after THR, and likewise the
deliveries of the control group were matched according to the index date.
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comparing before and after THR proportions in the patient group.
Means with SDs were calculated for normally distributed variables
and medians with interquartile ranges for non-normally distrib-
uted variables. Logistic regression model was used to calculate
odds ratios (OR) with 95% CI to compare adverse pregnancy
outcomes between the patient and control groups. The following
covariates from the available variates in the registers were
included and selected based on the previous literature in the
adjusted model: maternal age, smoking during pregnancy and
maternal RA. Statistical analyses were performed using IBM SPSS
for Windows, version 24.0 software.
All the data were linked by using the individual personal
identiﬁcation code that is issued to all permanent residents of
Finland. No written consent was required since none of the
participants were contacted, and hence no approval from the local
ethical committee was required. However, our study protocol did
undergo ethical evaluation by the National Institute for Health and
Welfare in order to gain access to register data, permission
number: THL/599/5.05.00/2010.
Results
Women in the patient group were older at the time of delivery
compared with the control group. A higher proportion of women
had their ﬁrst pregnancy after THR in the patient group. In 42% of
the deliveries in the patient group, the mother had RA. Baseline
information and background characteristics of the pregnant
women are presented in Table 1.
Stillbirth was more common in the patient group compared
with the control group (Table 2). In the patient group, neonates had
a lower birthweight and birth length. The neonates born in this
group were also more likely to be born preterm compared with the
control group. In addition, neonates born after THR also had higher
LBW and SGA proportions and needed more neonatal intensive
care treatment and phototherapy compared with the control group
(Table 2). When these ﬁndings were adjusted with potential
confounders, THR remained an independent risk factor in the
patient group for preterm birth, LBW and SGA, but not for stillbirth
(Table 3).
The pregnancies in the patient group were also compared to
pregnancies before THR. Our ﬁndings showed adverse pregnancy
outcomes were more common after THR than before THR.
Moreover, the rates of stillbirth (2.0% vs 0.3%, p = 0.004), SGA
neonates (8.3% vs 3.3%, p = 0.001) and preterm births (13.7% vs 7.1%,
p = 0.001) were all found to be higher after THR.
In subgroup analysis, deliveries with maternal metal-on-metal
THRs (n = 16) were compared with deliveries with non-metal-on-
metal THRs (n = 188). The groups had similar rates of stillbirths
(0.0% vs 2.1%, p = 1.00), preterm births (25.0% vs 12.8%, p = 0.25) and
LBW neonates (18.8% vs 11.7%, p = 0.42). In addition, neonates born
to mothers with metal-on-metal THR were more likely to be SGA
compared with those born to mothers with non-metal-on-metal
THR (25.0% vs 6.9%, p = 0.03).
The proportion of elective cesarean sections (CS) was higher in
the patient group than in the control group (Table 2). The overall
proportion of CS was 27% before THR and 53% after THR and trial of
labor more often resulted in emergency CS. The use of epidural
analgesia and amniotomies were more common in the control
group (Table 4).
Discussion
The results of this study raise concerns over adverse pregnancy
outcomes, such as preterm birth, LBW, SGA and stillbirth, that were
found to be more common in women after THR than in the control
group without THR.
In Finland, the national stillbirth rate has been between 3–5 per
1000 births for the last 30 years [23]. The stillbirth rate of the
control group, as well as the patient group before THR, was similar
to national levels, but in the patient group after THR it was four to
ﬁve times higher. One reason for the increased stillbirth rate might
be the underlying diseases of the THR patients. Two of the four
women with stillbirth in the patient group had RA. RA has been
shown to increase the risk of preterm birth and SGA neonate, but
not for stillbirths or perinatal mortality in large cohort studies [25–
27]. However, the prevalence of RA was also high in the patient
group before THR.
Some studies have described the possible effects of the ion
release of metal-on-metal implants on fetal health. Chromium and
cobalt have been shown to be toxic, but it is believed that the
increased blood metal ion concentration remains below terato-
genic levels. The placenta also prevents a large proportion of the
ions from entering the fetal circulation [18,20]. Although the
concentrations of metal ions may remain below teratogenic levels,
the slightly elevated fetal blood metal ion level might inﬂuence the
growth of the fetus and be involved in preterm births or stillbirths.
Metal-on-metal implants gained popularity in Finland in the year
Table 1
Background characteristics of women having singleton pregnancies ending in
delivery in the patient group and in the control group.
Patient group Control group
Total number 204 1417
n % n % P
Age at birth (years, mean SD) 33.4 5.2 32.6 5.2 0.046
Nulliparous 80 39.2 438 31.0 0.02
Previous cesarean section 37 18.1 161 11.4 0.006
Marital status
never married 28 13.7 205 14.5 0.78
ever married 176 86.3 1212 85.5
Maternal smoking
non-smoker 173 84.1 1191 84.1 0.63
quit during 1st trimester 4 2.0 43 3.0
Smoker 25 12.3 142 10.0
unknown 2 1.0 41 2.9
Rheumatoid arthritis 86 42.2 6 0.4 <0.001
Table 2
Perinatal characteristics and outcome in the patient group after THR and the control
group.
Patient group Control group
Total number 204 1417
n % n % p
Intended mode of delivery
Elective CS 69 33.8 124 8.8 <0.001
Trial of labor 135 66.2 1293 91.2
Fetal gender male 103 50.5 730 51.5 0.78
Birth length (cm) (mean; SD) 48.7 2.8 50.3 2.6 <0.001
Birth weight (grams) (mean; SD) 3240 670 3580 560 <0.001
LBW <2500g 25 12.3 41 2.9 <0.001
SGA 17 8.3 39 2.8 <0.001
LGA 3 1.5 57 4.0 0.04
Preterm, <37 + 0 weeks 28 13.7 65 4.6 <0.001
Perinatal mortality 4 2.0 10 0.7 0.09
Stillbirths 4 2.0 8 0.6 0.02
Neonatal deaths 0 0.0 2 0.1 0.99
1-minute Apgar score  6 13 6.4 73 5.2 0.47
Delivery related asphyxia 5 2.5 35 2.5 0.99
Phototherapy 19 9.3 63 4.4 0.003
Neonatal intensive-care unit 8 3.9 38 2.7 0.32
Neonatal status 7 days postpartum
at home 169 82.8 1284 91.4 <0.001
in hospital 31 15.2 111 7.9
THR = total hip replacement, SD = standard deviation, LBW = low birthweight,
LGA = large for gestational age, SGA = small for gestational age.
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2000 and were widely used for the following 10 years. In this study,
only the rate of SGA was signiﬁcantly higher among metal-on-
metal implants compared with non-metal-on-metal implants, but
the same trend was also noted in other outcome measures.
However, the number of patients with metal-on-metal THR was
low in this study. Furthermore, no information on maternal metal
ion levels was available.
The intended modes of delivery differed between groups.
Women in the THR group had more elective CS and fewer trials of
labor. One explanation for the higher rate of elective CS could be
that patients with a replaced hip opt to have elective CS because of
a possible fear of damaging the THR implant and negatively
affecting the delivery outcome in vaginal delivery [10,13,15].
Women in the THR group already had higher CS proportions before
THR compared with the control group, which might be explained
by their underlying diseases. A German cohort study showed that
women with chronic diseases were more likely to deliver by CS
than healthy referents [23].
The trials of labor were more likely to result in acute CS
compared with the control group. It remains unclear whether this
ﬁnding was because of abnormalities in cardiotocography or
prolonged labor as this information was not available. It is also
possible that not all THR patients classiﬁed as having a trial of
labor were really opting for vaginal delivery. The small percentage
of epidural analgesia and amniotomies after THR may be
explained by the possibility that a considerable number of
parturients in that group had actually planned elective CS, but it
had been converted to emergency CS for reasons such as early
onset of labor. Our results differ from those of the largest previous
study by Sierra et al. who observed a total of 47 deliveries after
THR and suggested that the percentage of CS (35.0%) in their
patient series did not differ from national levels [11]. A couple of
smaller patient series also reported similar CS rates compared to
national rates in their studies [28–30], while some smaller studies
have reported increased rates of CS (41.1%–100%) [10,13,15].
However, none of these previous studies have had control groups
without THRs.
One of the main strengths of this study is the large, nationwide
study population with long study period. A further strength is that
this is also the ﬁrst study to compare post-operative deliveries to
both preoperative deliveries and matching controls. Moreover, a
register-based study design further eliminates any possible recall-
bias. One of the beneﬁts of these registers is their good coverage so
that the data represents well the deﬁned population. The register
data are routinely collected using structured forms with nation-
wide instructions that reduce possible reporting bias.
A long study period is one complicating factor when analyzing
deliveries and neonatal outcomes. During the 20-year study
period, delivery methods and neonatal care changed, as did the
medications used for the treatment of RA. Moreover, there were
some important missing variables in the MBR. For example,
information on previous preterm deliveries or previous SGA
children was not available. In addition, no information on body
mass index was recorded before 2004, and the register data only
had information on 1-minute Apgar-scores, since 5-minute scores
only became part of the register in 2004. Also, durations of labor
stages were not found in most of the cases, since they also became
part of the register in 2004.
According to the ﬁndings of this study, adverse pregnancy
outcome (preterm birth, LBW, SGA and stillbirth) are more
common in women who have undergone THR. As a result, such
women are more likely to have elective and emergency cesarean
sections after THR. Further studies with combined multinational
registries would be needed to conﬁrm these novel ﬁndings.
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The most common indications for THR in very young patients 
aged under 30 years are rheumatoid arthritis (RA), avascular 
necrosis of the femoral head, and developmental dysplasia of 
the hip (Adelani et al. 2013). The incidence of primary THR 
among young patients (30 to 59 years old) has increased annu-
ally in Finland from 9.5 per 100,000 person years in 1980 to 
61 per 100,000 in 2007 (Skyttä et al. 2011). In 2017, over 
1,000 women aged under 55 underwent a primary THR opera-
tion in Finland (open access statistical report of the Finnish 
Arthroplasty Register 2018: National Institute of Health and 
Welfare 2018).
Only a few studies with rather small sample sizes and local 
data have analyzed the effects of delivery and THR on each 
other. None of these studies have reported problems with 
deliveries after THR, and they indicate that THR does not 
majorly affect the mode of delivery (Monaghan et al. 1987, 
Boot et al. 2003, Meldrum et al. 2003, Yazici et al. 2003, 
Sierra et al. 2005, Stea et al. 2007, Smith et al. 2008) Further, 
THR survival is not decreased, and the delivery method does 
not affect THR survival (Meldrum et al. 2003, Sierra et al. 
2005). However, women have reported concerns regarding 
vaginal delivery and fear of delivery positions harming the 
THR (Ostensen 1993, Meldrum et al. 2003, Stea et al. 2007). 
Very young patients seem to have worse clinical out-
comes in terms of pain relief and function after THR, even 
though implant survival rates and radiological outcomes have 
improved (Adelani et al. 2013, Swarup et al. 2017). Clinical 
outcomes may be limited by systemic diseases, such as RA, 
that still comprise the majority of indications for THR in these 
very young patients. The survivorship of the THR is often 
shortened due to the loosening of cup or stem in very young 
patients, men, and patients with a higher BMI (Melloh et al. 
2011). While in some studies underlying diseases have not 
negatively affected the survival of the hip prosthesis (Han-
nouche et al. 2016), dysplastic hips appear to have worse sur-
Background and purpose — Previous small studies have 
suggested that delivery does not adversely affect the sur-
vivorship of total hip replacement (THR). We investigated 
whether delivery after primary THR affects hip implant sur-
vivorship in a large population-based study sample
Patients and methods — In this register-based nation-
wide cohort study, all women aged 15–45 who underwent 
primary THR in Finland from 1987 to 2007 were included 
from the Finnish Arthroplasty Register. Data on deliveries 
were obtained from the medical birth register. After primary 
THR, 111 women (133 THRs) delivered and formed the 
delivery group. In the reference group, 1,878 women (2,343 
THRs) had no deliveries. We used Kaplan–Meier analysis 
with 95% confidence intervals (CI) to study implant survi-
vorship at 6 and 13 years, and Cox multiple regression to 
assess survival and hazard ratios (HRs), with revision for 
any reason as an endpoint with adjustment for age, rheuma-
toid arthritis, and stem and cup fixation.
Results — 51 (38%) revisions were recorded in the deliv-
ery group and 645 (28%) revisions in the reference group. 
The 6-year implant survivorship was 91% (CI 85–96) in 
the delivery group and 88% (CI 87–90) in the reference 
group. The 13-year survival rates were 50% (CI 39–62) and 
61% (CI 59–64). The adjusted HR for revision after deliv-
ery was 0.7 (CI 0.4–1.2) in ≤ 6.8 years’ follow-up and 1.1  
(CI 0.8–1.6) in > 6.8 years’ follow-up.
Interpretation — Based on the findings in this nation-
wide study of hip replacement in fertile-aged women, deliv-
ery does not seem to decrease THR implant survivorship; 
women should not be afraid of or avoid becoming pregnant 
after THR.
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vival rates compared with non-dysplastic hips (Tsukanaka et 
al. 2016). Metal-on-metal (MoM) implants have worse sur-
vival rates compared with non-MoM implants and are since 
2012 are no longer used in Finland due to common adverse 
local tissue reactions that have led to numerous revisions 
(Smith et al. 2012, Furnes et al. 2014, Varnum et al. 2015). 
Because THR implant survival is substantially lower in very 
young patients compared with older patients, THR should 
be considered as the treatment option of last resort for very 
young patients (Swarup et al. 2015, Hannouche et al. 2016). 
We evaluated whether delivery adversely affects the survi-
vorship of THR in a nationwide register-based study sample.
Patients and methods
Data for this nationwide register-based study were gath-
ered from 3 different national registers. Information on all 
women aged 15 to 45 who underwent THR operation in Fin-
land between 1987 and 2007 was obtained from the Finnish 
Arthroplasty Register (FAR). The register is maintained by 
the National Institute for Health and Welfare (THL), and it 
contains information on all orthopedic prostheses operated 
from 1980 in Finland. All the information in the FAR has been 
collected prospectively. The current (2017) completeness of 
the register is 95% for primary THR, and it matches well 
with data from the Finnish Hospital Discharge Register (open 
access statistical report of the Finnish Arthroplasty Register 
2018: NIHW 2018). 
In the present study, the operation day of the primary THR 
was used as the starting point of the follow-up. Because we 
did not have information on primary THR operations before 
1987, a revision THR as the first event in the FAR after Janu-
ary 1, 1987 was an exclusion criterion in the study. Women 
with bilateral prostheses were included, as earlier research 
has shown that this does not bias the results (Lie et al. 2004, 
Ranstam and Robertsson 2010). The endpoint for the follow-
up was either revision, death, emigration, or December 31, 
2007, whichever came first. The outcome was the revision of 
the hip for any reason.
2,012 women with 2,499 primary THRs were selected from 
the register. Of the THRs selected, 23 were excluded due to a 
lack of information on many key variables (Figure 1). 
Information on pregnancies and deliveries was gathered 
from the National Medical Birth Register (MBR) maintained 
by the THL. Pregnancies and deliveries from January 1, 1987 
to December 31, 2007 were included in this study. The MBR 
contains information on all pregnancies of at least 22 gesta-
tional weeks ending in delivery and information on deliveries 
and newborns. MBR data match well with hospital discharge 
data and the coverage of the register has improved over the 
years. If there was no information in the MBR, the woman 
was not considered to have been pregnant. In the study, 
women who had given birth after THR formed the delivery 
group, and women without pregnancy after THR formed the 
reference group. 
The Register for Reimbursable Diseases is maintained by 
the Finnish Social Insurance Institution of Finland. It contains 
information on reimbursable chronic diseases. A medical 
statement written by a certified doctor is needed to gain reim-
bursement for chronic disease. Information on all the reim-
bursements for this study population was obtained. If there 
was no information available, women were considered as not 
having chronic diseases. 
In this study, RA was the most common diagnosis. Other 
chronic diseases were rare, but the following diseases were 
found: asthma, diabetes mellitus type 1, epilepsy, hypothy-
roidism, hypertension, inflammatory bowel disease, and major 
psychiatric disease.
Statistics
Categorized variables were compared by chi-square test between 
the groups and reported as proportions. Continuous variables 
were compared by their distribution. Normally distributed vari-
ables were compared by Student’s t-test and reported by means 
with standard deviations (SD). Non-normally distributed vari-
ables were compared by Mann–Whitney U-test and reported 
by medians with interquartile range. A p-value under 0.05 was 
considered statistically significant in all analyses. Kaplan-Meier 
survival analyses with 95% confidence intervals (CI) were per-
formed to evaluate the survival of the hips in both the delivery 
group and the reference group. Survival rates were calculated 
for 6 years’ and 13 years’ follow-up. The follow-up was con-
tinued until 13 years when 20 THRs were still at risk (life table 
analysis) in the delivery group. The follow-up period was cal-
culated from primary THR until revision THR or until the date 
the patient was censored at the end of the study (December 31, 
2007), or date of emigration, or date of death. The Cox propor-
tional hazards model was used to analyze the effect of potential 
confounders and count hazard ratios (HR). The adjustments 
Figure 1. Flow chart of study population and events of total hip replace-
ment (THR) survival among fertile-aged (15 to 45) women having 
delivery compared with women not having delivery after THR. 
Women aged 15–45
with primary THR 1987–2007
in the Finnish Arthroplasty Register
n = 2,012
Included
n = 1,989
YES     Delivery after THR      NO
Excluded
missing data
n = 23 
Delivery group
111 women
133 THRs
  51 revisions
Reference group
1,878 women
2,343 THRs
   645 revisions
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used in the Cox proportional analysis were the following: age at 
the time of primary THR, RA, stem fixation, and cup fixation. 
Because the proportional hazards assumption was not met in the 
Cox model (crossing survival curves at 6.8 years), the follow-
up was divided into 2 time periods, and a piecewise Cox pro-
portional model was performed. The first follow-up period was 
the time before the crossing at 6.8 years, and the second period 
was from the crossing until the end of the follow-up (6.8–21.0 
years). All the analyses were performed using SPSS statistical 
software version 25.0 (IBM Corp, Armonk, NY, USA).
Ethics, registration, funding, and potential conﬂicts of 
interest 
In accordance with Finnish regulations, informed patient 
consent was not required as the women were not contacted. 
Our study protocol went through the ethical evaluation of 
the National Institute for Health and Welfare to gain access 
to register data, permission number: THL/599/5.05.00/2010.
This study was funded by the Competitive Research funds of 
Pirkanmaa Hospital District, Tampere, Finland, representing 
governmental funding. The authors have no potential conflicts 
of interests to declare.
Results
1,989 women with 2,476 THRs were included in the study 
(Table 1). Of these, 111 (5.6%) women with 133 (5.4%) 
THRs had a delivery during the follow-up. The mean follow-
up in the delivery group was 9.3 years (0–21), and the median 
age at the start of the follow-up was 29 years. In the reference 
group, 1,878 women with 2,343 THRs had no deliveries. The 
mean follow-up was 8.1 years (0–21), and the median age at 
the start of the follow-up was 40.
RA was the most common indication for THR in both 
groups. It was, however, more prevalent in the delivery group 
(47%) than in the reference group (33%) (p = 0.001). Other 
chronic diseases were more common in the reference group. 
The distribution of THR fixation method or bearing type was 
similar between the groups. The delivery group had 51 revi-
sions, and 30 (59%) of the revisions were performed due to 
aseptic loosening. In the reference group, 645 THRs were 
revised, and 318 (49%) revisions were performed due to asep-
tic loosening.
The deliveries were analyzed and recorded per THR. 170 
deliveries occurred during the follow-up (mean of 1.3 deliver-
ies per THR). The maximum number of deliveries per patient 
during the follow-up was 5. Of the deliveries, 75 (44%) were 
vaginal and 95 (56%) Cesarean sections. 50 women with 
53 THRs had at least 1 vaginal delivery after THR and 61 
women with 80 THRs had only Cesarean sections after THR. 
The primary THR diagnoses and revision indications were 
similar in the vaginal delivery group and Cesarean section 
group (Table 2).
At 6 years, the survival rate in the delivery group was 91% 
(CI 85–96) and in the reference group 88% (CI 87–90). At 13 
Table 1. Background characteristics of the study population, types 
of hip prosthesis, and indications for revisions between the delivery 
group and the reference group. Values are frequency (%) unless 
otherwise speciﬁed
 Delivery group Reference group
Factor n = 133 n = 2,343
Age at primary THR a 29 (8) 40 (8)
Follow-up period (years) a 9.1 (6) 8.0 (8)
Rheumatoid arthritis 62 (47) 774 (33)
Other chronic disease b 5 (4) 208 (9)
Nulliparous at primary THR 78 (64) 778 (33)
Indication for THR  
 Inflammatory arthritis (RA + others) 62 (47) 731 (31)
 Primary osteoarthritis 12 (9) 532 (23)
 Secondary arthrosis 21 (16) 363 (16)
 DDH c 22 (17) 493 (21)
 Other 16 (12) 224 (10)
Metal-on-metal bearing 16 (12) 390 (17)
Type of primary THR fixation  
 Uncemented 114 (86) 1,859 (79)
 Hybrid 7 (5) 237 (10)
 Inverse hybrid 0 (0) 1 (0)
 Cemented 12 (9) 245 (10)
Revisions 51 (38) 645 (28)
Revision indications  
 Aseptic loosening 30 (59) 318 (50)
 Deep infection 1 (2) 11 (2)
 Periprosthetic fracture 0 (0) 12 (2)
 Dislocation 1 (2) 30 (5)
 Others 14 (27) 193 (30)
 Missing 5 (10) 81 (12)
a Median and interquartiles. 
b Includes: asthma, diabetes mellitus type 1, epilepsy, hypothyroid-
ism, hypertension, inflammatory bowel disease, major psychiatric 
disease. 
c DDH = developmental dysplasia of the hip.
Table 2. Comparison of primary diagnoses and revision indications 
in the delivery group between women with at least 1 vaginal deliv-
ery after total hip replacement (THR) with women with only Cesar-
ean sections after THR
 
 Vaginal delivery Cesarean section 
 after THR after THR
Factor n = 53 n = 80
Indication for THR   
 Inflammatory arthritis (RA + others) 19 43
 Primary osteoarthritis 4 8
 Secondary arthrosis 13 8
 DDH 10 12
 Other 7 9
Revisions 15 36
Revision indications:  
 Aseptic loosening 10 20
 Deep infection 1 0
 Dislocation 0 1
 Others 4 10
 Missing 0 5
DDH = developmental dysplasia of the hip.
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years, the survival rate was 50% (CI 39–62) for the delivery 
group and 61% (CI 59–64) for the reference group, respec-
tively (Figure 2, Table 3).
During the first time period (0 to 6.8 years’ follow-up), the 
adjusted Cox regression model showed no statistically signifi-
cant difference in the risk for revision between the delivery and 
the reference groups (adjusted HR 0.7, CI 0.4–1.2). During the 
later follow-up (6.8 to 21 years), there was still no difference in 
adjusted HR between the groups (HR 1.1, CI 0.8–1.6). 
Discussion
To our knowledge, our study is the first to assess THR implant 
survivorship in fertile-aged women in a large population-
based study sample. Based on our results, delivery does not 
seem to adversely affect hip implant survivorship after pri-
mary THR.
Our results are in concordance with previous smaller stud-
ies. In their study, Sierra et al. (2005) reported that delivery 
after primary THR does not decrease the survival rate of the 
implant. They had the largest number of participants prior to 
our study. 343 women with 420 THR were contacted and 47 of 
those had pregnancy ending in delivery. However, the survival 
rates for 5-, 10- and 15-year follow-up periods were calculated 
for the whole cohort with no comparisons made between the 
delivery and non-delivery groups. Our 6-year survival rate 
in both groups was in line with these results. Meldrum et al. 
(2003) had 13 hips with deliveries in their study population 
and reported no adverse effects for THR. Yazici et al. (2003) 
reported 21 THR patients with deliveries and no decrease in 
the survival rate of the THR. All these studies were retrospec-
tive with alternative response rates (30–75%). McDowell and 
Lachiewicz (2001) reported 5 women with 7 uncemented 
THRs having deliveries and, compared with matched refer-
ents, no differences between survival or hip functions were 
reported. Our study was the only one to report a slight but not 
statistically significant decrease in implant survival rate in the 
Kaplan–Meier analysis after delivery.
Cesarean section (CS) rate was markedly increased in the 
delivery group compared with overall CS rate in Finland. 
There have been previous reports in which women with dys-
plastic hips have been discussed to have smaller pelvic diam-
eters and therefore could tend to have CS (Sierra et al. 2005; 
Stea et al. 2007). Developmental dysplasia of the hip was an 
equally common indication for THR in women who only had 
Cesarean sections after THR as in those who delivered vagi-
nally after THR in our study. Also, revision indications did 
not differ between them. The reason for the very high CS rate 
in the delivery group remains unknown. We can only specu-
late that the presence of THR may have affected the patients’ 
and/or the physicians’ choice of delivery. However, it did not 
have any effect on THR survival rates.
Age was the only statistically significant variable that nega-
tively affected THR implant survivorship. The delivery group’s 
median age at the start of the follow-up was 29 years compared 
with the reference group’s 40 years. Previously, only Sierra et 
al. (2005) have applied the Cox regression model to analyze 
implant survivorship after delivery. In their model, delivery 
seemed to decrease THR survivorship, but once age at the time 
of primary THR was taken as part of the model, no further differ-
ences between the delivery group and the reference group were 
obtained. Previous non-delivery-related THR survival studies 
have reported similar findings of weaker implant survivorship in 
younger patients (Dorr et al. 1994, Nam et al. 2016, Tsukanaka et 
al. 2016). In particular, very young patients under 30 years have 
been reported to have had decreased THR survivorship (Mohad-
des et al. 2019) probably because of higher activity levels (Dorr 
et al. 1994, Adelani et al. 2013). Our survival rates were slightly 
lower compared with the recent study of Mohaddes et al. (2019), 
in which the 15-year THR survival rate for patients aged under 30 
at the time of THR was 76%. 
In young patients (< 50 years or less), indications for THR 
differ in comparison with older patients (+50 years). In 
younger patients, inflammatory arthritis and developmental 
hip diseases are more common, and primary osteoarthritis is 
Table 3. Kaplan–Meier 6- and 13-year survival rates with 95% conﬁ-
dence intervals (CI) of primary total hip replacement of fertile-aged 
women aged 15 to 45 years at the time of THR
 K–M survivorship K–M survivorship
 at 6 years at 13 years
 No. of No. of  No. at survival No. at survival
Delivery hips revisions risk % (CI) risk % (CI)
Yes 133 51 100 91 (85–96) 22 50 (39–62)
No 2,343 645 1,411 88 (87–90) 456 62 (59–64)
Figure 2. Kaplan–Meier survival curves (with 95% confidence inter-
vals) of primary total hip replacement (THR) among fertile-aged 
women aged 15 to 45 years at the time of THR having 1 or more 
deliveries after THR (delivery group) compared with no deliveries after 
THR (reference group).
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rare (Adelani et al. 2013). Developmental dysplasia of the hip 
decreases the survival of the hip prosthesis in young patients 
(Havelin et al. 2000, Tsukanaka et al. 2016). There have been 
controversial results regarding the survival of the THR in 
RA patients. Some studies have suggested decreased THR 
survivorship, more common radiographic findings indicat-
ing implant failure, poorer function, and increased mortality 
among patients with RA (Creighton et al. 1998, Havelin et al. 
2000, Tang and Chiu 2001, Singh and Lewallen 2013, Good-
man et al. 2014, Schrama et al. 2015). Inflammatory arthritis 
as primary diagnosis for THR may also increase revisions due 
to deep infections (Dale et al. 2012). Previous large national 
cohort studies, however, have shown no decrease in THR 
survival due to RA (Havelin et al. 2000 , Furnes et al. 2001, 
Eskelinen et al. 2006). Because of the high prevalence of RA 
among young patients, it was taken as part of the Cox model. 
In our model, RA did not decrease THR survival. Indeed, it 
seemed patients with RA had better results during the first 
follow-up period (< 6.8 years). A similar finding was seen in 
a previous THR and delivery study, where Serra et al. (2005) 
found no decrease in the survival of hips operated due to an 
RA diagnosis in their step-by-step Cox results. 
The main strength of our study is the register-based design. 
Previous THR survival studies after delivery have been retro-
spective cohorts with questionnaires. Our design eliminates 
possible recall bias and has better completeness because revi-
sion indications are also reported to the Finnish Arthroplasty 
Register. In addition, we had by far the largest study popula-
tion with the longest follow-up, and our results are nationwide 
instead of from one hospital district catchment area. In addi-
tion, we were also able to combine information from several 
nationwide registers on patients’ long-term diseases and preg-
nancies. 
The first limitation of our study is the lack of patient-reported 
outcome measurements (PROMs), which forced our study to 
focus strictly on the survival of the implant. However, absence 
of PROM data does not affect our interpretation of the survival 
results. The second limitation was the study period. Our study 
period was from 1987 to 2007. Even though the implants used 
today differ greatly from those implanted 30 years ago, contem-
porary implant designs were used in the latter half of the study 
period, and this approach also enabled us to assess long-term 
implant survivorship in this rare cohort of patients.
In conclusion, based on the findings in this nationwide study 
offering hip replacement to fertile females, delivery does not 
seem to decrease THR implant survivorship. Women should 
not be afraid of or avoid becoming pregnant after THR.
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